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Current research focuses on developing a novel bone-inducing scaffold that could 
deliver controlled osteogenic growth factors. Several aspects, in particular those 
influencing the efficacy of such bioactive scaffolds, such as release kinetics of the 
growth factor, biocompatibility and biodegradability, need further study.  
The aim of this thesis was to determine a mode of bone morphogenetic protein-2 
(BMP-2) delivery from copolymer scaffolds that reduce the dose to improve clinical 
safety while retaining efficacy. A low dose of 1 μg BMP-2 was immobilised via four 
different functionalising techniques on recently developed poly(LLA-co-CL) 
scaffolds. Sustained release of low levels was seen from BMP-2 physisorbed on 
nanodiamond modified scaffolds (nDP-PHY) for up to 70 days in vitro compared to 
that from scaffolds modified with microspheres containing BMP-2 (MICS) and 
unmodified scaffolds with physisorbed BMP-2 (PHY). No release was detected from 
BMP-2 covalently bound to nanodiamond modified scaffolds. nDP-PHY, MICS and 
PHY scaffolds promoted bone regeneration in a rat mandible critical-sized defect after 
4 weeks, however, nDP-PHY and MICS scaffolds demonstrated osteogenic potential 
in vivo as well as in mesenchymal stem/stromal cell (MSC) cultures.  
Poly(LLA-co-CL) scaffolds modified with nanodiamond (nDP) and nDP with 
physisorbed BMP-2 were then evaluated through in vivo degradation, host tissue 
response and tumorigenic potential. Modified scaffolds degraded faster than 
unmodified scaffolds. Gene expression of proinflammatory, osteogenic and angiogenic 
markers were upregulated in the nDP and nDP-PHY scaffolds with ectopic bone seen 
at week 8 only from the latter. Inflammatory cells, foreign body giant cells and fibrous 
capsule tissue were significantly reduced around the modified scaffolds. Tissue 
regeneration markers were most highly expressed in the modified groups. 
Interestingly, nanodiamond particles were found in the implantation site after 27 




To evaluate the tumorigenic potential of the functionalised scaffolds in vivo, a 
sensitive and non-invasive model using xenotransplantation of early neoplastic oral 
keratinocytes transfected to express luciferase (DOKLuc) together with carcinoma 
associated fibroblasts (CAF) for monitoring microenvironmentally-induced 
carcinogenesis was developed. nDP scaffolds without BMP-2 reduced the 
bioluminescence intensity of positive control tumours formed by DOKLuc+CAF in 
vivo. When cultured in vitro as 3D organotypic models of neoplastic oral mucosa, 
DOKLuc previously cultured on nDP scaffolds demonstrated reduced tumorigenic 
potential compared to DOKLuc from nDP-PHY and unmodified scaffolds. nDP-PHY 
scaffolds showed enhanced tumorigenic potential in vivo and in vitro.  
These results suggest a role played by nanodiamonds in reducing tumorigenic 
potential of DOKLuc and also raises concerns for the therapeutic use of BMP-2 for the 
reconstruction of bone defects in oral cancer patients. This thesis also highlights that 
the mode of binding BMP-2 to a scaffold has a significant effect on its osteogenic 
potential. Furthermore, the efficacy of delivering low, sustained amounts of BMP-2 is 
emphasised and the modality of nDP-PHY is shown to provide a promising bioactive 
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1.1 BONE TISSUE ENGINEERING 
Bone serves as a mechanical support, a site for muscle attachment, a barrier protecting 
vital organs and a storage for ions (1). It is the second most commonly transplanted 
tissue after blood (2). Despite the bone’s capacity for self-repair, grafts are used to heal 
defects such as non-union fractures, critical-size defects caused by injury or tumour 
resection, chronic conditions such as congenital malformations or sometimes to create 
a base for dental implants (2). Autogenous bone grafts (autografts) are considered the 
‘gold standard’ since they hold strong biological properties of osteogenesis, 
osteoconduction and osteoinduction relevant to bone healing and homeostasis. 
Nevertheless, their limitations include inadequate availability, donor site morbidity 
and supporting tissue injuries (3). As an alternative, allogeneic bone (allografts) and 
xenogenic bone (xenografts) from humans and animals respectively are used, but they 
carry the risk of disease transmission, rejection and impaired osteoinductivity due to 
the pre-transplantation processing (3). 
The increasing emphasis on quality of life in healthcare led biologists, engineers, 
chemists and biomaterial scientists to assemble and propose the field of tissue 
engineering or regenerative medicine in an attempt to surpass conventional treatments 
and discover methods for providing custom-made body parts. It was proposed that the 
means could be found to allow the body to harness restoration of configuration and 
function of the injured tissue to a state that is biologically and functionally like the 
native tissue prior to injury (4). Bone tissue engineering (BTE) typically involves 
presenting physical and/or bioactive signalling molecules to transplanted cells in a 3 
dimensional (3D) scaffold or to the host cells which are capable of responding to these 
signals and forming new, functional bone tissue that can integrate with surrounding 
host tissue (Fig. 1.1). Bioactive signalling molecules can be in the form of soluble 
biochemical factors, such as growth factors, genetic material, drugs and small 
molecules, and they can be delivered from a 3D scaffold with control of both time and 
space (5, 6). 
   




Figure 1.1 Basic triad of bone tissue engineering construct. Inspired by the basic compositional 
elements of bone and recapitulating autografts, which provide osteogenic cells, osteoinductive growth 
factors, and an osteoconductive scaffold/carrier, which are all essential for bone regeneration. 
Bioactive signalling molecules and 3D scaffolds are the focus of this thesis. Figure inspired from (4, 
5). 
 
1.2 SCAFFOLDS IN BONE TISSUE ENGINEERING 
1.2.1 Inspired by nature 
The scaffolds used in BTE are generally meant to provide provisional substitutes for 
the skeletal extracellular matrix (ECM) (7). They provide a 3D physical/mechanical 
temporary support combined with specific signalling molecules to assist cells 
implanted with it or cells from the vicinity to produce their own ECM 
microenvironment (8). The ECM is organised in a structural manner that controls 
processes of morphogenesis such as adhesion, migration, proliferation, differentiation, 
and signal transmission to cell membrane receptors that eventually affect genetic 
expressions (9). ECM in human skeletal tissue is composed mainly of water, collagen 
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and proteoglycans containing glycosaminoglycan, attached to a main protein via a 
tetra-saccharide linkage (8). Another vital role of ECM is as a reservoir for growth 
factors or their precursors in addition to presenting many adhesion molecules with a 
signalling function (10). These growth factors are stored locally in an insoluble/non-
active form via low affinity binding with ECM molecules that protects them from 
degradation. They can be liberated in response to physiological need, for example 
bone repair after injury (10). ECM proteins such as fibrin, collagen, fibronectin and 
vitronectin can also bind to a number of growth factors either indirectly via their 
heparin-binding domains or more directly via their growth factor-binding domains 
(11). Therefore, it is important that these interactions between cell surface receptors 
and the ECM characteristics are mimicked to guide the design of a bioactive scaffold-
cell interaction. 
 
1.2.2 Designing and fabricating scaffolds 
When designing a scaffold for bone tissue, several complex parameters need to be 
considered. These include material composition, porous architecture, mechanics, 
surface properties, degradation properties and by-products, together with the 
composition of any added biological components that affect its bioactivity (7, 12). To 
mimic ECM and modulate osteogenesis, the geometrics of porosity and pore size are 
important (13). Although the pore size for BTE scaffolds is controversial, it has 
generally been found that there is a minimum requirement of around 100 μm for 
adhesion and migration of cells and more than 300 μm are recommended for bone 
matrix ingrowth and neovascularization to promote osteogenesis (14). Porosity of 
around 90% and interconnectivity of almost 100% is necessary to facilitate nutrient 
and waste passage and to provide interlocking with the surrounding tissue (13). Also 
important are the mechanical, degradation and biocompatibility properties, which are 
inter-related. A scaffold should express adequate mechanical properties, as close as 
possible to the replaced tissue, and prevent stress shielding (7). The scaffold 
degradation rates should be tailored to correspond to the bone regeneration timeframe 
in vivo allowing load transfer gradually; and as it degrades, the selected materials 
should not elicit any by-products causing adverse responses (7). In general these 
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parameters promote the osteoconductivity of the scaffold, allowing the bone cells to 
adhere, proliferate, and form extracellular matrix on its surface and pores (15). 
To tune the architecture of a scaffold, the choice of fabrication technique is 
essential. Several technologies have been and are being developed to provide state-of-
the art fabrication of 3D porous degradable scaffolds. One commonly used 
conventional method is particulate leaching, where a polymer solution is added over 
granular porogens which are leached out once the polymer has solidified (16). 
Drawbacks of this method include lack of reproducibility and preciseness in 
architecture; however, it is inexpensive and easy production makes it a popular 
method. Foaming techniques are an alternative, in which gas bubbles are produced by 
expansion of carbon dioxide (17). Nonwoven constructs may be produced by 
electrospinning giving fibrous polymer scaffolds (18). Emulsion freeze drying and 
thermally induced phase separation has also been studied to provide scaffolds with 
high porosity and interconnectivity (19). During the last decade, rapid prototyping or 
solid free form fabrication methods have emerged with the introduction of 
computerised technologies facilitating layer by layer plotting design of scaffolds (20). 
Bone defects can be captured by magnetic resonance imaging (MRI) or micro-
computed tomography (micro-CT), reconstructed using computer-aided design 
manufacturing and then based on the printing strategy: solid free form fabrication 
scaffolds can be produced either via laser-bed stereolithography, selective laser 
sintering, extrusion based fused deposition modelling (21) or 3D printing (22). Some 
of these advanced options require more specific material than the simpler techniques, 
but they bring us forward towards personalised treatment. 
 
1.2.3 Materials used in fabricating BTE scaffolds 
A variety of materials have been investigated to fabricate BTE scaffolds with the aim 
of identifying the most appropriate physical, chemical and biological properties to 
encourage bone production (12). These materials can be generally considered either 
degradable or non-degradable, either organic or inorganic, either natural or synthetic. 
They include metals, ceramics, polymers and their composites/combinations are now 
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emerging (12). Titanium and tantalum are the most commonly used metals to produce 
porous scaffolds exhibiting biocompatibility together with a mechanical stiffness close 
to bone, promoting enhanced osteoconduction, calcium deposition and bone formation 
in vivo (23). However, lack of degradation, corrosion, ionic leaching and costly 
processing limits their applications (23, 24).  
Bone is composed of an inorganic portion of hydroxyapatite (HA) and calcium 
phosphates (CaP), thus ceramic scaffolds are characterised with comparable 
crystallinity to bone mineral components making them biocompatible and bioactive 
(25). Co-culturing MSC and endothelial cells for pre-vascularisation attempts in 
porous beta-tricalcium phosphate (β-TCP) have also shown success in large segmental 
defects in rabbits (26). Furthermore, in a recent prospective clinical study bone defects 
caused by bone tumours were treated with biphasic CaP granules consisting of 60% 
HA and 40% β-TCP, in combination with a fibrin matrix (27). Of the patients with a 
mean defect size of 11.8 cm3, 98% showed complete bone healing after approximately 
2 years (27). In general, CaP granules have been restricted to small bone defects, 
however changing physicochemical compositions and structural features displayed 
osteoinductivity equivalent to autologous bone grafts in a sheep critical sized defect 
(28). Clinical applications of ceramic scaffolds are limited due to their inherent 
brittleness and difficulty of shaping as well as a slow degradation rate (25). 
Polymers are categorised into either natural or synthetic and they can be shaped 
into different scaffold types in addition to 3D porous solids, ranging from gels to 
fibres. The common natural materials used in bone regeneration are polysaccharide 
derivatives such as alginate, chitosan, hyaluronic acid and protein derivatives such as 
collagen, fibrin and silk (12). They can be biologically recognised, which supports 
cellular response. Collagen type I is the main organic component of bone ECM, which 
made it the most studied natural polymer in BTE scaffolds playing a role in cell 
adhesion, growth and differentiation (29). Drawbacks such as the possibility of 
pathogenic contamination, lack of control over mechanical properties, degradability 
and production stability are presented in this group (30). 
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1.2.3.1 Synthetic polymers 
Drawbacks from natural polymers encouraged the development of synthetic polymers 
that have shown capacity as scaffold materials for BTE. This is due to their 
reproducibility in large scale in addition to the ease of tuning their chemical, physical, 
mechanical and degradation properties (31). Commonly studied synthetic polymers for 
potential scaffolding applications include aliphatic polymers, poly(carbonates), 
poly(propylene fumarates), and poly(anhydrides) (32-35). 
The research presented in this thesis utilised degradable aliphatic 
polyesters/polymers, a group of synthetic polymers that contain the ester functional 
group in the main chain. Aliphatic polyesters synthesised from monomers such as L-
lactide (LLA), ɛ-caprolactone (ɛ-CL) and glycolide forming homopolymers or 
copolymers are the most commonly used aliphatic polyesters for BTE applications (18, 
35, 36). These degrade by non-enzymatic hydrolysis (37) and their degradation 
products can be removed by natural metabolic pathways. Certain devices for other 
applications based on these polymers, regulated by the US Food and Drug 
Administration (FDA), have been approved after clinical trials and patented (35, 38, 
39). Nonetheless, they have important shortcomings such as lack of biological cues 
and hydrophobicity that causing poor wetting and affects cellular adherence (40).  
Amalgamating different polyesters and tuning the molar ratios or polymer 
molecular weights have been used to produces a copolymer with customised properties 
(41, 42). Mixing poly(LLA) and poly(caprolactone triol) for example was used to 
produce membranes and in vitro results with osteoblasts showed that this modifies its 
mechanical, thermal, and biological properties, i.e. improved cellular migration, 
attachment, proliferation and matrix production (43). A recently developed copolymer 
matrix yielded porous scaffolds composed of 75% poly(LLA) and 25% ɛ-CL or 1,5-
dioxepan-2-one (DXO). The poly(LLA-co-CL) and poly(LLA-co-DXO) scaffolds 
were produced by random ring opening polymerisation (16) and the former is the 
copolymer scaffold used in this thesis. These copolymer scaffolds were evaluated and 
compared in vitro to the poly(LLA) scaffolds using MSC (16, 44) and human 
osteoblast (HOB) (45). Cellular responses demonstrated the MSC to spread and 
   
Bioactive copolymer scaffolds  
7 
 
proliferate better on copolymers compared to poly(LLA) after 1 and 7 days and also 
exhibited differentiation potential towards an osteogenic lineage (44). Furthermore, the 
same trend was also seen with HOB, where surface analysis disclosed improved 
attachment, spreading and growth of the cells into the pores of the copolymer scaffolds 
compared to the PLLA, which induced higher collagen type I and osteocalcin 
production (45). Poly(LLA-co-DXO) scaffolds also showed enhanced bone 
regeneration and suitability for BTE when cultured with a mix of MSC and endothelial 
cells and then implanted in a rat calvaria defect model (46).  
Thus, while these synthetic copolymers have exhibited excellent osteoconductive 
qualities, they lack biological recognition on the material surface that renders them 
less bioactive than natural polymers or ceramics. In an effort to overcome this 
drawback, hybrid or composite scaffolds were produced that were modified with 
ceramics or natural polymers or both (47). These showed variable advantages from 
good biocompatibility and improved mechanical properties (48) as well as 
obsteoblastic lineage cell responses due to increased wettability accompanied with 
improved bone formation in a mouse calvarial model (49). 
In addition to mixing different materials, other modification strategies have also 
employed to functionalise scaffolds, specifically synthetic polymers that render more 
representative of native ECM. These modifications may be categorised as 
morphological, chemical or biological (40, 50). Surface topography modifications 
providing micro- to nano-meter scale architecture resembles the physical arrangement 
of components in the ECM. For example, silica nanoparticles have been applied onto 
the fibre surface of 3D polycaprolactone (PCL) fibrous scaffold and were found to 
improve the fibre wettability and surface roughness thus enhancing osteoblastic 
attachment and differentiation (51). Carbon-derived nanodiamond particles (nDP) 
have been employed on poly(LLA-co-CL) scaffolds improving mechanical properties 
(52, 53) and biological influences due to enhanced hydrophilicity that promoted 
cellular attachment and differentiation leading to bone formation in a critical defect 
(54). Furthermore, the addition of functional chemical groups by grafting, radiation, 
plasma treatments, or alkali treatments to the polymer has been shown to increase the 
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hydrophilicity of the scaffold, promoting cellular attachment and diffusion of nutrients 
(50). These functionalisation modalities also offer opportunities to tether bioactive 
signals (50). Alternatively, incorporation of biomolecules meant to mimic ECM, such 
as growth factors, adhesion proteins or bioactive peptide motifs into the scaffold’s 
surface promotes integrin-mediated cellular responses (55). Therefore, in an attempt to 
make synthetic scaffolds osteoinductive, researchers have developed bioactive 
scaffolds delivering signalling cues which stimulate cells and initiate repair by actively 
participating in bone tissue regeneration (15).  
The research in this thesis is focused on functionalising synthetic copolymer 
scaffolds to deliver growth factors for BTE. 
 
1.3 BIOACTIVE SIGNALLING MOLECULES IN BONE HEALING 
The mechanism of bone regeneration after injury is complex and it follows the natural 
embryonic skeletogenesis in addition to normal responses to tissue injury. Bone 
healing may occur through intramembranous or endochondral ossification or a 
combination of both (56). It involves several phases: such as inflammation, reparative 
and finally remodelling. This complex regenerative process involves multiple cell 
types in the microenvironment, including inflammatory cells, osteoprogenitor and 
differentiated osteogenic cells, endothelial cells, and fibroblasts. The cells produce and 
release bioactive signalling molecules that facilitate coordinated biological actions 
(Fig. 1.2). The secreted bioactive molecules are usually characterised under the 
following groups; (a) proinflammatory cytokines, (b) growth factors (c) 





   




Figure 1.2 Bioactive molecules involved in bone healing. The relative levels of some of the 
significant bioactive molecules involved in bone regeneration process and the ability to recapitulate 
and manipulate those signalling processes on a similar spatiotemporal scale could provide control over 
the regenerative process. SDF-1 is stromal cell-derived factor 1. Figure adapted and modified from 
(58). 
 
When a bone is injured, the haematoma formed stimulates inflammatory cytokines to 
initiate the regenerative cascade. Inflammatory cells secrete mainly interleukins (IL) 
(IL-1 and IL-6) and tumour necrosis factor alpha (TNF-α) during the first 24 hours, 
which recruit other inflammatory cells as well as MSC before declining after the acute 
inflammatory phase (59). Simultaneously, the release of growth factors initiates the 
reparative phase, several growth factors are expressed during the different phases. 
Among them, the most significant are the superfamily of transforming growth factor 
beta (TGF-β), which also includes the bone morphogenetic proteins (BMP), followed 
by the fibroblast growth factor (FGF), platelet-derived growth factor (PDGF), vascular 
endothelial growth factor (VEGF) and insulin-like growth factor (IGF) (60). Platelets 
at the site of the defect release PDGF and TGF-β starting the repair cascade. They 
stimulate bone repair by recruiting and expanding the osteoprogenitor cells (61). 
Consequently, BMP expressed in bone matrix and from recruited MSC promote their 
differentiation into chondrocytes and osteoblasts. These MSC secrete growth factors, 
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such as IGF and FGF which play important roles in enhancing vascularity (62). 
Secreted angiogenic growth factors such as VEGF and angiopoietins 1/2 (ANGPT 1/2) 
regulate the vascular supply which plays a critical role in maintaining bone 
homeostasis (63). VEGF was found to work synergistically with BMP enhancing the 
recruitment and differentiation of MSC (64). Matrix metalloproteinases (MMP) 
degrade cartilage and shape bone to allow infiltration of blood vessels in the final 
phases of ossification and the remodelling (57). 
 
1.3.1 Bone Morphogenetic Protein 2 
Over the past several decades, the growth factors most studied as therapeutic agents to 
enhance bone repair are the BMPs. In 1965 Marshall R. Urist made a pioneering 
discovery through the implantation of de-mineralised bone matrix, which was found to 
induce bone formation in heterotopic sites (65). This phenomenon shed light on bone 
BMP, a group of proteins with osteoinductive potential (66). Scientists today suggest 
describing them as ‘body morphogenetic proteins’ due to their versatile involvement in 
several developmental processes (67). Currently there are around 20 identified human 
BMPs and they are involved in skeletal development and the physiological process 
during embryogenesis of tissues as teeth, brain, heart, lung, kidney, spleen and liver, in 
addition to glucose homeostasis and modulation of iron homeostasis (68). BMPs are 
synthesised by osteoprogenitor cells as well as differentiated osteoblasts and 
chondrocytes and were also localised in megakaryocytes and platelets (69). Except for 
BMP-1, the BMPs belong to the multifunctional TGF- β family. The structure of the 
primary amino acid sequence homology stratifies BMPs into four groups: BMP-2/4, 
BMP-5/6/7/8a/8b, BMP-9/10 and BMP-12/13/14 (70). During early studies, 
recombinant adenoviruses expressing fourteen human BMPs were constructed to 
infect pluripotent mesenchymal progenitor cells, preosteoblastic cells, and osteoblastic 
cells. Results of these studies suggested differences among their osteogenic potentials, 
but BMP-2, -4, -6, -7 and -9 were most able to induce osteogenic factors as well as 
matrix mineralisation (71). BMP-2 and BMP-7 are the ones used in clinical 
applications (72). 
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BMP-2 is initially synthesised as a pro-protein with 453 amino acids before it is 
glycosylated and broken down by enzymes to produce the mature, biologically active 
BMP-2 which is a homodimer of two subunits, each consisting of 114 C-terminal 
amino acids (73). Each monomer has a molecular weight of approximately 16 kilo 
Dalton and contains six additional cysteine residues, which are involved in three intra-
chain disulphide linkages (73). BMP-2 contains a heparin binding domain in an N-
terminal region that enables interactions with ECM elements (73). Murine studies 
inhibiting the expression of BMP-2 demonstrated the role played by this protein in 
morphogenetic regulation of post-natal osteoprogenitor differentiation. In the same 
study, the addition of BMP-2 to osteoprogenitor cells liberated runt-related 
transcription factor 2 (RUNX2) and osterix expression with observed mineral deposits 
(74). In vitro studies showed the exogenous addition of recombinant (rh)BMP-2 to 
human adipose-derived stromal cells (75) or MSC (76) augments their osteogenic 
potential. 
It has been reported that mice lacking the ability to produce BMP-2 in their limb 
bones have experienced spontaneous fractures with impaired healing capabilities and 
lack of callus formation (77). In vivo gene modified mouse investigations revealed the 
initiation of the osteogenic and chondrogenic differentiation of periosteal progenitors 
during repair in cortical periosteum-mediated repair to be controlled by endogenous 
BMP-2 (78). A study examining the fate of injected labelled MSC in nude mice, 
demonstrated their chemotactic homing towards the carrier of BMP-2 and their 
differentiation into osteogenic cells (64). The multifaceted roles of BMP-2 were also 
demonstrated in dentin formation and pulp vascularisation (79). Following the 
secretion of the active form of BMP-2 from cells, osteogenesis is initiated by the 
binding of BMP-2 to serine/threonine kinase BMP type I and type II receptors. It 
follows an osteodifferentiation canonical (Smad) signalling pathway (see Fig. 1.3) and 
a non-canonical (p38 MAPK) signalling pathway (72).  
   




Figure 1.3 Bone morphogenetic protein 2 canonical signalling cascade. BMP-2 can bind to either 
preformed complexes of type I or type II receptors or to solitary receptors. The type II receptor kinase 
phosphorylates the type I receptor in the membrane proximal part initiating the cascade by recruiting 
(R)-Smad proteins 1, 5 and 8 (80). These Smad proteins bind to (C)-Smad 4 to translocate to the cell’s 
nucleus inducing the expression of osteogenic transcription factors. Figure modified from (68) and 
made using Servier Medical Art. 
 
1.4 CLINICAL IMPLICATIONS OF BMP-2 DELIVERY - Status Quo 
Several clinical orthopaedic trials have been carried out using the FDA approved 
rhBMP-2 product, Infuse® (Medtronic, Minneapolis, MN)/InductOs® (UK) (81). This 
BMP-2 is carried in an absorbable collagen sponge at a concentration of 1.5 mg/ml. Its 
approval was grounded on the results of a prospective clinical trial. The trial compared 
patients with degenerative disc disease randomised to receive either BMP-2/collagen 
sponge construct or autogenous bone from the iliac crest to treat anterior lumbar 
interbody fusion (to induce new bone formation in the disc space to fuse the vertebrae 
and alleviate pain). Radiographic evidence of osteogenic induction and maintained 
   
Bioactive copolymer scaffolds  
13 
 
fusion for 2 years were reported in BMP-2/collagen sponge group with improved 
neurological symptoms (81). More recent uses in posterolateral fusion to substitute for 
the gold standard procedures were also reported with positive results, however they 
were off-label uses, utilising much higher doses and different carrier and location than 
already approved (82). BMP-2 delivery and subsequent spinal fusion has also been 
facilitated by ceramics and synthetic polymers clinically in addition to the 
aforementioned collagen carriers (83).  
A large randomised clinical trial including 450 patients to evaluate BMP-2 
(Infuse®) reported accelerated bone regeneration from the test group of open tibial 
fracture repair surgeries with intramedullary nail fixation. The authors also described a 
dose dependant reduction of second surgical intervention and reduced infection for the 
group treated with BMP-2 in addition to standard care when compared to the group 
that received standard care alone (84). Despite the high costs of recombinant proteins, 
these results demonstrated that medical costs could be reduced due to reduced post-
surgical interventions (85). 
Oral and maxillofacial defects include causes such as congenital malformations, 
trauma, tumour removal and deficient bone in ridges for dental implants. The very first 
clinical study was a pilot evaluating the BMP-2/collagen sponge construct in maxillary 
sinus floor augmentation using a concentration varying from 1.77 to 3.40 mg per 
patient (86).  Significant bone growth was seen in 91% of the patients but side effects 
of swelling in the face, redness and pain in the mouth were observed. A further 
randomised controlled trial reported 8 years later by the same group increased the dose 
to 0.75 mg/ml and 1.50 mg/ml and assessed bone induction after 4 and 6 months (87). 
It showed considerably increased alveolar ridge and bone density after 4 months in the 
treatment group, concluding that BMP-2/collagen sponge accelerated bone formation 
for the placement and functional loading of dental implants (87). Off-label use in 
mandibular continuity reconstructions in defects due to tumours or bone infections 
were evaluated in a few patients followed up to 18 months (88). This study 
demonstrated the ability of BMP-2 delivered in a collagen carrier without bone graft 
material to regenerate critical sized mandibular defects with a potential of enabling 
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prosthetic fitting (88). However, further studies will be required to assess the quality of 
the regenerated bone.  
Due to the potential advantages of rhBMP-2 in a construct as a substitute for auto, 
allo- or xenografts deduced from pre-clinical studies, enthusiasm for rhBMP-2 led to 
its off-label usage for unapproved amounts indications, age groups or carrier. As a 
result, many complications were reported from its use in lumbar spine and cervical 
spine surgery, i.e. post-operative radiculitis and nerve injury, vertebral osteolysis and 
oedema, excessive bone formation heterotopically and hematomas obstructing 
respiration (89). A case of non-healing ulnar defect in a child’s forearm was treated 
with BMP-2 and led to an unwanted inflammatory reaction with bone resorption (90), 
while a case in a child cleft palate treatment resulted in excessive gingival swelling 
(91).  
The association of cancer with BMP-2 usage is controversial. A review trying to 
quantify cancer incidence and rate with spinal fusion using BMP-2 concluded that 
there might be an increased tumour risk but it was not statistically significant (92). 
Moreover, products with very high BMP-2 concentration (40 mg) used to treat spinal 
diseases have been connected with higher cancer risk when compared to controls (93). 
An in vivo pre-clinical analysis of oral squamous cell carcinoma (OSCC) cell line pre-
treated with BMP-2 before xenografting reported that human oral cell carcinoma, 
when treated with BMP-2, became more locally aggressive and the host had decreased 
survival, suggesting the need for caution when using BMP-2 in reconstructing bone 
defects caused by oral cancers (94).  
When loaded in collagen sponges, BMP-2 shows a pharmacokinetic profile of 
burst release (95). This required researchers to employ supra-physiological loading 
quantities to maintain BMP-2 biological activity in the vicinity in suitable amounts for 
longer times. Therefore efforts to design controlled release strategies for scaffold-
based delivery of BMP-2 for dose reduction and localisation is an ongoing challenge. 
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1.5 STRATEGIES FOR A CONTROLLED BMP-2 DELIVERY- Quo Vadis 
Localised, sustained release of BMP-2 can be potentially beneficial by lowering 
required doses and thus costs, and avoiding local or systemic side effects (58, 96). The 
concept of spatiotemporal dosage based on native ECM is challenging and significant 
research has focused on it.  
In general, there are several approaches being developed to deliver BMP-2 from 
scaffolds: direct delivery of the protein itself, indirect delivery of genes encoding for 
BMP-2 or its peptides, or antibodies delivered to harness endogenous BMP-2. The use 
of scaffolds to deliver cells transduced ex vivo with virus encoding BMP-2 (97) or 
delivering the viral vector alone with no cells has the potential of rapidly achieving a 
high concentration of BMP-2 endogenously (98). Furthermore, gene therapy based on 
non-viral plasmid is being pursued to reduce immunogenicity (99). Synthetic peptides 
that mimic BMP-2 activity and activate receptors are smaller molecules that can easily 
be modified with chemical groups and have been shown to significantly stimulate 
heterotopic ossification in vivo (100). Entrapment of endogenous BMP-2 by using 
biomaterials to deliver murine monoclonal antibody demonstrated antibody-mediated 
de novo osseous regeneration (101). Safety concerns and production costs with gene 
therapy limit its clinical translation and due to advances in recombinant protein 
technology, delivery of the actual protein has become widely used. Researchers in the 
field have used a large variety of natural, synthetic and inorganic materials and their 
composites as carriers for BMP-2. The carrier or material is crucial for an optimal 
release profile (102), but a significant point also is the strategy of incorporating the 
protein in these materials, which exerts control on its release profile (58).  
Discussion in the following sections considers the strategies envisioned for the 






   






Figure 1.4 Strategies for a controlled scaffold-based release of BMP-2. Schematic illustrations of 
examples from the different strategies. (A) Physical entrapment using layer by layer polyelectrolyte 
multilayer. (B) Chemical immobilisation by heparin conjugation. (C) On demand release. Figure made 
using Servier Medical Art. 
 
1.5.1 Physical mixtures/entrapment  
The prevailing strategy of incorporating BMP-2 protein into polymer scaffolds is by 
directly mixing them into the matrix, either during the solidification of the polymer or 
after the fabrication of the scaffold (102). Adsorbing in prefabricated scaffolds is most 
easily achieved by dipping the scaffolds in a protein solution. However, during this 
process only minute amounts of protein are adsorbed to the scaffold, and in an 
uncontrolled fashion, resulting in similarly uncontrolled/unpredictable release profiles 
(103). Adsorbing BMP-2 onto a prefabricated scaffold leads to a variety of non-
specific, non-covalent or electrostatic interactions (104). This has been associated with 
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a burst release and incomplete association of the BMP-2 to the carrier because most of 
it remains in the solution. Before scaffold fabrication, the entrapment of BMP-2 in 
porous scaffolds is most commonly carried out by the conventional method of solvent 
casting/particulate leaching, but the harmful solvents used may denature the BMP-2. 
In supercritical fluid, carbon dioxide under high pressure is used as an alternative 
solvent to produce porosity and entrapment of BMP-2. This method has shown 
suitability for sensitive growth factors (17).  
A technology developed for the controlled release of growth factors adsorbed in 
scaffolds is layer by layer polyelectrolyte multilayer film (Fig. 1.4 A). Three-
dimensional printed β-TCP/PCL scaffolds were repeatedly dipped in positively and 
negatively charged polymer baths, producing a film and trapping the charged BMP-2 
while preserving its activity. This modality showed BMP-2 release in micrograms; 
80% of the incorporated amount was released over a 2 day period with less than 1% in 
the first 3 hours and the remaining 20% over 2 weeks. Released BMP-2 induced 
differentiation of pre-osteoblasts and formed ectopic bone by 4 weeks (105). In 
another approach designed to produce a more sustained release that could last over 
several weeks, BMP-2 emulsified in acetic acid was incorporated in the polymer 
solution prior to electrospinning or by using co-axial electrospinning to produce a core 
containing BMP-2 surrounded by fibres. It was reported to accelerate bone 
regeneration and ossification foci in a 5 mm critical size rat calvarial defect (18). The 
pattern of release with these methods is usually a burst release followed by a continued 
slower release by diffusion through the polymer (104). Physical 3D printing 
technology has also been employed recently in order to achieve spatial control over 
BMP-2 by printing a pattern of BMP-2-containing bio-ink on the surface of circular 
acelluar dermal matrix implants (106).  
The major challenge associated with physical adsorption is the loss of bioactivity 
of the incorporated growth factors due to their undergoing conformational changes in 
the organic solvents at temperatures used or other harsh fabrication methods. Addition 
of a separate release system to the scaffold was introduced as a solution. Encapsulation 
within a biomaterial vehicle can provide protection from enzymes and increased 
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protein retention at the target site. Microspheres or nanospheres are particles with 
diameters from 10-1000 μm and 10-1000 nm respectively (36). They were loaded with 
BMP-2 and incorporated into different types of scaffold matrices, either solid, 
hydrogel made of polymers or ceramics or fused together by sintering to make a 
scaffold (107). Microspheres typically exhibit burst release in the first few days 
followed by a more linear sustained release (108). When incorporating BMP-2 
encapsulated in poly(lactic-co-glycolic acid) (PLGA) microspheres into polyurethane 
scaffolds, they reduced the burst release compared to scaffolds without microspheres 
(109).  
A study comparing the release of BMP-2 from microspheres with or without being 
incorporated in a 3D scaffold showed that after 3 days, BMP-2 was released from 
PLGA microspheres and increased sharply with time for only 14 days. However, the 
3D scaffolds with BMP-2-loaded microspheres released BMP-2 after 7 days but 
sustained linear release up to 4 weeks. This was attributed to the entrapped 
microspheres in the scaffold that have less surface exposed to the medium, reducing 
diffusion and hence sustaining BMP-2 for longer, forming more bone in a rat cranial 
defect (110). The particles can be made of different materials or different compositions 
or molecular weights compared to the matrix scaffold, which gives them the benefit of 
faster degradation while the scaffold still provides structural support. To bypass the 
drawback of exposure to organic solvents, techniques such as electro-spraying, with 
more control over the size of the sphere, have developed (111).  
Besides adding separate release systems to enhance physical entrapment of BMP-
2, attempts to increase electrostatic and non-covalent interactions by increasing the 
charged components in the surface, changing the pH of the media to increase the 
BMP-2 charge, or increasing the immersion time have been reported (104). 
Researchers have also expanded by developed nano-scale structures that provide 
increased surface area and non-covalent interactions that intensify binding between the 
protein and the scaffold or carrier (112). The surfaces of nanodiamond particles (nDP) 
show distinctive features depending on the production method (113). Detonation 
synthesis is a production method that has gained wide interest owing to the unique 
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mechanical, chemical and biological properties nDP acquire; making them useful in a 
variety of applications (114). In the case of detonation diamond, particle size of about 
4-5 nm is yielded and a variety of functional oxygen-containing groups are usually 
present on the particle surface (Fig. 1.5).  
 
Figure 1.5 Nanodiamond particles. The structure and functional groups present in pristine 
nanodiamonds after purification with acidic treatment and deagglomeration with attrition milling. 
Adapted from (115). 
 
These groups include carboxyl, lactone, ketone, hydroxyl as determined by infrared 
spectroscopy and mass spectrometry rendering it hydrophilic (116). These groups 
originate from the reaction in the detonation reactor and/or from the acid etching 
purification process (115). Also, more hydroxyl groups were found to be added from 
the milling process developed to deagglomerate/disperse them (117). 
These nDP have many potential uses in a variety of biological applications (118). 
In BTE, BMP-2 was found to bind to nanocrystalline diamond (NCD) films produced 
by substrate-free chemical vapour deposition of acetylene in a microwave-enhanced 
plasma oven and then oxidised at high temperature (119). The oxygen-terminated 
nanocrystalline diamond (O-NCD) coating titanium implants showed highly stable, 
non-covalent physisorption of BMP-2 occurring in a reduced energy that would not 
alter the protein’s conformation (119, 120). To confirm bioactivity of this bound BMP-
2, MSC expressed high levels of osteogenic markers after being cultured on O-NCD 
implants and this same group also yielded enhanced osseointegration in sheep calvaria 
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defects (120). The nDP with hydrophilic oxygen-containing surface groups is very 
prone to adsorb molecules by hydrogen bonding and other polar interaction. In this 
study (120), theoretical calculations displayed BMP-2 binding with a combination of 
individual hydrogen bonds and van-der-Waals interactions up to 500 kJ/mol to the O-
NCD. Therefore, comparable strengths to covalent binding were attained without 
chemical cross-linking providing sustained short distance BMP-2 delivery, which was 
confirmed histologically (120). In another study BMP-2 was delivered from NCD 
coated titanium screws in pig’s mandible after 4 weeks of exposure to radiation; 
results showed osteoinductivity in irradiated bone (121). Drug delivery via nDP is an 
innovative matter in nanotechnology, and a few research groups have begun to 
investigate their uses for outstanding adsorption of biomolecules and bone 
regeneration.  
In another recent study BMP-2 delivery from nDPs in suspension induced C2C12 
myoblasts into alkaline-phosphatase (ALP) producing osteoblasts (122). There was a 
delayed cellular response observed in this study that was explained to be due to the 
strong binding and sustained delivery of BMP-2. This study showed how delivering 
BMP-2 in an nDP suspension can be a great advantage to bone defect surgeries where 
space is limited (122). nDP can also be incorporated into scaffolds for BTE to mediate 
the release of controlled therapeutics and at the same time provide structural support 
when the defect is large. 
 
1.5.2 Chemical immobilisation 
The chemical immobilisation of BMP-2 inhibits nonspecific adsorption and may also 
reduce the amount of BMP-2 needed, preventing uncontrolled release (123). BMP-2 
will be available to cells in contact with the scaffold, providing a highly localised 
signal and enhanced phosphorylation of receptor cascade (124). Techniques to 
chemically bind BMP-2 to scaffolds have been employed to control its release, either 
covalently or biochemically. This can be done after scaffold functionalisation by either 
using temporary or permanent and direct or indirect linkers (96). Non-covalent indirect 
interaction via proteins or other biological molecules such as oligopeptides can by 
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controlled by chemical conjugation onto scaffolds to provide binding sites and 
demonstrate a strong affinity to BMP-2 (96). A widely used example of this is heparin-
conjugated systems that mimic the physiological role of heparin in regulating growth 
factors by binding proteins in the extracellular matrix (Fig. 1.4 B) (73). Studies 
verified that heparin-conjugated fibrin systems, after activating its carboxylic acid 
groups, enabled a slower and more controlled release of BMP-2 compared to BMP-2 
absorbed in collagen sponge, leading to reduction in unwanted adipose tissue 
formation in ectopic sites and enhanced mineralisation (103, 125). The chemical 
functionalising of scaffolds with biomimetic peptides like arginine glycine-aspartic 
acid (RGD) has enhanced cell attachment and differentiation, while showing promise 
to reduce the doses of BMP-2 needed when combined with collagen sponges (126).  
Covalent bonding on the other hand provides more prolonged attachment 
compared to physical and non-covalent chemical immobilisation, preventing its actual 
release in the vicinity until the scaffold degrades or the covalent bond is broken (123). 
One of its advantages is that the BMP-2 remains competent to activate receptors. A 
recently developed method to covalently tether BMP-2 by self-assembly using a bi-
functional linker showed C2C12 myoblasts to express BMP-2 signalling pathway 
without BMP-2 being released in the medium (127). However, selection of the binding 
site of the protein without damaging the functional group activity is a challenge of 
covalently linking BMP-2, and the chemistries used to functionalise carriers and 
covalently immobilise BMP-2 can lead to protein denaturation or inactivation (123). 
 
1.5.3 On-demand delivery and hybrids 
‘Smart’ biomaterials release BMP-2 in response to surrounding environmental 
stimuluses. These factors commonly include changes in pH or temperature, presence 
of enzymes that cleave linkers used for immobilising or external factors such as drugs, 
light, electrical, magnetic or ultrasound applications (Fig. 1.4 C). In one study 
polyethylene glycol (PEG)-based scaffolds containing disulphide bonds were 
fabricated and implanted in a rabbit radius critical defect. This modification was made 
reactive to the cell-secreted redox microenvironment, thus the degradation rate and 
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subsequent BMP-2 release was dependent on the proteases secreted by the cells during 
remodelling (128). A pH/thermo-sensitive copolymer hydrogel showed high adsorbing 
efficacy of BMP-2 up to 85 % jellified in physiological pH and temperature. Release 
kinetics of the BMP-2 was not quantified but the scaffold formed mineralised tissue in 
an ectopic mouse model after 7 weeks (129). 
Composite or hybrid materials are also used to improve the release profile of 
BMP-2. For example, this was seen in a study aimed to develop a system to release 
low amounts of BMP-2 from a collagen-HA scaffold. Preserved bioactivity of BMP-2 
was seen up to 21 days, with enhanced mineralisation from cultured pre-osteoblasts 
and enhanced bone regeneration in rat calvaria after 8 weeks (130). In another study, a 
composite hybrid system using RGD- functionalised alginate hydrogel containing low 
amounts of BMP-2 was injected inside a PCL nanofiber mesh tube and compared it to 
the standard clinical method of absorbable collagen sponge delivery or alginate 
hydrogel alone to evaluate the regenerative process with respect to space and time 
(131). In a rat femoral segmental critical defect, the hybrid scaffolds slowed the 
release of BMP-2 and promoted significant increase in bone volume compared to the 
other groups while also preventing heterotopic mineralisation (131). Thermo-sensitive 
polymeric nanoparticles with hydrophobic and ionic complex interactions with BMP-2 
in a hydrogel showed sustained release of BMP-2 for 3 weeks. These dual interactions 
led to increased bone regeneration in an ectopic and orthotopic model after a single 
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1.6 CONSIDERATIONS FOR A SCAFFOLD DELIVERING BMP-2  
The field of BTE is continuously developing; thus the definitions of an ideal scaffold 
construct delivering bioactive molecules continue to evolve. However, the optimal 
scaffold to deliver BMP-2 for bone regeneration should fulfil fundamental 
considerations in the clinic, in addition to the general scaffold requirements mentioned 
earlier (summarised in Table 1.1). These include the inter-related characteristics of; 
efficacy in osteoinduction in addition to osteoconduction, degradability and, most 
importantly, to be biologically harmless for its host (133). 
 
Table 1.1. Scaffolds designed to deliver growth factors. Necessary and desirable characteristics. 




Release of a therapeutic dosage of bioactive growth factor over a 
period of time relevant to rate of bone formation 
Biocompatibility Low immunogenic response and no carcinogenicity 
Degradability Controllable degradation simultaneously with bone formation 
maintaining desirable mechanical properties 
Readily sterilisable Without loss of mechanical function or denaturation of growth 
factor 
Ease of manufacture Cost-effectiveness 
Long shelf-life Ease of access to the user 
 
1.6.1 Osteoinductivity 
Osteoinduction is the process by which osteoprogenitor cells are actively recruited and 
differentiate into osteoblasts under the influence of an osteogenic signal (65, 66). For 
effective osteoinduction, a scaffold must present bioactive signalling molecules to the 
tissues at a concentration that is optimal. It should be neither too low to be ineffective, 
nor so high as to cause toxic side effects. This optimum concentration range is called 
the therapeutic window (58). The mode of BMP-2 delivery to its potential site of 
action is an essential determinant of its osteoinductive efficacy. Preserved bioactivity 
at the site of interest is the primary goal, but effective concentration within the 
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therapeutic window is equally important. For BMP-2 as most growth factors, this 
index is rather small due to low solubility and short biological half-life (68). 
 
1.6.2 Host response and degradability of implanted scaffolds  
Once a scaffold is implanted in vivo, the host responds by activating its defence 
mechanisms and an inflammatory/immune reaction, known as the foreign body 
response (FBR), is elicited (135). The interactions taking place between the implanted 
scaffold and its surrounding tissues significantly influence the ability of the scaffold to 
perform. This is described as biocompatibility (136). An appropriate host response 
must not only be local but also systemic, with an absence of cytotoxicity and 
carcinogenesis in addition to the ability of the scaffold to efficiently produce an 
osteoinductive response (136, 137). The innate defence system is a non-specific 
response that plays a crucial role in the early recognition and subsequent triggering of 
an inflammatory response to implanted scaffolds. The adaptive defence develops 
rapidly and efficiently to identify and respond to foreign materials that come in contact 
with the tissues, and is therefore referred to as specific or acquired (138). Scaffolds are 
associated with the innate immune response, and the adaptive response is only 
involved when they contain antigens (foreign proteins) that are recognised by the 
immune cells (139). The resultant tissue responses by the FBR are therefore quite 
complex, difficult to predict and involve both innate and adaptive immune cells with 
both short-term and long-term consequences (135, 137, 140). 
The acute inflammatory host response towards the implanted scaffold is the 
beginning of the FBR, mediated by the injury of tissue vasculature during implantation 
and the adsorbed layer of blood plasma proteins on its surface (141). Fibrinogen with 
leukocyte integrin activation recruits macrophages and polymorphonuclear leukocytes 
that control severity of the response (141). These activated phagocytic cells then 
release cytokines and chemokines, including IL-1, TNF-α, and monocyte 
chemoattractant protein-1, which causes leukocytes extravasation and attract 
fibroblasts (142). Macrophages play important roles in the host response by secreting 
an array of products, including proteolytic enzymes, free radicals, and reactive oxygen 
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species (ROS) that degrade the scaffold and thus affect the release of BMP-2 (142, 
143). They can also be differentiated towards pro- or anti-inflammatory phenotypes: 
M1 or M2 respectively (144). Macrophages have been shown to be capable of 
physiological osteoinduction by producing BMP-2, which promotes osteogenic 
differentiation of MSC in vitro (145). As the FBR progresses, the proinflammatory 
cells and cytokines decrease and macrophages express higher levels of anti-
inflammatory IL-10, IL-4 and IL-13, which have been shown to have a role in 
macrophage fusion to form foreign body giant cells (FBGC) and in the inflammatory 
suppression (146). Recruited fibroblasts contribute to the formation of a fibrous 
capsule surrounding the implanted scaffold, isolating it from the surrounding 
vascularisation which may impair osteogenesis (135). Improved fibrous capsule 
vascularity has been stimulated through the local sustained release of BMP-2 from 
scaffolds (147). 
 
1.6.2.1 The importance of the rate of degradation 
The long term host response to an implanted scaffold is affected by many factors, one 
of which is scaffold degradation (140) (Fig. 1.6). The optimal scaffold-based BMP-2 
delivery should degrade at a rate corresponding to the rate of tissue restoration while 
maintaining release of the appropriate concentration of the protein. Resolution of the 
FBR is essentially dictated by the degradation profile and the products of scaffold 
degradation. The degradation process of degradable aliphatic polyesters generally 
occurs in two phases in vivo. First, hydrolysis causes cleavage of ester bonds and 
decrease in molecular weight of the material. When the oligomers are removed, there 
is a loss of mass and mechanical strength (37). The second phase is characterised by 
FBGC releasing degradation enzymes and ROS that begin to engulf the breakdown 
(148).  
 
   




Figure 1.6 Foreign body reaction to a degradable scaffold. Schematic illustration of the inter-
related stages of early and late host response and bone regeneration after implanting a degradable BTE 
scaffold. Inspired and modified from (140) and made using Servier Medical Art. 
 
As the scaffold degrades, the acidic by-products, if not washed away, create an acidic 
environment shown to affect the inflammatory cytokines and neovascularisation and 
also to cause demineralisation of the bone formed (149). However, this acidity may be 
buffered by incorporating or coating polymer scaffolds with biomimetic agents (150). 
BMP-2 incorporated into a surface in polymer scaffolds coated with CaP compared to 
adsorbed directly onto the surface provided a slower, cell-mediated release as the 
scaffold degrades which was associated with a significant reduction of the 
inflammatory response, suppressing FBR and enhancing osteogenic potential (147, 
151). In a rat mandible defect model, acidity from degrading polymer scaffolds 
affected bone formation and accordingly a continuous supply of BMP-2 was required 
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to overcome the drawbacks (152). The delivery of immunosuppressive agents with 
BMP-2 has been shown to modulate host response and enhance osteogenesis (153).  
 
1.6.2.2 Host response and its long-term consequences 
There may be many long-term consequences of a FBR or when an inflammation gets 
out of control, but the most alarming is tumour formation. Based on increasing 
evidence, it appears that the cause of foreign-body sarcomas is not the chemical 
content of the biodegradable polymer alone, but also promoting events that lead to 
tumours due to prolonged presence of the irritant in tissues (154). The implantation of 
several materials in rodents can produce tumours. These effects have been described as 
solid-state carcinogenicity and it has been assumed that the mechanism is related to the 
development of the FBR (154). There has been an increasing emphasis on the role of 
inflammation on cancer (155). Irreversible genetic damage leads to a neoplastic state 
which, when exposed to chronic inflammatory chemokines, progresses through cell 
proliferation and reduced genetic repair (156). Chronic inflammation such as that seen 
with the prolonged presence of an implanted scaffold plays a promoting role. A study 
using p53 tumour suppressor gene deficient mice, where plastic discs were implanted 
subcutaneously, found that sarcomas developed in 79% of the mice with implants 
compared to those without. This was found to be associated with increased oxidative 
stress from chronic inflammation (157). Rats also developed a peri-implantation 
chronic inflammatory FBR reaction and a high incidence of malignant mesenchymal 
tumours in response to different implanted biomaterials (158).  
A thick fibrous capsule associated with a chronic inflammatory foreign body 
presence was frequently related to carcinogenicity, due to the acellularity and 
avascularity which render the environment susceptible for mutations with no repair 
(154). Foreign body carcinogenesis has a rare incidence in humans (159). In rodents, it 
contains stages that involve at least half its life-span, making it species-dependant 
(159-161). Although rarely encountered, it cannot be ignored and all new biomaterials 
require rigorous testing. Scaffolds are associated with many factors that influence host 
response, including the chemistry, ability to degrade, surface and bulk architecture 
(160, 161). In the case of the presence of a bioactive ligand such as in BMP-2 carriers, 
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the side effects can be attributed to uncontrolled release of high amounts of BMP-2. 
The observed increase in the cancer incidence remains a real concern for the 
carcinogenic potentials of BMP-2 (89, 92). Concern also arises for the safe delivery of 
BMP-2 from scaffolds when reconstructing bone defects caused by carcinomas, since 
both chronic inflammation as well as the effects of BMP-2 can have effects on areas 
prone to recurrence (94, 162, 163). Therefore, this necessitates long-term safety 
biocompatibility evaluations of a scaffold delivering BMP-2. 
 
1.6.2.3 Evaluating host response and its unwanted consequences 
Extensive assessments relevant to Standardisation and Regulatory Body Guidelines are 
commonly followed for biomaterial safety and registration purposes (164, 165). 
Assessments are primarily based on the evaluation of cytotoxicity, immune response, 
genotoxicity, mutagenesis and/or carcinogenesis, in addition to the primary function, 
which is, in the current case, bone formation (166). In vitro cytotoxicity testing using 
direct contact with cell lines or elution of biomaterials into cell lines cultures has been 
used to make testing of BTE scaffolds reproducible (45). Although many complex in 
vitro cell culture models have been employed, animal testing is still considered to be 
the most reliable system. In vivo evaluation of immune response typically uses rodents, 
where the scaffolds or biomaterials are implanted subcutaneously, intramuscularly or 
in the bone itself, and evaluated after various time points. Depending on the 
degradation rate of the scaffold tested, sample harvesting between 6-12 months may be 
used to allow time for degradation, regeneration and remodelling to take place (167). 
Organ and body weights and blood biochemistry all serve as evaluation tools (168). 
Histopathology has been the gold standard, however, traditional histological 
evaluation is unable to identify the dynamics between different cell types.  
Therefore, real-time non-invasive models to monitor inflammatory host response 
have been developed recently. A model to measure the release of ROS which were 
found to be involved in early and late FBR to evaluate biocompatibility using 
bioluminescence has been reported (148). Another model using a fluorescence 
imaging probe system that allows the assessment of the recruitment and interactions 
between polarised M1 and M2 macrophages has recently been developed (169). 
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Biomaterials used in fabricating tissue engineering scaffolds and drug delivery were 
used to develop the model and find approaches that optimised macrophage response 
(169, 170).  
In vitro genotoxicity and mutagenicity utilising proto-oncogenes and tumour 
suppressor genes from mammalian or bacterial cells exposed to biomaterials of interest 
have been used as methods for evaluating chromosomal damage (166, 171). 
Carcinogenicity or tumorigenic potential of biomaterials in general is typically tested 
in rodent 2-year cancer bioassays (160, 161, 172). However, these assays are no longer 
the only efficient or feasible way to detect possible human carcinogenicity; alternative 
mouse models are now available for increased sensitivity (172-174).  
Few reports of scaffold constructs tested in vivo for carcinogenicity currently 
exist, as this is more commonly done for physical materials or chemicals. Bioglass-
polylactic acid composite scaffolds populated with progenitor cells were evaluated in a 
rat calvarial critical size defect and tumorigenicity potential was evaluated based on 
the activity in serum of the free radicals involved in tumorigenicity (168). Carbon 
nanotubes, another type of scaffold, have been tested in rasH2 mouse models 
expressing human-derived c-H-ras proto-oncogene (175). Non-invasive real time 
methods have not been developed to monitor carcinogenesis in response to 


















   
Bioactive copolymer scaffolds  
30 
 
1.7  RATIONALE 
Previous efforts from our research group examined degradable aliphatic polyester 
porous scaffolds, poly(LLA-co-CL) as candidates for BTE. These scaffolds showed 
cytocompatibility (45) and encouraging potential for osteoconductivity (16, 44). Also, 
attempts to enhance their mechanical properties (52) and wettability by modifying the 
surface with nDP improved cellular responses and bone formation (54). 
Functionalising these copolymer scaffolds and immobilising BMP-2 could augment 
their osteoinductive properties. The development of more effective, sustained and 
controlled scaffold-based BMP-2 delivery systems in the near future is crucial. 
Enormous efforts have been made in recent years in this field in order to overcome 
side effects, however, optimal controlled release and a sustained therapeutic 
concentration has yet to be attained.  
Several aspects will need to be considered concerning the efficacy of the bioactive 
scaffold. The scaffold and mode of growth factor delivery determines the efficacy of 
the bioactive scaffold; i.e. bioactivity, release kinetics, biocompatibility and 
degradability. Evaluation of these requires an understanding of inflammatory and 
regenerative tissue responses as the scaffold degrade. The host response to a bioactive 
scaffold may lead to the development of responses that adversely affect the host 
tissues, thus early and late host responses to degradation of these functionalised 
scaffolds will direct their success or failure. Validated animal models need to be 
developed together with in vitro models, to facilitate investigations of long-term 
responses.
  





The aim of the work described in the following chapters was generally to determine 
efficient modes of delivering bioactive signalling molecules from copolymer scaffolds 




1 To determine the release profile and efficacy of recently developed and 
established functionalising techniques for delivering BMP-2 from poly(LLA-co-
CL) scaffolds (Paper I). 
 
2 To evaluate the in vivo host response and degradation of functionalised bioactive 
poly(LLA-co-CL) scaffolds (Paper II). 
 
3 To develop a non-invasive in vivo model to evaluate the tumorigenic potential of 
scaffolds used in tissue engineering (Paper III). 
 
4 To assess the tumorigenic potential of functionalised bioactive poly(LLA-co-CL) 










3. METHODOLOGICAL CONSIDERATIONS 
3.1 THE CHOICE OF METHODS 
To evaluate a bone regenerating scaffold while observing active bone formation and 
preventing adverse effects, clinically-relevant in vivo environments are strongly 
required. Despite the criticism of in vivo research due to ethical and economic reasons, 
this helps to evaluate complex interactions between different cells, growth factors and 
scaffold biomaterials. The methods used in the four papers are summarised in Fig. 3.1. 
In Paper I, in vitro and in vivo methods were used to evaluate the bioactivity of 
BMP-2 incorporated on copolymer scaffolds using four different modalities. The 
relative release of the incorporated BMP-2 was quantified using SRM. Assays were 
performed in order to confirm that the scaffolds supported MSC attachment, 
cytoskeletal re-organisation and proliferation. Furthermore, differentiation of MSC 
cultured on the different scaffolds in vitro was evaluated at the mRNA level. The 
effects of the different modes of delivery on the scaffolds’ osteoinductivity were 
compared in a rat mandible critical-size defect. Based on data obtained from Paper I, 
the most distinctive BMP-2 functionalising modality was chosen to conduct the 
following investigations where effects of nDP modification and BMP-2 physisorption 
on copolymer scaffolds on their degradation and host response were determined using 
Balb/c mice (Paper II). Molecular weights of the degrading scaffolds were analysed 
after 1, 8 and 27 weeks. Correspondingly, host response was evaluated using a 
customised RT2 Profiler PCR Array and infiltration of inflammatory cells was 
quantified in H&E sections. To investigate potential harmful properties of the 
functionalised bioactive scaffolds, the tumorigenic potential was evaluated. For this 
purpose, a non-invasive BLI microenvironmentally-induced oral carcinogenesis model 
was first established using NSG mice in Paper III. Early neoplastic oral keratinocytes 
(DOK) were first transduced with luciferase (DOKLuc) and cultured with or without 
CAF to develop the model. To confirm that the DOK phenotype was preserved after 
transduction, the development of tumours from orthotopic and ectopic xenografts of 
DOKLuc or DOKLuc+CAF inoculations was monitored manually and by BLI.  
  






Figure 3.1. Schematic summary of the study designs used in the four studies. Figure made using 








Development of tumours from DOKLuc grown on poly(LLA-co-CL) scaffolds under 
different microenvironmental cues was monitored non-invasively by BLI. In Paper 
IV, the in vivo model established as part of this thesis was applied to study the 
tumorigenic potential of copolymer scaffolds modified with nDP and nDP plus 
physisorbed BMP-2, and tumour formation was followed with BLI for 14 weeks. 
Harvested tumours were evaluated immunohistologically. Also, after being cultured on 
modified and non-modified scaffolds, DOKLuc were evaluated by functional in vitro 
tumorigenicity assays including a 3D organotypic model. 
 
3.2 SCAFFOLD FABRICATION  
The poly(LLA-co-CL) was synthesised from 75 mol % LLA (Boehringer Ingelheim, 
Germany) and 25 mol % ε-CL (Sigma-Aldrich, , St Louis, MO, USA), by ring opening 
polymerisation at 110oC for 72h using stannous 2-ethylhexanoate as catalyst and 
ethylene glycol as the initiator. The composition was determined by proton nuclear 
magnetic resonance spectrometry (Bruker AC 400, Bruker, Switzerland). Poly(LLA-
co-CL) with about 25 mol% ε-CL provides amorphous, elastic physical properties 
which makes it suitable for cell applications (42). The polymer number average 
molecular weight (Mn) was measured on a Verotech PL-GPC 50 size-exclusion 
chromatography system (SEC) (Polymer Laboratories, Varian Inc., USA) described in 
Section 3.6. 3D porous scaffolds were prepared by the solvent-casting particulate-
leaching method described earlier (16). Briefly, the copolymer was dissolved in 
chloroform (1g/ml) and mixed with sodium chloride particles by a weight ratio of 10:1 
before being poured into moulds. Scaffolds were punched out in different dimensions. 
Salt particles were removed by soaking in deionised water and then scaffolds were 
vacuum dried and electron beam sterilised. Scaffold porosities were characterised 








3.2.1 Scaffold functionalisation and BMP-2 immobilisation 
rhBMP-2 expressed in Escherichia coli (E. coli) was produced and obtained from our 
collaborator at The University of Wuerzburg, Germany as described previously (176). 
In (Paper I, II and IV), poly(LLA-co-CL) scaffolds were modified to deliver BMP-2 
using different modalities as follows: 
 
3.2.1.1 Physisorbed BMP-2 on unmodified scaffolds (PHY scaffold)  
A total of 1 μg of BMP-2 in 50 μl phosphate buffered saline (PBS) (Gibco, Thermo 
Scientific, MA, USA) was added in two increments onto the unmodified poly(LLA-
co-CL) scaffolds. 
 
3.2.1.2 Physisorbed BMP-2 on scaffolds modified with nDP (nDP-PHY scaffold)  
Detonation nDP were purchased from Gansu Lingyun Corp. (Lanzhou, China), acid-
purified and dispersed according to previously described protocols (117). The particles 
were attrition milled with micro-sized zirconia beads producing particles of ~5 nm 
diameters. Mechano-chemical reactions during the milling produced particles with 
hydrophilic surface, containing oxygen-containing terminal groups detected by 
infrared spectroscopy. Scaffolds were then modified with the nDP solution (2% (w/v) 
by a vacuum technique described in Paper I. Later, physisorption of BMP-2 on the 
nDP modified scaffolds was carried as Section 3.2.1.1. 
 
3.2.1.3 Scaffolds modified with nDP covalently functionalised with BMP-2 (nDP-
COV scaffold)  
First nDP were functionalised with benzoquinone by adding 189 mg of de-
agglomerated nDP in 20 ml of PBS (pH 8) and 150 mg of benzoquinone (1.38 mmol) 
(VWR International, Radnor, PA, US) for 24h at room temperature. This was followed 
by the immobilisation of BMP-2 to the functionalised nDP in PBS (pH 6) for 24h. The 
scaffolds were then finally modified with the functionalised nDP by the vacuum 
technique.  
  




After the reaction of functionalising the nDP with BMP-2, which corresponds to a 
loading of 0.5 mg BMP-2 per 1 g of nDP (approx. 19 nanomoles/g), the supernatant 
solution was found not to contain any organic material (checked by thin layer 
chromatography and infrared). It can thus be assumed that all of the BMP-2 was bound 
to the diamond surface, likely due to the large excess of reactive diamond surface 
moieties. This amount is too small to be analysed by quantitative methods, as the 
expected changes are within the error range of the instruments.  
 
3.2.1.4 Microsphere preparation and scaffold modification (MICS scaffold)  
It has been shown that the properties of the microspheres have a major effect on their 
efficacy (36). PLGA was chosen owing to its biocompatibility and FDA approval. The 
molecular weight of PLGA5050 purchased was very close to that used in a previous 
report (108). BMP-2-loaded PLGA5050 (Purac Biochem, Gorinchem, Netherlands) 
microspheres were fabricated using a previously described water-in-oil-in-water 
double emulsion solvent extraction technique, detailed in Paper I. The microspheres 
were incorporated into the porous scaffold using a seeding technique (177). The 
loading efficiency of the microspheres was determined using a solvent-extraction 
technique (178) and the concentration of BMP-2 was analysed by a commercially 
available human BMP-2 enzyme-linked immunosorbent assay (ELISA) (RnD 
Systems, Minneapolis, Minnesota, USA). With an evaluated loading efficiency of 
0.04%, the amount of microspheres needed to contain exactly 1 μg of BMP-2 was 
calculated. The morphology and distribution of microspheres in the scaffolds were 
examined using scanning electron microscope. 
 
3.3 CELL SOURCE AND MAINTAINENCE  
3.3.1 Cell culture 
3.3.1.1 Primary human MSC  
Primary human MSC (StemCell™ Technologies, Vancouver, BC, Canada) were 
expanded in MSCGM™ complete medium (Lonza, Basel, Switzerland). Passages 3 to 
6 were seeded (2×105 cells per scaffold). Once they reached confluence, the medium 
  




was replaced with osteogenic medium (Paper I). MSC cultures were performed in a 
minimum of triplicates and the experiments were repeated three times. 
 
3.3.1.2 Human osteoblast-like cells (HOB)  
HOBs were used as a positive control for the in vitro mineralisation staining in Paper 
I. They were isolated using a protocol that has been previously described (179). They 
were maintained in the alpha modification of Minimum Essential Medium 
supplemented with 1% antibiotic and 10% Foetal Calf Serum (FCS) (all from Gibco). 
 
3.3.1.3 Early neoplastic, dysplastic oral keratinocytes (DOK)  
Transformed, non-tumorigenic DOK were purchased from The European Collection of 
Cell Cultures (Salisbury, Wiltshire, UK) (180) and were routinely maintained in 
Dulbecco’s Modified Eagle’s Medium (DMEM), 10% FCS, 20μg⁄ml L-glutamine and 
5μg⁄ml hydrocortisone (all from Sigma-Aldrich). 
3.3.1.3.1 DOK cells as a screening tool for developing the tumorigenicity model 
Over 90% of head and neck cancers are, as are the majority of human malignancies, of 
epithelial origin and their consequences for patients are dramatic. In addition, most of 
the bone defects are due to resection of OSCC (181). Since scaffolds used for bone 
regeneration in the oral and maxillofacial area might come in contact with the oral 
epithelium and be influenced by their components, there is a need to study the 
potential carcinogenic effect of degradable bioengineered scaffolds on oral epithelial 
cells. In Paper III, we chose to develop an animal model with DOK cell line derived 
from premalignant oral mucosa (180). The use of normal cells in tumour models is 
time consuming and it is difficult to reproduce the several mutagenic events required 
for carcinogenesis in an experimental setting (155). DOK was established from a 
tongue dysplasia that progressed after 11 years into a well-differentiated OSCC. They 
were found to be partly transformed but non-tumorigenic in NUDE mice and our 
previous research on non-obese diabetic/severe combined immundeficient 
(NOD/SCID) mice (182) showed that DOK at a low density were tumorigenic only 
when co-inoculated with carcinoma associated fibroblasts (CAF). Spontaneously 
  




immortalised cells possess a more stable phenotype than virally immortalised cells. 
Thus they are preferred in models of tumorigenesis (183). 
3.3.1.3.2 Luciferase transduction of DOK  
The process of transducing DOK wild type (DOKWT) cells is explicitly described in 
the methodological paper (Paper III). Briefly, infectious retroviral vector particles 
were produced in Phoenix A cells (LGC Standards AB, Boras, Sweden) and  DOKWT 
cells transduced with a luciferase expressing construct, L192, coding for the luciferase 
enzyme and co-transduced with the tetracycline-regulated transactivator (tTA) (184) and 
gene transfer enhanced with protamine sulfate (5μg/mL) as previously described 
(Paper III). L192 has a puromycin resistance gene, so cells were selected with 1μg/ml 
puromycin (Sigma).  
Proliferation of transduced DOKWT and DOKLuc was compared using Methyliazol 
Tetrazolium Assay (Sigma). Both cell types, DOKWT and DOKLuc were seeded (1000 
cells/well) in 96-well plates (n=6). Cells were fixed every 24h for 7 days and the 
absorbance expressed as optical density using a microplate reader. 
 
3.3.1.4 Carcinoma associated fibroblasts (CAF) 
CAF were obtained from patients with oral cancer after informed consent and 
histologically confirmed OSCC lesions. They were isolated using the previously 
described explant technique (185). They were maintained in FAD medium 
(DMEM/Ham's F12 1:3 mixture, 1% L-glutamine, 0,4μg/ml hydrocortisone, 50μg/ml 
ascorbic acid, 10 ng/ml EGF, 5μg/ml insulin and 20μg/ml transferrin and linoleic acid 
(all from Sigma), with 10% FCS. 
CAF were characterised by fluorescence-activate cell sorting for expression of 
lineage-specific markers such as: epithelial specific antigen 0.00%, leukocyte marker 
CD45 0.02%, endothelial cell marker CD31 0.09%, pericyte marker/MSC marker 
CD146 1.48% and mesenchymal markers: CD140b 95.67%. Immunohistochemistry 
carried on culture dishes showed expression of vimentin 99.5% and α smooth muscle 
actin 50.2% of cells. 
  




To collect the conditioned medium, medium from CAF at 70-80% confluence was 
replaced for 18-24h by serum-free DMEM (Sigma). That was then replaced with half 
the volume of their routine medium for another 24h before the conditioned medium 
was collected, centrifuged and filtered through 0.40 μm filters. 
 
3.3.1.5 Primary gingival fibroblasts (GF) 
GF were isolated from samples of normal human oral mucosa of individuals with no 
clinical signs of inflammation at time of undergoing third molar extraction after 
informed consent. They were isolated using the explant technique protocols previously 
described (185). They were maintained in DMEM high glucose + 10% FCS (Sigma). 
 
3.4 QUANTIFYING THE RELEASE OF BMP-2 FROM SCAFFOLDS  
Selected reaction monitoring (SRM) was used to relatively quantify the release 
kinetics of BMP-2 in Paper I. The scaffolds were immersed in PBS at dynamic 
conditions and the supernatant was collected and replaced at determined time points up 
to 70 days. Briefly, the SRM strategy involved quantitative comparison of endogenous 
peptides and a spiked-in peptide standard, referred to as light and heavy peptides 
respectively, to determine the relative abundance of the protein. The method consists 
of a triple quadrupole (QQQ) mass spectrometer, as illustrated in Fig. 3.2. The mixture 
was subjected to digestion and the proteolytic peptides exposed to liquid 
chromatography (LC) and electrospray ionisation (ESI). The heavy and the light 
peptides were eluted with the same retention time from the LC column. In the QQQ, a 
predefined precursor peptide (the light and heavy forms of the signature peptide 
respectively characterised by different masses) is selected and isolated in Q1. In Q2, 
the collision energy produces charged fragments of a target peptide and in Q3 
predefined fragment ions selected by mass are transmitted for detection. A 
chromatogram shows retention time and signal intensity for each transition. 
rhBMP-2 (residues 283-396) expressed in E. coli was purchased (RELIATech 
GmbH, Wolfenbüttel, Germany). A preliminary step in SRM strategy consists of 
choosing a peptide that is ideal for SRM method based on specific criteria. An ideal 
  




SRM peptide has to be present in a unique form for the targeted protein and post-
translational and chemical modifications must be considered (186). To choose the 
peptide, the protein was digested and run in a mass spectrometer (MS), after which 
each peptide with a specific mass was fragmented in MS-MS (Orbitrap, 
ThermoScientific). The four representative peptides of BMP-2 that showed high 
intensities in the MS spectrum were tested in SRM mode.  
rhBMP-2 expressed in E.coli is a small protein of no more than 13 kilo Dalton 
molecular mass as monomer, so due to a short protein sequence (total 114 amino acid 
residues) the number of tryptic peptides was limited, with only 4 peptides providing 
strong specific signals. After testing all 4 peptides with direct infusion on 5500QTRAP 
for transitions status, it was found that only 1 peptide, NYQDMVVEGCGCR, 
revealed good transitions and was therefore selected for relative quantification of 
BMP-2. This peptide, is however, not optimal for absolute quantification as it contains 
2 cysteines (C) able to form inter- and intra-chain disulfide bridges. De-folding of 
protein by urea followed by carbamidomethylation of cysteine was performed in the in 
vitro SRM assay. The peptide contains glutamine (Q) and asparagine (N) residues but 
their conversion to aspartate and glutamate, depending on the surrounding sequence, 
would probably not occur (187). Therefore, it was selected as stable isotope-labelled 
internal standard (SIS) candidate as there was no better alternative. A SIS (heavy 
peptide) corresponding to that signature peptide was purchased in AQUA QuantPro 
quality (ThermoScientific). The C-terminal arginine for the SIS was labelled with 13C 
and 15N resulting in a peptide with 10 Dalton additional mass compared to the non-
labelled peptide. In addition cysteines were carbamidomethylated. In order to obtain 
the chosen peptide in a unique form, methionine residue had to be oxidised. 
The assay for detection of peptide was optimised by direct infusion on a Q-Trap 
5500 (AB SCIEX, MA, USA). SIS peptide NYQDMoxVVEGCcmGCcmR13C15N [25 
femtomoles (fmole)] were spiked into samples containing unknown amounts of BMP-
2. The mixture was lyophilised (Centrivap® Centrifugal, USA) prior to in-solution 
protein digestion according to a previously established protocol 
(http://www.uib.no/file-archive/in-solution-proteindigestion.pdf). Prior to liquid 
  




chromatography SRM-MS (LC SRM-MS) analysis, the mixtures of reduced and 
alkylated tryptic peptides were desalted as described previously (188). LC SRM-MS 
analysis was performed on a Q-Trap 5500 coupled to a Dionex Ultimate system 
(Thermo Scientific) as previously described (188). For quantification of the signature 
peptide from BMP-2, all y transitions with significant intensity were used to obtain 
ratio Light/Heavy (L/H).  
 
Figure 3.2 Schematic workflow of SRM-based proteomic experiment. A triple quadrupole (QQQ) 
mass spectrometer (Q-Trap). Figure modified from (186).  
 
3.4.1 Optimising the use of MS as a method for assessing release of BMP-2 
ELISA is the most commonly used method for detecting protein release from scaffolds 
(189), provided the amount is within the detection range. The BMP-2 Quantikine 
ELISA kit (RnD) was used initially when designing the study, but no BMP-2 could be 
detected. Kits commonly used, detect mammalian BMP-2 which is glycosylated, and 
the rhBMP-2 used in this study is bacterial BMP-2 and thus non-glycosylated. Protein 
labelling techniques to quantify fluorescence have been employed previously but 
unreliable release profiles have been encountered because they depend on the 
fluorophore tagging which in return depends on its dissociation factor (95). Using 
radiolabelled proteins commonly radioactive 125Iodine requires adjusting for 
radioactive decay and accompanying risks and drawbacks of radioactivity are not 
sustainable for longer periods (190). Hence, to quantify low abundant amounts 
released for a long period a highly sensitive, selective and reproducible method was 
required. SRM was thus chosen as a new strategy for quantification of BMP-2. We 
tested 3 assays (series) with slightly different SRM methods and progressively 
improved the ability to measure the release of BMP-2. 
  




In all triplicate samples (series), the heavy signature peptide with the following 
sequence NYQMVVEGCGCR was spiked in samples with endogenous BMP-2. 
However, in the first run, the heavy signature peptide was NYQMVVEGCGCR with 
labelled R and spiked-in in the amount of 5 fmoles. In the second run, due to the fact 
that the signature peptide contains a methionine (M), making the side chain of the 
amino acid prone to oxidation, the heavy signature peptide used was not only labelled 
on R, but in addition synthesised with M oxidised (Mox) NYQMVVEGCGCR and 
spiked-in in the amount of 5 fmoles. In this assay, M residues from the endogenous 
samples were oxidised in vitro. In third run, an assay similar to that described in the 
2nd was performed, with the exception that 25 fmoles (instead of 5 fmoles) of heavy 
peptide were spiked-in, in order to obtain more robust results and because the SIS 
peptide should be added to the sample in amounts corresponding to the endogenous 
peptide levels. All 3 series analysed with slightly different SRM conditions revealed 
comparable profile of BMP-2 release from the different scaffolds (data not shown). 
Finally, in an attempt to obtain not only a relative quantification of BMP-2 
expressed as ratio (L/H), but an absolute quantification of BMP-2, standard curves 
were generated alongside our analyses of series samples. Values of peak area for 
various samples (heavy peptide with Mox spiked in various amount of synthetic light 
peptide with Mox) prepared for the standard curve were highly reproducible under our 









Figure 3.3 SRM standard curves generated. Standard curve performed with spiked-in 25 fmoles 
heavy peptide in various amount of synthetic L peptide NYQDMVVEGCGCR. Data (blue, red) from 
2 experiments performed on different occasions. 
 
Data from various analyses (different colours in Fig. 3.3 correspond to experiments 
performed on different days) show good correlation and a relatively good linearity, 
arguing for reproducibility using our developed method and parameters for SRM assay 
and encourage efforts for future absolute quantification. The slight discrepancy may be 
attributed to the fact that the SIS could not be synthesised by the manufacturer in the 
quality required for absolute quantification.  
The SRM work was carried out in collaboration with the Proteomics Unit (PROBE) 
with the help of Dr. Anne P. Døskeland. 
 
3.5 INVESTIGATING OSTEOINDUCTIVITY AND HOST REPSPONSE  
3.5.1 In vitro experiments 
3.5.1.1 Cell attachment and mineralisation  
Attachment and spreading of MSC on the scaffolds at days 1 and 3 post-seeding in 
Paper I were analysed by scanning electron microscopy (Jeol JSM 7400F, Tokyo, 
Japan). To evaluate the mineralisation in the scaffolds as evidence of MSC developing 
an osteogenic phenotype and depositing calcium, the MSC /scaffold constructs were 
harvested after 1 week culture and stained with Alizarin red (2%). 
  




3.5.1.2 Real-time reverse transcribed polymerase chain reaction (PCR) and PCR 
Array  
Total RNA was isolated from in vitro cultures (Paper I) and in vivo samples (Paper 
II) using a Tissue RNA isolation kit (Maxwell®, Promega, Madison, WI, USA). 
Quantity and purity were checked using a Nanodrop spectrophotometer 
(ThermoScientific, Wilmington, Delaware, USA). Total RNA was reverse transcribed 
according to the manufacturer's instructions using the High-capacity complementary 
DNA Reverse Transcription Kit (Applied Biosystems, Carlsbad, CA, USA) in Paper I 
and reverse transcribed according to the manufacturer’s instructions using the Rt2 PCR 
Array First Strand Kit (SABiosciences, Hilden Germany) in Paper II. Quantitative 
real time PCR was conducted on a StepOne Plus system, using TaqMan gene 
expression assays (Applied Biosystems) (Paper I) and a customised Rt2 Profiler PCR 
Array (Superarray Bioscience) was used and PCR was performed on a StepOne Plus 
system with Rt2 Real-time SyBR Green/Rox PCR mix (SABiosciences) in Paper II. 
Reference genes were glyceraldehyde 3-phosphate dehydrogenase (GAPDH) in Paper 
I and GAPDH, beta-actin, and beta-2 microglobulin in Paper II. 
 
3.5.1.3 ELISA  
MSC and scaffold culture constructs were incubated with RIPA buffer, 1×Halt™ 
protease and phosphatase inhibitor cocktail (all from ThermoScientific) to extract total 
intracellular protein and quantitate intracellular BMP-2. To measure the endogenous 
BMP-2 released extracellularly, culture medium was collected at week 1 and 3. 
Human BMP-2 ELISA Development Kit (Peprotech, Rocky Hill, NJ, USA) was used 
to measure extracellular and intracellular endogenous BMP-2 from MSC in Paper I. 
 
3.5.2 In vivo experiments 
3.5.2.1 Rat mandible defect model and subcutaneous ectopic mouse model  
Several critical-sized defect models have been described in the literature including 
calvarial defects (46) and long bone segmental defects (48), but none of them simulate 
the specific microenvironment and masticatory stresses seen in the oral and 
  




maxillofacial area. An incision was made along the lower border of the mandible of 
male Sprague–Dawley rats (300–350 g) and after muscle retracting a round-shaped 
bone defect was created using a trephine burr (Komet Medical, Lemgo, Germany) (5 
mm diameter) in the mandibular angle region (Fig. 3.4 A, B). The defect was filled 
with a scaffold (n = 8 per scaffold type). Rats were sacrificed after 2 weeks.  
In Paper II, two (1 cm length) incisions were made on the back of 8-10 weeks old 
Balb/c mice (Fig. 3.4 C, D) (n = 4 scaffolds implanted per animal). Mice were 
sacrificed after 1, 8 and 27 weeks (n = 8 per scaffold type). 
 
Figure 3.4 Animal procedures to evaluate osteoinductivity and host response. (A) Anaesthetised 
rat through a custom-made mask and an incision along the lower border of the mandible showing a 
defect made in the mandibular angle region. (B) X-ray of a rat mandible showing the defect’s location. 
(C) Two incisions made in the back of a mouse and scaffolds being carefully placed. (D) Dissection of 
a mouse after 1 week showing distribution of 4 scaffolds distributed in the subcutaneous scaffold 
implantation model.  
 
  




3.5.2.2 Histologic and histomorphometric analysis  
All harvested samples were fixed in 4% paraformaldehyde (PFA) before they were 
decalcified. Paraffin embedded sections (3-4 μm) were stained with Masson's 
Trichome to confirm the osteoid-like tissue (Paper I) and stained with hematoxylin-
eosin (H&E) in Paper II. The amount of bone formation within the mandible defects 
(Paper I) was examined using micro-CT after 4 weeks (micro-CT 40, Scanco Medical 
AG, Bruettisellen, Switzerland). In Paper II, mineralised ectopic areas were evaluated 
within the scaffolds using micro-CT (Skyscan 1172) after 8 weeks.  
Qualitative and semi-quantitative histological evaluation was carried out to assess 
the host response to implanted scaffolds based on the morphology of infiltrating 
inflammatory cells and connective tissue surrounding the scaffold area in Paper II. 
H&E sections were evaluated in six fields of vision (magnification 40×) using a 
modified scoring system (150) by two blinded examiners. The H&E sections were also 
visualised with an ultra-resolution imaging system (CytovivaTM 130, Auburn USA) to 
identify nanodiamond particles still present in the implantation site. 
 
3.6 CHEMICAL ANALYSIS OF DEGRADING SCAFFOLDS  
In Paper II the Mn of the scaffolds degrading in vivo, after 1, 8 and 27 weeks, was 
analysed after dissolving the harvested scaffolds in chloroform. Mn were recorded by 
SEC on a Verotech PL-GPC 50 (Polymer Laboratories, Varian Inc., MA, USA), with a 
refractive index detector and two Polar-Gel-M organic SEC columns (300×7.5 mm) 
from Varian Inc. Samples were injected using chloroform and the system was 
calibrated against a narrow polystyrene standards. The decrease in Mn was calculated.  
 
  




3.7 NON-INVASIVE MICROENVIRONMENTALLY-INDUCED ORAL 
CARCINOGENESIS: AN IN VIVO BLI MODEL 
3.7.1 In vivo experiments 
3.7.1.1 Orthotropic and ectopic cell inoculation and tumour measurements  
The tumorigenic potential of human cells in an animal can be tested only in an 
environment which favours tumour development, hence the need for immunodeficient 
animals. In this context, non-obese diabetic severe combined immunodeficient 
IL2rgnull (NSG) mice with multiple immunological dysfunctions provide a high 
engraftment level for xenografts and more rapid tumour formation and progression 
than less immunodeficient mice (191). The cell inoculation method in orthotopic and 
heterotopic sites was used in Paper III to assess the tumorigenic potential of DOK 
before and after cell transduction with luciferase and the effect of co-inoculation with 
CAF. This method was also used to assess the sensitivity of bioluminescence imaging 
(BLI) to differentiate between tumours formed by different strains of CAF.  
Both DOKWT and DOKLuc were cultured and allowed to reach their log phase 
before they were suspended in 50 μl of growth factor reduced matrigel (BD 
Biosciences, San Jose, CA, USA). The cells were inoculated at two different densities, 
low (1×103) and high (1×105), in the tongue (Fig. 3.5 A) and subcutaneously in the 
back of 8-10 weeks old male NSG mice (University of Bergen, Norway) (n = 6 per 
group).  
To create a positive tumour formation control as a reference, 1×103 DOKWT were 
suspended with 1×105 CAF in 50 μl matrigel and co-inoculated in the tongue (n=6 per 
group). To assess the sensitivity of BLI to differentiate between tumours formed by 
different strains of CAF, DOKLuc (1×103) were co-inoculated with 1×105 of one of two 
different strains of CAF (CAF15_13 and CAF15_23) in the tongue (n=6 per CAF 
strain). The development of the tumours formed was followed manually by digital 
calliper (Fig. 3.5 B) and by BLI weekly for approx. 45 days. The tumour volumes 
from inoculations were calculated using the formula: Volume = [length × (width2)/2] 
  




(192). In addition, the tumour areas were calculated from areas of interest in H&E 
sections using Olympus DP Soft 5.0 software (Munster, Germany). 
  
3.7.1.2 Scaffold xenotransplantation subcutaneously and optical in vivo imaging  
The scaffolds were first pre-wet with DOK medium before being seeded with DOKLuc 
alone or DOKLuc+CAF and then allowed to attach overnight. Three different densities 
of DOK were used (1×103), (1×105) and (1×106) in Paper III and in Paper IV the 
density was only (1x104). The density of CAF was fixed to 1x105 in all experiments. 
The different densities were distributed among all mice (n = 6) in Paper III and in 
Paper IV n = 6 per each scaffold type. The same subcutaneous operating procedure as 
in Section 3.5.2.1 was followed but only 2 scaffolds were implanted into each NSG 
mouse, one scaffold with DOKLuc alone and the other with DOKLuc+CAF. At 12 weeks 
(Paper III) or 14 weeks (Paper IV) animals were euthanized and scaffolds harvested.  
To monitor tumour formation in vivo non-invasively, mice were depilated and 
scanned 10 min after intraperitoneal injection with 150 mg/kg of D-luciferin (Biosynth 
AG, Staad Switzerland) (Fig. 3.5 C). Images were captured using In Vivo MS FX PRO 
(Carestream Health Inc. Rochester, NY) and analysed using Carestream MI SE version 
5.0.6.20. For the bioluminescent reaction to happen: the catalyst enzyme (luciferase) 
and the luciferase substrate (D-Luciferin) are needed. The general mechanism is the 
decarboxylation of the luciferin in the presence of oxygen to produce light. 
 
Figure 3.5 In vivo cell inoculation and optical imaging. (A) Inoculation of DOK into the tongue of 
an NSG mouse under gas anaesthesia. (B) Manually measuring a subcutaneous tumour 8 weeks post-
inoculation using a calliper. (C) Intraperitoneal injection of a depilated mouse with D-luciferin. 
  




3.7.1.3 Immunohistochemistry of tumour xenotransplants 
In Paper III and IV, 3-4 μm paraffin sections of tumour xenotransplants were stained 
with H&E (Sigma). Immunostaining of xenotransplants was also performed on 
paraffin sections as follows (Table 3.1). All bound reactions were visualised using 3, 
3’-diaminobenzidine tetra hydrochloride. 
 
Table 3.1 Immunostaining of tumour xenotransplants. 
Primary antibody Dilution Manufacturer Paper 
Monoclonal Mouse Anti-human p53 1:50 Dako III 
Monoclonal Mouse Anti-human Vimentin 1:1000 Dako III 
Monoclonal Mouse Anti-human Involucrin 1:500 Novocastra IV 
 
3.8 FUNCTIONAL IN VITRO TUMORIGENICTIY ASSAYS  
3.8.1 In vitro assays 
In paper IV, DOKLuc (2.5×104 per scaffold) were cultured on 3 different scaffolds: 
unmodified poly(LLA-co-CL) scaffolds (CL scaffold), poly(LLA-co-CL) scaffolds 
modified with nanodiamond particles (nDP scaffold) and nDP scaffold plus 
physisorbed BMP-2 (nDP-PHY scaffold) for 1 week. After seeding adherent cells like 
DOK in copolymer scaffolds, extracting viable cells required a careful optimising 
procedure. Several concentrations of Trypsin/EDTA (Sigma) were used along with 
several initial seeding densities and culture days as well as methods of manipulating 
and cutting the scaffolds. The final protocol involved adding warm (0.25%) 
Trypsin/EDTA followed by plate vortexing for 30s followed by incubation for 5min. 
The plate was removed for mechanical trypsinisation before further incubation for 
3min. Supernatant was removed and the trypsin was then deactivated with FCS in a 
separate tube to prevent clumping of cells in the scaffold. The DOKLuc trypsinised 
from the different scaffolds were allowed to propagate before they were subjected to 
the following in vitro functional tumorigenicity assays: 
  




3.8.1.1 Transwell migration assay 
A cell’s migratory and invasive behaviour is a surrogate measure, used to evaluate its 
tumorigenic and metastatic potential (155). Inserts (8 μm, Corning Incorporated, NY, 
USA) were used in 24-well plates (Nunc, Roskilde, Denmark). The DOKLuc were 
allowed to migrate against one of 2 gradients; (1) high serum or (2) conditioned 
medium from CAF (in a 1:1 mix with fresh routine culture medium). The DOKLuc 
extracted from the scaffolds were re-suspended in DOK medium and seeded on top of 
the insert. The lower chamber contained either DOK medium with 20% FCS or 
conditioned medium from CAF (Fig. 3.6 C). After 18-20h, the cells were fixed and 
stained with DAPI (1:1000). Inserts were imaged to count migrated cells using a 
fluorescence microscope (Nikon TE 2000, Nikon, Japan). 
 
3.8.1.2 Sphere formation assay  
This assay tests the ability of a cell to grow independent of anchorage, giving an 
understanding to its renewal potential and resistance to anoikis and hence its 
tumorigenic potential. Plates (48-well) were coated overnight to obtain the non-
adherent surface with 1% solution of poly 2-hydroxyethyl methacrylate (Sigma) in 
95% methanol. DOKLuc were seeded (500 cells per well) in 500 μl of FAD medium + 
10% matrigel (BD Biosciences). The cells were allowed to grow for 21 days and the 
spheres with diameter > 40 μm were counted. 
 
3.8.1.3 3D Organotypic cultures (3D-OT) 
Organotypic culture help overcome the limitations of 2D culture which lack complex 
microenvironment, intercellular and dynamic interactions. These models have been 
considered as high throughput preclinical models in tumorigenesis (193), although 
they are limited by a short culture span (they can only last for approx. 12 days) and the 
lack of vascular and immune compartments. These limitations have been compensated 
for here by the parallel use of in vivo experiments.  
We attempted the reconstruction of an oral mucosa that mimics the primary tissue 
by co-culturing epithelial and mesenchymal (stromal) cells in a 3-D model. To assess 
the invasive potential of the DOKLuc extracted from the scaffolds, they were seeded on 
  




a matrix incorporating different types of fibroblasts (GF or CAF). CAF were used as a 
positive control for invasion, since a previous report from our group (182) showed that 
an oral cancer cell line underwent deeper invasion in organotypic cultures populated 
with CAF compared to normal oral fibroblasts. Using a well-established protocol in 
our laboratory (194), the fibroblasts were seeded on prepared collagen bio-matrices 
(constituents described in Paper IV) at a final concentration of 2.5×105 cells per 
matrix. They were incubated until the matrix solidified before adding the routine 
culture medium for the respective fibroblasts.  
One day later, DOKLuc extracted from the scaffolds were re-suspended in DOK 
medium and seeded on top of the collagen bio-matrices populated with fibroblasts at a 
concentration of 5×105 per matrix to re-construct the epithelial compartment of the 
3D-OT. After 2 days of co-culture, the OT were detached and lifted on a stainless steel 
metal grid to keep them at an air-liquid interface and cultured in serum-free OT 
medium (constituents described in Paper IV) (Fig. 3.6 A). Two thirds of the medium 
was changed every 2nd day and the 3D-OT were harvested after 10 days of co-culture 
and fixed.  
  






Figure 3.6 In vitro functional tumorigenicity assays. (A) Schematic diagram of reconstructing 
oral mucosa in a 3-D organotypic culture. (B) Measuring invasion of DOKLuc in the sectioned 3D-OT 
(red line). (C) Illustration of the transwell migration assay. Figure made using Servier Medical Art. 
 
Preliminary tests using different seeding densities were performed to optimise the 3D-
OT. In higher fibroblast densities the matrices were found to contract earlier than 
expected preventing the fibroblasts from multiplying and at higher DOK seeding 
densities, it caused rolling of the 3D-OT from the sides. The best architecture was 
found from 3D-OT made of GF in densities mentioned above. 
 
3.8.1.4 Histomorphometry and immunohistochemical quantification of 3D-OT 
Paraffin sections of 3D-OT (3-4 μm) were stained with H&E (Sigma) for measuring 
invasion using the software Olympus DP.Soft 5.0. The sections were imaged and 
analysed for invasive capacity. Briefly, in the section, the central and the two outer 
parts of the 3D-OT were excluded because these areas were usually found to show 
  




variable invasion since they are the focal points of the matrix handling and seeding of 
DOKLuc. The depth of invasion was determined every 100 μm from a line drawn 
through the upper remnants of the collagen bio-matrix towards the epithelium (Fig. 3.6 
B). This line was considered to represent the original, upper level of the collagen bio-
matrix and thus the basement membrane. The depth of invasion was measured from 
this line to the deepest point of invading DOKLuc. Two areas per section were 
evaluated, with 3 readings per area.  
Immunostaining of 3D-OT was also performed on paraffin sections (Table 3.2). 
All bound reactions were visualised using 3, 3’-diaminobenzidine tetra hydrochloride. 
The open resource digital image analysis software ImageJ (v.1.46r) (National Institute 
of Health, USA) was used to count positively stained Ki67 cells. To quantify cells 
positively stained for involucrin, epithelial growth factor receptor (EGFR) and E-
cadherin cells, a plug-in IHC Profiler compatible with ImageJ was used for scoring 
(195). 
Table 3.2 Immunostaining of 3D-OT. 
Primary antibody     Dilution Manufacturer 
Monoclonal Mouse Anti-human Ki67 1:25 Dako 
Monoclonal Mouse Anti-human Involucrin 1:500 Novocastra 
Monoclonal Mouse Anti-human E-cadherin 1:3000 Dako 
Monoclonal Mouse Anti-human EGFR 1:1000 Dako 
EGFR, epidermal growth factor receptor 
 
3.9  STATISTICAL ANALYSIS  
All data are presented as the mean values together with either the standard deviation or 
the standard error of the mean or 95% confidence interval. For Real time RT-PCR 
analysis (Paper I), the comparative Ct method (2-∆∆Ct) was used to analyse data and 
One-way ANOVA was used followed by a multiple comparison Tukey test. The in 
vivo data (Paper I) were analysed with the Kruskal–Wallis test. PCR Array data in 
Paper II were analysed using the web-based analysis software RT2 Profiler PCR 
Array Data Analysis (v 3.5, Superarray Bioscience).  
  




In Papers III and IV, paired t-test or the independent Mann Whitney U tests were 
used to compare differences between the tumours. Spearman’s correlation was used to 
correlate the manual tumour measurements and histological measurements with 
corresponding BLI signals (Paper III). In Paper IV, significant difference in the 
sphere formation, depth of invasion between groups in 3D-OT, and significant 
difference in immunostaining quantification was tested using One-way ANOVA 
followed by a multiple comparison Tukey test. SPSS ver. 21/22 (IBM, NY, USA) was 
used for the evaluation and the level of significance was set to p < 0.05. 
 
3.10 ETHICAL STATEMENT  
All animal experiments were approved by the Norwegian Animal Research Authority 
and conducted in strict accordance with the European Convention for the Protection of 
Vertebrates used for Scientific Purposes (FOTS nos. 2012/4178, 2013/5042, 
2013/4643, 2012/3961 and 2013/5297). All animals were anaesthetised with isoflurane 
(IsobaVet®; Schering-Plough, Kenilworth, NJ, USA) combined with O2 and were 
euthanized with an overdose of CO2. The ethical approvals for OSCC patient samples 
and individuals undergoing third molar extraction samples were obtained from the 
Regional Committee for Medical and Health Research Ethics (REK # 2010/48 and 
REK Vest# 177.04). The samples were collected following an informed consent of the 
patients.  
 




4. MAIN RESULTS AND GENERAL DISCUSSION 
4.1 OSTEOINDUCTIVITY  
4.1.1 Osteogenic potential of a controlled, sustained release of BMP-2  
In Paper I, we investigated how the release and bioactivity of BMP-2 from copolymer 
scaffolds are affected by binding techniques. Four different functionalising techniques 
were used to immobilise a low dose of 1 μg rhBMP-2 on recently developed poly 
(LLA-co-CL) scaffolds. BMP-2 was either (i) physisorbed onto unmodified scaffolds 
(PHY), (ii) physisorbed onto scaffolds modified with nDP (nDP-PHY), (iii) covalently 
linked onto nDPs that were used to modify the scaffolds (nDP-COV) or (iv) entrapped 
in microspheres distributed on the scaffolds (MICS).  
BMP-2 administered in excess amounts in order to efficiently repair bone creates 
undesirable side effects which limits its therapeutic use (92, 94). In a clinical trial of 
alveolar cleft palates in children the high concentrations of BMP-2 delivered resulted 
in a significant amount of severe unwanted postoperative swelling (91). Furthermore, 
studies emphasised the necessity of using a controlled, sustained release of BMP-2 
within physiological and therapeutic limits for clinical success (196, 197). Hence it 
was fundamental to understand the release kinetics of the loaded BMP-2, before 
further bioactivity evaluations were initiated. The SRM method used was able to 









Figure 4.1 Release profile of BMP-2 from different scaffolds. Axis-(A) Relative amount released 
where 100% value corresponds to the highest value observed for the total amount of BMP-2 measured 
at a specific time point. Axis-(B) Release over time of BMP-2 from the different scaffolds expressed 
by the ratio (L/H) between endogenous light (L) and heavy synthetic (H) peptide spiked-in our sample. 
Figure reprinted with permission from Elsevier Ltd. (Paper I). 
 
The early time points gave a vivid depiction of the variation between the different 
modes of binding; the PHY scaffolds showed an initial burst of release followed by a 
drop and MICS showed a higher level of release starting at 24 h (compared to nDP-
COV and nDP-PHY scaffolds) and remained steady up to 7 days only. Passively 
adsorbed BMP-2, such as on the PHY scaffold, is the easiest way to load growth 
factors onto a carrier since it simply requires immersion in protein solution but has the 
disadvantages of uncontrolled release and short release duration caused by the burst 
release. This mode of delivery can be used when delivering multiple growth factors 
and wanting to tailor release onsets; i.e. wanting to initiate vascularisation first by a 
spurt of VEGF before commencing prolonged osteogenesis (198). This can be needed 
in cases where vascularisation is impaired, for example due to radiation therapy. 
However, for our purpose (Paper I) a prolonged controlled delivery of growth factors 
might be the best option since it promotes healing coordinated with the normal 
physiological expressions of these factors. It has also been proposed that the ideal 
pharmacokinetics for BMP-2 should include an initial burst first to recruit 
 




osteoprogenitor cells followed by sustained release to induce osteogenesis (199). 
Studies have shown burst followed by a sustained release of BMP-2 regenerated 50% 
more new bone than a collagen sponge loaded with BMP-2, whereas a sustained 
release without the burst did not enhance bone more than a scaffold without BMP-2 
(199). It seems reasonable that the delivery of BMP-2 ought to be based on the normal 
physiological microenvironment of bone, where it is an extended dynamic process. 
This would necessitate maintaining protein bioactivity in the carrier for a sustained 
release. The ideal time point of BMP-2 delivery has not been elucidated yet, but the 
increased expressions at 1 and 21 days after injury is remarkably useful (58, 96, 200). 
Several studies explored the spatiotemporal effect of BMP-2 delivery; some suggested 
that BMP-2 plays an important role in osteoinduction, especially at the early stages 
(201). However, there is evidence suggesting that sustained delivery of BMP-2 
enhances bone formation, attributed to its effect on a larger population of 
osteoprogenitor cells at the fracture site at later stages following injury (197).  
In comparison to the MICS scaffolds, the PHY scaffolds showed a smaller 
increase in release between days 21 and 40 than that seen from MICS, probably 
attributed to degradation of the scaffold and/or microspheres and liberating the low 
amounts entrapped (37). The difference seen between MIC and PHY scaffolds in 
amounts released suggests that perhaps not all the BMP-2 added to PHY scaffolds was 
able to be adsorbed. The nDP-PHY was seen to have a controlled release sustained in 
comparable low amounts compared to the other groups until the termination of the in 
vitro release experiment. In a rat tibia osteotomy model, sustained BMP-2 delivery 
resulted in enhanced mineralised bone healing and biomechanical properties at 84 days 
compared to BMP-2 delivered at much higher amounts released in a burst fashion 
(202). Also in line, a larger animal model showed efficient bone healing when using a 
slow sustained release of BMP-2 (203). In nDP-PHY, BMP-2 was strongly bound to 
the nDP, since protein interactions with nDP are known to be relatively strong  (204) 
(discussed further in Section 4.1.2).  
 
 




ALP expression is an early differentiation marker of the osteoblast phenotype and 
studies often test bioactivity of BTE scaffolds using ALP expression from cells in the 
osteoblastic lineage, considering it a robust cytochemical marker for mineralisation 
(205). Our findings of increased ALP mRNA in vitro at 3 weeks from cells on nDP-
PHY scaffolds in Paper I are in line with the significant increase in ALP mRNA 
expression (p = 0.014) from the first week for nDP-PHY implanted subcutaneously 
compared to nDP and CL scaffolds in Paper II. Osteosarcoma cells cultured on BMP-
2 treated O-NCD implant surfaces were reported to significantly increase ALP activity 
in less than 2 weeks of culture (119). Another study showed polyester carriers with 
hydroxyl terminals similar to those terminating nanodiamond particles used here 
promoted increased ALP activity in differentiating osteogenic cells (206). However, in 
Paper I, in vivo significance for ALP mRNA at 2 weeks was only demonstrated from 
MICS scaffolds compared to other osteogenic markers, but micro-CT and histology 
supported the interpretations and conclusions related to the comparable osteogenic 
potential of MIC, nDP-PHY and PHY scaffolds. The bioactive BMP-2 might have 
caused the recruitment of osteogenic progenitor cells from the local circulation, 
leading to the pronounced ectopic mineralisation in nDP-PHY scaffolds (Paper II) 
and de novo bone formation in the critical-sized mandible defect (Paper I). Previous 
reports have shown that a controlled local concentration of BMP-2 modifies the 
recruitment of osteogenic progenitor cells and regulates the formation of bone (207).  
mRNA of the potent osteogenic markers osteocalcin and BMP-2, was highly 
expressed from MSC grown on nDP-PHY and MICS scaffolds at week 1 and week 3 
in vitro and at week 2 in vivo, implying increased osteogenic potential in comparison 
to that seen from PHY scaffolds (Paper I). Confirmed by the in vitro mineralisation 
assay, nDP-PHY and MICS scaffolds demonstrated vast extracellular dark spots 
evident of calcium deposits in the matrix produced by seeded MSC while on PHY 
scaffolds which showed less extracellular matrix staining indicating lack of sustained 
mineralisation. Corroborating to this pattern in PHY scaffolds are the high levels of 
mRNA collagen type I, an early marker of bone formation, produced by cells in the 
PHY group in vitro as well as in vivo in Paper I. Release as a burst from PHY was 
 




perhaps above therapeutic threshold, and then rapidly declined to levels that were too 
low for effective mineralisation.  
The data from Paper I confirmed that nDP-PHY and MICS scaffolds showed 
both in vitro and in vivo evidence that a more controlled release is needed to induce a 
commitment to bone phenotype. Furthermore, the amounts released from nDP-PHY 
scaffolds were far less than from MIC, and release continued until 70 days with 
bioactivity also displayed in an ectopic model (Paper II). 
 
4.1.2 Effects of nanodiamond particles on the scaffold’s osteogenic potential 
Nanodiamonds are known to amplify surface areas due to their size, providing chances 
of surface functionality in addition to their biocompatibility, rigidity and chemical 
stability (115). The nanodiamond particles used to modify the poly(LLA-co-CL) 
scaffolds in this work increased hydrophilicity of the scaffold material via the 
previously described increased oxygen-containing groups which also facilitate strong 
binding of organic groups (114). Unpublished data from optimising experiments 
demonstrated a reduction from 119o contact angle on pure Teflon to almost <10o when 
modified with nDP. Poly(LLA-co-CL) scaffolds modified with nDP terminated with 
oxygen-containing groups produced composites that are not only mechanically 
reinforced (52) but also enhanced hydrophilicity and thus cellular responses and de 
novo bone formation in a sheep defect (54). Another study using titanium implant 
surfaces coated with O-NCD and physisorbed BMP-2 demonstrated enhanced bone to 
implant contact ratio which was not entirely due to the activity of BMP-2 since O-
NCD implants on their own, still improved healing when comparing the results (120). 
The nDP scaffolds without BMP-2 (Paper II) also showed enhanced osteogenic 
potential and this was in line with recent reports that showed cultivated osteoblast-like 
cells in O-NCD films exhibited a higher growth rate compared to hydrogen-terminated 
NCD, and supported more deposition of ECM proteins and ECM mineralisation (208). 
A study exploiting functionalised monolayers containing various surface chemistries 
demonstrated that the hydrophilic monolayers selectively permit osteoblastic 
differentiation, inhibiting adipocytic differentiation, while the positively charged 
 




monolayers supported both adipocytic and osteoblastic differentiation (209). The 
osteoconductivity demonstrated by our data can also be attributed to the difference in 
surface charge in the modified scaffolds that caused wettability, that in return 
modulates the absorption of cell adhesion molecules and proteins from the surrounding 
fluids in vivo (210, 211). O-NCD coating titanium implants bound BMP-2 physically 
by electrostatic interactions, van der Waals forces and hydrogen bonds (119), 
supporting the contention that nanodiamonds in nDP-PHY scaffolds express similar 
properties and bind  BMP-2 by increasing the magnitude of the electrostatic 
interactions between BMP-2 and the scaffold, which in turn decrease the initial burst 
release.  
Several drug delivery systems have been reported that take advantage of the 
unique nDP electrostatic surfaces, daunorubicin (anti-cancer drug), for instance, has 
been reversibly bound to nDP, providing a sustained and steady release profile in vitro 
and in vivo (212). The nDP conjugate (212) improved drug maintenance in target cells 
along with treatment safety. Acidic pH was found to be a trigger for the anti-cancer 
drug’s release from nDP and also shown to affect the release in another study where 
BMP-2 was delivered from nDP in suspension (122). In our release profile we 
demonstrated a slight increase in release kinetics from nDP-PHY scaffolds at day 40 
and this correlates with increase in the scaffold degradation (37) and the subsequent 
acidic environment may be caused by polymer hydrolysis.  
In addition to the results of Paper I discussed above, osteoconductivity from nDP 
modified scaffolds was further shown in a mouse ectopic model (Paper II) by virtue 
of mRNA levels of selected osteogenic markers. At week 1 nDP and nDP-PHY 
scaffolds expressed upregulated trends of osteogenic markers (such as RUNX2, 
Collagen type Iα2, Collagen type Iα1, BMP-2) compared to the unmodified scaffolds, 
CL. The effect of nDP modification was also underlined after physisorbing BMP-2 in 
this study. These osteogenic markers were more upregulated in nDP-PHY compared to 
the other two groups. In Paper II, BMP-2 receptors and transcripts’ activation in the 
host showed that the mRNA levels of BMPRIA and RUNX2 were upregulated in the 
nDP-PHY scaffold group at week 1, demonstrating conserved bioactivity of the 
 




physisorbed BMP-2 and indicating activation of the BMP signalling pathway and a 
consequent increase of osteogenicity (213).  
With regards to the nDP functionalising in nDP-COV (Paper I), this modification 
was not as successful as the nDP-PHY scaffolds. No BMP-2 release was detected 
during the course of the in vitro release experiment. Furthermore, reduced osteogenic 
potential both in vitro and in vivo was observed. This can be attributed to increased 
strength of the covalent immobilisation of the protein on the diamond surface, as was 
previously reported with enzymes (214). The loss of the BMP-2 functionality might 
also indicate that the protein was deformed during binding onto the nanodiamond 
surface by the covalent linker or the BMP-2 denatured during scaffold sterilisation, 
which had to take place after functionalising. BMP-2 engineered to irreversibly bind to 
titanium did not induce osteogenic gene expression in C2C12 cells compared to BMP-
2 that were reversibly bound to titanium surfaces (215). Nonetheless, nDP-COV can 
be improved to be a good modality for immobilising molecules that do not require 
release, for example adhesion molecules (216). In such circumstances, controlled 
release of adhesion molecules can be considered as the controlled provision of a 
bioactive molecule in its most appropriate state, not necessarily in a diffusible state. 
 
4.1.3 Importance of a controlled release of BMP-2 in low amounts 
Our release profiles from MICS and PHY scaffolds in Paper I showed a starting 
higher release followed by a sustained release but this soon increased again to very 
high levels compared to other scaffolds. The FDA approved BMP-2 carrier Infuse® 
delivers BMP-2 from an absorbable collagen sponge and shows a burst release profile, 
and complications have been reported due to uncontrolled release of high amounts 
(89). Reports underscored the importance of decreasing the dose of BMP-2 to the 
lowest level that is compatible with the desired degree of bone formation (217). Cells 
with osteogenic potential can be recruited and differentiated at low doses. In addition, 
the rapid release of BMP-2 may result in transient osteoclast-mediated resorption of 
newly formed bone whereas osteoclasts are transiently activated at high doses of 
BMP-2 (218). This was seen with the significantly increased in vivo expression of 
 




tartrate-resistant acid phosphatase (TRAP) and Cathepsin K (CTSK) in the MICS 
scaffolds followed by a high trend in PHY scaffolds for TRAP, which could cause 
resorption of bone before its maturation (Paper I). Another in vivo study using the rat 
femoral segmental defect model indicated that an increased concentration of BMP-2 
above a certain threshold did not improve bone healing and could actually promote 
lower bone quality with an abnormal structure and potentially inferior mechanical 
properties (219). It has been reported that high concentrations significantly inhibited 
Wnt signalling pathway activity by a dramatic increase in released inhibitory proteins 
that lead to potential toxicity and side effects such as decreased human periosteal cell 
proliferation and induced apoptosis (220).  
There is a large disparity in BMP-2 concentration between clinical and 
experimental use, with clinical trials using high doses of at least 1 mg BMP-2 per ml, 
and higher doses of BMP-2 mask differences in bone regeneration, as we have 
observed for different release profiles. The dose used in the present thesis, 1 μg, falls 
in the lower range used for osteogenic threshold in rodents with similar defects (221). 
However, it is important to be careful when extrapolating results across different 
animal models and sites. The protein on nDP-PHY was bioactive with comparable 
efficacy to MICS in vitro and in vivo despite being strongly bound to the carrier, 
holding greater promise compared to growth factors adsorbed onto a polymer in the 
PHY scaffolds. The osteogenicity observed in vivo with PHY scaffolds compared to 
other groups in Paper I is intriguing despite its burst release, but the current inability 
to control burst release within the therapeutic window makes us favour a more 
controlled sustained release of low amounts.  
Taken together from the data in Papers I and II of osteogenic importance, nDP 
modification of the poly(LLA-co-CL) scaffolds was found to enhance 
osteoconductivity. nDP modification also provided a platform for binding BMP-2 
strongly, allowing its sustained release in low amounts and rendering the scaffold 
osteoinductive. These attributes suggest they may provide ideal growth factor carrier 
characteristics and lead to further investigations into the characteristics of this scaffold 
 




and mode of BMP-2 delivery, including evaluating the host response during 
degradation as described below. 
 
4.2 DEGRADABILITY  
4.2.1 Degradation of functionalised poly(LLA-co-CL) scaffolds  
The degradation profile of unmodified poly(LLA-co-CL) porous scaffolds with similar 
compositions to those used in this work has been evaluated previously (37). In Paper 
II the effect on degradation of modifying these scaffolds with nDP or nDP and BMP-2 
was evaluated up to 6 months. Greater molecular weight loss was observed from the 
nDP and nDP-PHY scaffolds than from the CL scaffolds at time points 1, 8 and 27 
weeks. The data showed that after 27 weeks, all three scaffolds lost almost 90% of 
molecular weight. Hydrolysis is the main mechanism for the degradation of these 
synthetic polymers, where the speed and amount of water capable of diffusing 
throughout the polymer determines the degradation rate. The nDP used to modify our 
scaffolds has been shown previously to increase hydrophilicity due to the hydroxylated 
surfaces, thus absorbing water (115). A more hydrophobic scaffold, such as CL 
scaffold, will make it difficult for water to be absorbed. This promotion of hydrolysis 
may have increased polymer degradation seen in nDP and nDP-PHY scaffolds relative 
to unmodified counterparts at weeks 1 and 8. It has been reported that incorporating 
hydrophilic bioactive fillers such as TCP into hydrophobic polymers caused the 
composite PCL/TCP scaffolds to degrade faster than PCL homopolymer scaffolds in a 
6 months rabbit model. This acceleration in degradation is owed to the increase in 
water diffusion into the composite bulk (222).  
Increased water diffusion into the nDP modified scaffolds may have promoted a 
bulk pattern of erosion. In bulk erosion, the polymer chain scission occurs throughout 
the scaffold in the amorphous part of the polymer, thus although it does not change 
much in external dimensions, the molecular weight decreases early. This was seen in 
the macroscopic pictures (Paper II) of the harvested scaffolds after 8 and 27 weeks 
where the nDP and nDP-PHY scaffolds were physically present but showed 
considerably thinner and translucent areas in the centre. The decrease in Mn from the 
 




first week in these scaffold groups compared to CL also reflects their bulk degradation. 
Our data demonstrated that after 2 months almost 60% of Mn of unmodified scaffolds 
decreased and previously reported data (37) demonstrated that these same scaffolds 
implanted into rat calvaria decreased around 70% of the molecular weight after 91 
days. Hence a comparable rate of degradation is appreciated although the implantation 
site and size of the animal were different. Mechanical properties were outside the 
scope of this paper but they would have added complementary information to the 
degradation characteristics of the modified scaffolds. 
Tissue response also plays a role in in vivo degradation. The nDP modified 
scaffolds exerted an upregulated inflammatory response at the mRNA level (Section 
4.3.1) relative to the CL scaffolds, suggesting the presence of the early stage ROS, 
which has been reported to degrade polymers. The ROS induce migration of 
inflammatory cells that can oxidise polymer chains (199). Previous studies reported 
that relatively delayed degradation of a biomaterial enhances enhances 
biocompatibility, reducing the inflammatory cells infiltration (150). However, this was 
not the case in Paper II, where it is more likely the result of nDP and BMP-2 
additions.  
 
4.3 HOST RESPONSE  
4.3.1 Inflammatory response  
Bone regeneration after scaffold implantation starts with an inflammatory reaction that 
initiates the healing process, but chronic persisting inflammation or lack of 
initial/acute inflammation affects the process of regeneration (223). Thus, when 
evaluating host response it is important to discriminate between the short-lived 
inflammation that is a normal component of the healing response and a long-term, 
persistent chronic inflammation that may indicate an adverse response such as 
tumorigenesis. A shortcoming of Paper II design was the absence of a sham surgical 
control. Another study comparing the immune response towards different scaffold 
carriers concluded that the implantation of scaffolds itself caused tissue injury that 
intensified immune response (224). Thus it might be either important to deliver the 
 




tissue-engineered construct as non-invasively as possible or to include a sham control 
in order to avoid overlooking any immunological responses to implantation itself. 
However, in Paper II the initial inflammatory response between the scaffolds groups 
differed, which is more likely to be related to the modifications than to the surgical 
injury.  
In Paper II, proinflammatory markers at the mRNA level displayed a gradual 
decrease with time from week 1 to week 8 in all groups, with the highest week 1 
expressions being from the nDP scaffolds followed by nDP-PHY scaffolds. The 
mRNA level of tissue healing markers showed almost the reverse pattern, with the up-
regulation at week 8. Here too, the greatest expression was from nDP and nDP-PHY 
scaffolds. The early upregulated proinflammatory expressions from nDP scaffolds can 
be attributed to nano-scale particles that have been shown to induce a low to 
intermediate amount of oxidative stress from the generation of ROS (225). This might 
induce proinflammatory responses, which here were initiation of a regeneration or 
healing phase. Previous reports showed similar patterns in vitro where adherent 
monocytes on hydrophilic polymers expressed higher amounts of proinflammatory 
cytokines such as IL-1β and IL-6 than cells from corresponding hydrophobic polymers 
detected at protein level up to 10 days (226, 227). It has been shown that there were 
fewer cells and minimal FBGC formation on the hydrophilic/neutral surface but these 
adherent cells demonstrated greater levels of activation and produced significantly 
greater amounts of cytokines/chemokines tested than the other surfaces (226). This is 
in agreement with the upregulated proinflammatory mRNA expressions, such as 
TNFα, IL-1β, Chemokine C-C motif ligand 5 (CCL5), CCL12 and IL6 seen here at 
week 1 from the implanted nDP scaffolds followed by nDP-PHY scaffolds, which 
have been previously shown to be hydrophilic, again supporting the idea that material 
surface chemistry is a factor in modulating the phenotypic expression of FBR cells. 
Histologically, the presence of inflammatory cells and FBGC was more prominent 
in the CL scaffold group than in the nDP and nDP-PHY scaffolds, except that at 8 
weeks more lymphocytes were present in nDP-PHY scaffolds (Paper II). Hydrophilic 
surfaces have also been reported to show reduced adhesion of monocytes and 
 




macrophages and a reduced amount of macrophage fusion into FBGC (226, 228), 
which may explain the reduced number of inflammatory cells or FBGC on nDP 
modified scaffolds. It was reported that hydrophilic surfaces promote the apoptosis of 
biomaterial adherent FBGC and the authors proposed that inducing apoptosis in the 
adherent FBGC would reduce the negative effects and improve tissue remodelling 
(229).  
The reason for the persistent presence of FBGC around a scaffold or a degradable 
implant in general has been an area of controversy. It has been considered as an 
indication of foreign bodies with lack of biocompatibility and inflammation or a sign 
of degradation leading to regeneration. Another postulation is the faster degradation of 
the modified scaffolds and hence less number of FBGC required or observed at the 
certain time point (140, 147). Also, hydrophilic titanium surfaces decreased 
macrophage immune response and reduced FBGC formation by promoting the 
polarisation of macrophages towards a pro-healing phenotype via (Nuclear factor) NF-
kappaB signalling (230). A recent study showed that it is not only chemistry by itself, 
but selective adsorption of proteins by different surfaces and ligand orientation could 
account for observed differences in FBR and have a potential to modulate immune 
response and macrophage polarisation from pro to anti-inflammatory (227, 231).  
Moreover, fibrous capsule formation as a result of extended inflammation may 
impair the capacity of the scaffolds to degrade in the intended manner or to promote 
tissue regeneration. The reduction in the fibrous capsule thickness and the chronic 
inflammatory cells’ infiltrate after 8 weeks in nDP and nDP-PHY scaffolds suggests 
the good compatibility of these scaffolds. Previous reports demonstrated the 
attenuation of inflammation by the slow release of BMP-2 from polymeric scaffolds 
(151). The efficacy of the BMP-2-functionalised scaffolds in reducing the fibrous 
capsule and the FBR has also been attributed to the initiation of the formation of 
ectopic bone in this group (147); therefore, homing of endogenous MSC (64) may also 
be a involved, since MSC have been shown to demonstrate immunomodulatory and 
immunosuppressive effects (232). The nDP and nDP-PHY scaffolds showed superior 
osteogenic potential as described earlier and higher proinflammatory markers (TNF-α 
 




and IL-6) at week 1, although the inflammatory cellular infiltrate was less in these 
groups than in CL. The cytokines TNF-α, IL-6 and stromal cell-derived factor 1 have 
been associated with migration of MSC in vivo (233) and mice deficient in IL6 have 
shown compromised bone regeneration (234). While TNFα is generally considered to 
be a proinflammatory cytokine, it also has confirmed important roles in bone by 
promoting vascularisation and recruitment of osteogenic cells; however, persistent 
upregulation of TNFα negatively affects the bone (235, 236). Exaggerated 
inflammatory environments decreased induced bone mass in vivo after implanting a 
scaffold carrying BMP-2, by suppressing BMP-2-induced osteoblastic differentiation 
and by increasing the number or activity of osteoclasts (237). This highlights the 
concept that immune cells and inflammatory cytokines play an important role in the 
bone healing process and are required from its initiation, but over a prolonged period 
can have adverse effects.  
The relatively avascular fibrous capsule that encapsulates foreign bodies limits its 
interaction with the host tissue and the subcutaneous area is relatively lacking in 
circulation (238), which is a challenge for tissue regeneration after scaffold 
implantation. Angiogenesis is perceived as being able to reduce fibrous capsule 
formation (239). Levels of angiogenic markers’ mRNA (ANGPT1 and FGF2) were 
significantly upregulated in nDP and nDP -PHY scaffolds at week 1 compared to CL. 
Previous reports have shown the hydrophilic surface in O-NCD titanium implants to 
enhance vascularisation when implanted subcutaneously in rats, in addition to 
decreasing the inflammatory response (211). This may explain the reduction in the 
fibrous capsule thickness in these groups at 27 weeks.  
As time progressed, the level of proinflammatory cytokines reduced, and higher 
levels of healing/regenerating marker (IL-4) showed higher trends in nDP scaffolds at 
1 week and were significantly higher in nDP-PHY scaffolds at 8 weeks. These levels 
may play a role in macrophage fusion, suppression of inflammatory responses during 
the FBR and leading to a healing phase (240). In a study of ectopic bone induction by 
demineralised xenogenic bone matrix, the expression of angiogenic markers were 
affected by deficiency of IL-4 and IL-13 (241). The observed increase in expression of 
 




IL-4 in nDP and nDP-PHY scaffolds is in agreement with the enhanced angiogenic 
markers and resolved FBR. It has also been reported that IL-4 and IL-13 positively 
influence the migration of osteoblastic cells (242). The role of BMP-2 as a 
chemoattractant and angiogenic factor, recruiting endothelial cells has also been 
displayed in studies in vitro (243). This highlights the interdependence of 
inflammation, angiogenesis, and tissue regeneration, and the necessity of 
immunomodulation to prevent impaired regeneration. 
To conclude, this demonstrates the osteoconductivity and osteoinductivity of nDP 
and nDP -PHY scaffolds respectively in Paper II. nDP and nDP-PHY modification of 
scaffolds offer the prospect of modulating cellular activation and cytokine profiles that 
may provide a means to control or manipulate inflammation, the foreign body reaction, 
and ultimately biocompatibility and regeneration.  
 
4.3.2 Persistence of nanodiamond particles at the implantation site  
The presence of nanodiamond particles in the implantation site of the scaffolds at 
week 27 indicated that the particles stayed in the tissue even after almost 90% of the 
scaffold has degraded without eliciting side effects (Paper II). It can be postulated that 
the acidic environment created from the by-products of the polymer scaffold 
degradation led to the agglomeration of the particles, which immobilised them and 
thus were not able to distribute in cells or elicit nano-scale side effects (244). One must 
therefore be careful when considering this copolymer/nDP scaffold construct 
degradable. Thus, this motivated our following evaluations of long-term 
tumorigenicity (Paper IV). nDP is a factor determining the host tissue response 
towards the functionalised scaffold. The host response to nDP as a construct with a 
polymer scaffold/carrier in vivo has limited reports in the literature. Investigations on 
the cytotoxicity and genotoxicity of nDP in suspension have been commonly carried 
out by exposing cells to the particles in suspensions or by growing the cells on 
nanodiamond coated substrates/scaffolds (53). Results were controversial, most studies 
concluded that they do not alter cellular proliferation and that they have no obvious 
 




cytotoxic effects (245), but others revealed size and concentration dependence on 
macrophages (246).  
In vivo assessments, more relevant to our current study, injected nDP into the 
peritoneum, and into the tail vein to study their biocompatibility, distribution and fate. 
Most of them reported absence to minimal inflammatory responses with slightly 
elevated blood indices in rabbits after intravenous administration (247). Previous 
reports reported them to accumulate mostly in the liver, followed to a lesser extent by 
the lungs and some traces detected around other organs such as the brain, bone, 
muscle, stomach and intestines after intravenous administration in mice (248). The 
observation of nDP remaining in the implantation site after 27 weeks was 
accompanied with no macroscopic adverse effects in Paper II. However, harvesting 
organs to monitor distribution, if any, may have added information. Preliminary 
unpublished data from our laboratory have shown the highest tolerated dose of nDP (3 
times higher than what is added in a scaffold) suspended in glucose and injected 
intravenously in rats did not affect the haematological profile. 
 
4.3.3 Tumorigenicity  
The scaffold construct and its degradation products should not have any potential 
adverse systemic effects including carcinogenicity. Since the nDP and nDP-PHY 
scaffolds elicited inflammatory responses that initiated bone formation or foreign body 
reactions and the nanodiamond particles do not degrade, it was necessary to carry out 
long-term biocompatibility evaluations, such as the tumorigenic potential. 
4.3.3.1 Developing an non-invasive carcinogenicity testing model in vivo 
The selection and relevance of DOK as a ‘screening sensor’ in this developed model 
has been discussed in Section 3.3.1.3.1. To achieve real-time BLI and facilitate non-
invasive visualisation after xenotransplantation, DOK cells were transduced with the 
luciferase gene, successfully generating a new cell line, DOKLuc (Paper III).  DOKLuc 
retained comparable morphology, growth in vitro, and in vivo behaviour after 
inoculation in mice compared to DOKWT. Introducing viral vectors into primary cells 
or cell lines carries many risks, including the risk of causing phenotypic variations 
 




(249). After transduction, DOK demonstrated bioluminescent stability together with 
preservation of the phenotype, proving thus to be a valuable tool for screening 
tumorigenesis and ruled out the possibility that transduction can be the cause of 
tumour formation in Papers III and IV.  
Manual measurement of the size of tumours formed by both DOKLuc and DOKWT 
showed that when injected in the tongue of NSG mice at high density, bigger tumours 
resulted than when low density was used at all time points (6 weeks). The tumour area 
measured from the histological sections after 6 weeks was also bigger when high 
density inoculation was used. The growth of DOK in vitro depends on seeding density; 
in an orthotopic site (tongue) this phenomenon would be expected due to the 
favourable surrounding environment (250). Similar in vivo growth curves were 
observed in the tongue between DOKLuc and DOKWT with low density inoculations.  
However, in the skin, an ectopic site for the DOK, tumours were only formed by the 
high density inoculation, possibly due to the injection technique or the site.  
In addition to the manual measurement by digital calliper for 6 weeks, tumour 
volumes formed by skin and tongue inoculations were also measured weekly by BLI 
for the DOKLuc group only. The BLI signals were always significantly higher (p < 
0.01) for the inoculations of DOKLuc at higher density at both tongue and skin, in line 
with the tumour growth curve as assessed by manual measurements. BLI proved 
sensitivity and validity during detection of tumours formed by DOKLuc inoculations, 
where 50% of the total number of tumours formed in the tongue by DOKLuc was 
detected by BLI much earlier than manual detection, even by the first week. Therefore, 
the detection of tumours was consistent between manual and BLI measurements, but 
BLI detection of tumours was more sensitive than manual measurement. In the skin 
more than 85% of the tumours were visible by BLI from the first week.  
BLI is performed in darkness with no interference from background light or 
autofluorescence, which makes it possible to detect small tumours. A study comparing 
the sensitivity of BLI with another non-invasive optical imaging modality, 
fluorescence, suggested that BLI was more sensitive due to the lower background 
 




(251). One of the tumours detected by BLI in Paper III, which was from a low density 
inoculation, was not detected by manual detection but was confirmed histologically. A 
stronger significant correlation (r = 0.846, p < 0.001) was found between the tumour 
area from histological sections and BLI signals at the last time point than between the 
tumour area from histological sections and the manual measurement (r = 0.739, p < 
0.001). Previous reports developing a model for a brain tumour also showed 
correlation and validation of BLI with MRI, a more established method for that 
tumour, and their results also corresponded with histology (252).  
Important for this screening model using DOK, was the inclusion of a positive 
control as a reference or guideline. The duration of the screening and the end point 
were set based on this positive control. Previous work has shown the significant role of 
microenvironmental cues, specifically CAF, in tumour progression (182, 253). In line 
with these findings, our data showed that co-inoculating DOKWT with 1×105 CAF in 
the tongues of NSG mice significantly increased tumour incidence by 40.48% and the 
tumours showed typical OSCC histology with invasive epithelial islands growing in 
the host stroma and keratin pearl formation. The only considered tumour formed here 
by the DOKWT, detected only manually, was found histologically to be surviving 
DOKWT cells within remnants of undissolved matrigel underscoring the drawbacks of 
manual measurements that include subjective evaluations. The sensitivity of the BLI 
was again confirmed when DOKLuc was co-inoculated with two different types of CAF 
and their effect on tumour formation compared. BLI seemed to be more sensitive than 
manual measurement in detecting differences in the tumour growth of xenografts, 
although not statistically significant.  
4.3.3.2 Using the newly established model to test tumorigenicity of scaffolds  
DOKLuc were cultured on unmodified poly(LLA-co-CL) scaffolds at three different 
densities with or without CAF and implanted subcutaneously in NSG mice. BLI 
showed significantly higher intensity from scaffolds xenotransplanted with DOKLuc + 
CAF compared to DOKLuc alone at all densities throughout the 12 weeks of in vivo 
imaging (1×106: p < 0.001, 1×105: p < 0.001, 1×103: p = 0.017). A challenge for using 
BLI method would be monitoring of bigger tumours. We monitored a drop in intensity 
 




for a tumour developed from the highest seeding density of DOKLuc + CAF xenografts. 
This tumour was found to be cystic, thus we considered this drop to be an 
underestimation of the real BLI signal from the DOKLuc cells. The formation of 
bioluminescence requires the coenzyme adenosine triphosphate and therefore only 
metabolically active cells can produce it. Cystic content can occur in large tumours, 
reducing the overall signal due to decreased proliferation or hypoxia (252). 
Oxyhemoglobin and deoxyhemoglobin in the bloody content of the tumour might also 
absorb light output in the visible spectrum, reducing the signal output.  
In a study of orthotopic bladder xenografts correlating BLI with MRI results of tumour 
volume to determine the role of hypoxia and necrosis, they found the correlation to be 
variable and reduced in xenografts that got too large for their vascularisation (254). 
Another study found that changes in hypoxic conditions affected the reported BLI by 
affecting tumour cell growth (255). Thus it may be challenging to use the BLI method 
for monitoring bigger tumours. To circumvent these limitations and monitor tumour 
formation for longer period of times, a relatively smaller number of DOKLuc (1×104) 
cells were used to test functionalised scaffolds (Paper IV). Several studies 
investigated the sensitivity of BLI in different tumour models using different 
inoculation sites, i.e. subcutaneously, intravenously, intraperitoneally, intramuscularly, 
intracranially, or via bone marrow (256, 257) and concluded that sensitivity is highest 
when the tumours are solid masses closer to the surface of the animal. These studies 
support our choice of implanting the scaffolds subcutaneously for testing.  
The histology of the xenografts of DOKLuc+CAF scaffolds (Paper III) showed 
squamous epithelial tumour nests (confirmed by p53 positive staining) with many of 
the islands retaining differentiation and containing keratin pearls, growing within and 
outside the scaffold area, invading the surrounding connective tissue and musculature 
as small groups or cords of infiltrating cells of greater than 15 cells in number. 
Staining for human specific vimentin showed few human CAF were still found in the 
tumours formed by the xenotransplants after 12 weeks of growth in mice. When this in 
vivo model was applied to study the tumorigenic potential of nDP scaffolds and nDP-
PHY scaffolds (Paper IV), the positive control of DOKLuc+CAF showed the same 
histological features, displaying the characteristic hallmarks of OSCC. However, the 
 




number of invading tumours in positive control xenografts formed by nDP-PHY 
scaffolds was higher (100%) when compared to the CL (50%) and nDP scaffolds (only 
30%). The increased invasion in nDP-PHY scaffolds is in line with the increasing 
evidence for the role played by BMPs in the promotion of tumours derived from 
epithelium. A study evaluating the expression of BMP-2/4 and their receptor and their 
implications for the prognosis of OSCC from patient specimens found strong 
expression of these proteins in both metastatic and non-metastatic cases, suggesting 
disturbances in the BMP-mediated signalling pathway during malignant developments 
(258).  
The pro-tumour activity of BMPs occurs in more advanced stages of neoplastic 
development and exhibits metastasis by inducing VEGF, thus inducing 
neovascularisation. Elevated expression of this cytokine in tumours may be associated 
with a poor prognosis (259). This is in agreement with results from Paper II, where 
mRNA expression of VEGFA from the nDP-PHY scaffolds was upregulated at both 1 
and 8 weeks compared to CL and nDP scaffolds. Although it is a different animal 
model, these results support the enhanced invasive potential observed in Paper IV.  
When considering the nDP scaffolds in Paper IV, BLI from the positive 
xenografts carrying DOKLuc+CAF in this scaffold group showed a decreasing trend 
from 8 weeks until it reached values comparable to the negative control, indicating a 
reduction in the size of the tumour in this scaffold group. This conclusion was 
supported by the histological examination of these tumours that showed least number 
of invasive tumours formed with nDP scaffolds compared to the higher number of 
invasive tumours from nDP-PHY and CL scaffolds. Hence tumours formed by 
xenografts carrying DOKLuc+CAF in nDP scaffolds had the least aggressive potential.  
A similar pattern of invasion was displayed when in vitro functional assays were 
used to assess the tumorigenic potential of the functionalised scaffolds were carried. 
Significant decrease in DOKLuc invasion was also observed in vitro in the 3D-OTs that 
were seeded with DOKLuc from nDP scaffolds compared to DOKLuc previously seeded 
on nDP-PHY scaffolds and to the positive control in 3D-OT (Paper IV). The role of 
 




BMP-2 was further demonstrated in a migration assay where preliminary results 
showed that when DOKLuc were grown on nDP-PHY scaffolds they displayed an 
enhanced potential to migrate towards a high serum gradient and with an even higher 
migration capacity towards conditioned medium from CAF (Fig. 4.2). Invasive and 
migratory phenotypes are caused by a complex process where the cell loses epithelial 
morphology and gains a motile fibroblast-like mesenchymal phenotype. Of the 
epithelial markers that are lost during this process, the E-cadherin molecules are some 
of the most thoroughly investigated (260). Recent studies have reported that 
stimulation of human pancreatic cancer cells with BMP-2 induces epithelial-
mesenchymal transition (EMT) by reducing E-cadherin expression and MMP-2 
secretion, which contributes to increased invasiveness (261). These results are in line 
with E-cadherin staining results from 3D-OT, where DOKLuc previously grown in 
nDP-PHY scaffolds showed weaker expression accompanied with negative areas 
superficially in the epithelium. DOKLuc previously grown in nDP scaffolds had the 
strongest expression of E-cadherin in the epithelial compartment of the 3D-OT. There 
are reports that suggest stem-like properties generated by EMT are accompanied by an 
increase in expression of stemness markers, which would then increase in sphere-
forming ability in vitro (262). This was in agreement with our results where the 
extracted DOKLuc, after being cultured on nDP-PHY scaffolds, formed more spheres 
than cells from CL and nDP scaffolds. A recent study also showed that BMP-2-treated 
colon cancer cells formed spheres that displayed significantly elevated expression of 
stemness markers via STAT3 activation (263). Cells from nDP scaffolds formed 
significantly reduced number of spheres compared to cells cultured on the other type 
of scaffold. 
 





Figure 4.2 Results of migration assays. DOKLuc cells after culture on different scaffolds for 1 week 
migrating against CAF conditioned medium and against a high serum gradient. 
 
4.3.3.3 nDP promoted DOKLuc differentiation and decreased their tumorigenic 
potential 
Although controversial, there are studies that show a clinical correlation between the 
degree of differentiation of a tumour and its clinical behaviour; generally, a poorly 
differentiated tumour is more aggressive than the more (well-) differentiated tumours 
(264).  In Paper IV, the epithelial differentiation marker involucrin was assessed in 
vitro in the 3D-OTs formed by DOKLuc previously grown on the different scaffolds. 
Cells from nDP-PHY scaffolds showed a significantly reduced expression of 
involucrin with low expression in the supra-basal layers and abnormal expression in 
the para-basal layers of the epithelium in the 3D-OT. This suggests an abnormal 
pattern of differentiation, similar to the positive controls for tumorigenesis of DOKLuc 
populated on CAF biomatrices. In the 3D-OT formed by DOKLuc extracted from nDP 
scaffolds, involucrin was significantly more strongly expressed in the supra-basal 
epithelial layers, as evidenced by higher staining score compared to the 3D-OT made 
by DOKLuc from nDP-PHY scaffolds and the positive control. This pattern of 
expression was the closest to that in normal human oral mucosa. Recent research 
efforts have attempted to exploit the reprogramming of cancer cells in order to drive 
them towards terminal differentiation with consequent loss of tumorigenicity (265). 
 




The nDP scaffolds exhibited a favourable topography and charge for the cells as 
described previously, and may have played a role in enhancing the differentiation of 
DOKLuc, suppressing their tumorigenic ability as a result.  
Dedifferentiation is a process by which cells develop from a more differentiated to 
a less differentiated state. BMP-2 has been recently shown to engage in signalling to 
Smad2/3, causing progression from benign to metastatic disease, and showing that 
BMP-2 is a critical component of dedifferentiation and cancer progression (266). This 
may explain why some parts of the epithelium in 3D-OT made by DOKLuc from nDP-
PHY scaffolds were completely negative for involucrin. In vivo, all the different 
scaffolds carrying the negative control (DOKLuc alone) showed constant low photon 
intensities in BLI and histologically presented with proliferating DOKLuc accompanied 
with fibrous tissue and few differentiated keratin pearls confined to only the scaffold’s 
area (Papers III and IV). Although not statistically significant, the nDP modification 
also enhanced the differentiation pattern in vivo, with stronger involucrin staining in 
nDP and nDP-PHY scaffolds carrying DOKLuc alone than in CL scaffolds. 
Proliferation is a fundamental biological process because of the role it plays in 
tissue homeostasis, and it is highly perturbed in cancer, with cancer cells being able to 
survive beyond the life span of a normal cell and to proliferate abnormally (155). 
Dysregulations of homeostasis and the inverse association of differentiation with cell 
proliferation capacity appear to be associated with many different human tumours 
(155). Ki-67 expression in our re-constructed 3D-OTs showed the DOKLuc cells from 
the nDP and CL scaffolds had proliferation more confined to the basal layer, like the 
normal pattern of proliferating cells in oral epithelium. DOKLuc previously grown on 
nDP scaffolds had significantly reduced proliferation in the supra-basal layers, 
compared with cells from nDP-PHY scaffolds (p = 0.11) and the positive control (p = 
0.007). It is generally accepted that presence of cell proliferation in the supra-basal 
layers marks the switch from normal oral epithelium to dysplasia and malignancy. 
Previous authors have showed Ki-67 to be over expressed in the supra-basal 
epithelium in dysplastic lesions and correlated with the severity of dysplasia (267). 
Studies have revealed that the invasive tumour front of an OSCC is composed of 
 




highly proliferative cells expressing Ki-67 and positively correlated with histological 
grading in malignancy (268). The increased expression of Ki-67 in the basal and 
supra-basal epithelial layers of 3D-OTs formed by DOKLuc from nDP-PHY scaffolds 
parallels the increased invasion seen in vitro and in vivo (Paper IV). These findings 
argue for the role played by BMP-2 in enhancing proliferative capacity and thus 
motility of DOKLuc, in line with studies which showed the effect of BMP-2 in 
enhancing aggressiveness of OSCC (94) and evidence from lung cancer after 
supressing BMP-2 activity significantly inhibited proliferation and migration of lung 
cancer cell lines (269).  
These results again highlight the role nanodiamonds might play in supressing an 
abnormal epithelial phenotype, thus pinpointing their potential for reducing the 
tumorigenic risk of scaffold materials. 
 
4.3.3.4 BMP-2 plays dual roles in modulating tumorigenesis and inflammation  
The action of BMPs during carcinogenesis is complex and involves both pro- 
(oncogenes) and anti-tumour (tumour suppressor) characteristics. This has been 
reported to be dependent on the stage of the disease and cell type. The physiological 
concentration of the BMP-2 has been also considered a factor affecting tumorigenesis 
(270). Several studies have investigated the biologic effects of BMPs on cancer cells 
(271). BMP-2 has been shown to stimulate cancer cells such as lung, breast and 
prostate (272, 273). Other reports suggest that BMP-2 may have inhibitory effects on 
tumours of gastrointestinal origin, for example, inhibits gastric and colorectal cancer 
cell growth (274, 275). However, the effects of BMPs on oral cancer cells in vitro or in 
vivo are poorly understood. It has been reported that OSCC frequently expresses BMP- 
2/4, BMP-5, and BMPR-IA protein (276) and others reported lack of biological 
adverse effects on OSCC as far as proliferation and angiogenesis are concerned (277). 
The use of BMP-2 for bone regeneration in the oral cavity is contraindicated for oral 
cancer patients because the effects of stimulating the BMP signalling pathway on these 
cancer cells are contradictory.  
 




Prolonged inflammatory response has been reported to be associated with several 
chronic inflammatory diseases, such as gingivitis and lichen planus as well as playing 
roles in modulating cancer (278). Studies of the role played by BMP-2 in inflammation 
have produced conflicting results, which appear to be related to the dose administered 
(218, 237). Our results showed an attenuated inflammatory reaction at cellular level 
from nDP-PHY scaffolds compared to CL and nDP scaffolds, and this was attributed 
to the controlled delivery of low amounts of BMP-2. Nevertheless, cells from nDP-
PHY scaffolds showed the most aggressive tumorigenic activities in vitro, and the in 
vivo invasiveness was also most pronounced in nDP-PHY scaffolds. As the difference 
in invasiveness was seen in the positive control only, the contribution of CAF and its 
secretome and the synergy between their secreting molecules and BMP-2 also have to 
be taken into consideration when evaluating these results.  
Nevertheless, this points out the suppressive effect of nDP scaffolds on malignant 
progression of early neoplastic cells. While this malignant progression may have been 
due to the presence of early neoplastic cells, the model used is representative of the 
postsurgical situation in oral cancer patients where the tumour has been removed but 
the oral mucosa may contain spots of transformed, premalignant oral cells due to the 
field cancerisation phenomenon, well described for OSCC (279). This again points out 
the necessity of delivering BMP-2 in a controlled manner to avoid adverse effects. It 
also suggests that detection of premalignant signs is important prior to BMP-2 
treatment and that clinicians should recognise the possible patient-dependant dangers 
of BMP-2, as smokers and patients with previous OSCC have patches of cells 
molecularly altered (p53 mutations) that are not detectable clinically or even by 
routine histology (280). 
 




4.3.3.5 The carcinogenicity BLI model: an alternative to the 2-year rodent model?  
Regulatory experts advise that a biomaterial that will be implanted for more than 30 
days to be screened for carcinogenicity using the two-year ‘life time’ carcinogenicity 
assays in rodents (172, 174). This has been considered difficult for several reasons, 
and questions have been raised regarding the extrapolation of results to humans. This 
long period of testing has been justified with the likelihood of a latent period before 
tumour formation, which may be measured in years (159). Furthermore, the rasH2 
transgenic mouse has often been used to shorten the duration of screening to 6 months 
(175). The nDP used to modify our scaffolds renders them topographically and 
physically altered and warrant screening in a relevant model. It was reported that 
contact by pre-neoplastic cells with an implanted biomaterial surface may promote 
carcinogenesis in animals (281), rather than the biomaterial initiating tumorigenesis. 
Several studies support the concept that carcinogenesis, including head and neck 
cancer, is a multistep involving a premalignant phase of long-term accumulated 
chromosomal alterations (181). We therefore chose to use early neoplastic cells such 
as DOK as a tool to evaluate the tumour promoting potential of scaffolds, providing a 
faster alternative to the long ‘life-time’ models.  
The functionalised bioactive scaffolds showed success in a critical defect in the 
mandible area (Paper I); hence they can be developed for use in the oral maxillofacial 
area. Experimental data and clinical experience suggest that BMP-2 can be used to 
regenerate bone in segmental defects of the mandible (88). However, the most 
common reason for bone regeneration in the maxillofacial region is resection due to 
OSCC, and the biological effects of BMP-2 on these carcinoma cells are unknown. 
The use of human cells also brings to our model a substantial benefit with respect to 
clinical safety in humans.  
Non-invasive in vivo monitoring for only 12-14 weeks using BLI gives robust 
evaluation in a shorter period than the aforementioned established carcinogenicity 
testing systems. While ISO 10993-3 standards require the inclusion of a positive 
control of comparable form and shape when screening an implantable biomaterial 
(166), the use of these controls is not necessary since the inclusion of a positive 
 




environment with the use of CAF has been developed. In addition, this model is also 
highly practical because it provides quantitative analysis and is the only approach that 
can image cancer burden from the moment the cancer cells are administered to the 
animals. The processing time is reduced due to the ability of screening several animals 
simultaneously. BLI is also starting to expand in regenerative medicine and might 








5. CONCLUDING REMARKS 
The main conclusions based on the findings of the studies in this thesis are: 
 
1. The amounts of BMP-2 released from nDP-PHY scaffolds were found to be far 
less than MIC and PHY scaffolds and its release continued up to 70 days in 
vitro. Therefore, compared to BMP-2 adsorbed onto a polymer, nanodiamond 
particles provided a platform for strongly physisorbing BMP-2 with sustained 
release in low amounts, holding great potential promise for bone tissue 
engineering. 
 
2. A low dose of 1 μg of BMP- 2 was found to be bioactive for bone regeneration 
in a rodent model. 
 
3. PHY, MICS and nDP-PHY scaffolds showed accelerated bone regeneration in a 
rat mandible critical-sized defect after 4 weeks; both nDP-PHY and MICS 
scaffolds showed osteogenic potential both in vitro in MSC culture and in vivo. 
nDP-COV showed reduced osteogenic potential in vitro and in vivo. The mode 
of binding BMP-2 to poly(LLA-co-CL) scaffolds was thus shown to have a 
significant effect on their osteogenic potential in vitro and in vivo. 
 
4. nDP and nDP-PHY scaffolds showed enhanced osteoconductive and 
osteoinductive potential respectively, in a mouse ectopic model.   
 
5. nDP functionalisation of poly(LLA-co-CL) not only promoted osteogenicity but 
also reduced foreign-body reactions, confirming that this new modality of nDP-
PHY attenuates inflammation while lowering the pharmacological dose of 
BMP-2, promoting its clinical application.  
 
 




6. nDP and nDP-PHY scaffolds exhibited faster degradation than unmodified CL 
scaffolds. Nanodiamond particles were found in the implantation site after 27 
weeks when 90% of the scaffolds degraded.   
 
7. A sensitive and reliable in vivo model was established using DOKLuc and CAF 
for monitoring microenvironmentally-induced carcinogenesis providing early, 
non-invasive surveillance of tumour development associated with implantation 
of scaffolds. The model was successfully applied to evaluating functionalised 
copolymer scaffolds. 
 
8. In an in vitro 3D-OT, DOKLuc cells demonstrated a reduced tumorigenic 
potential after being cultured on nDP modified scaffolds, as shown by 
proliferation, invasiveness and differentiation compared to DOKLuc from nDP-
PHY and CL scaffolds.  
 
9. The nDP modified scaffolds reduced the bioluminescence intensity from 
positive control xenograft scaffolds of DOKLuc+CAF, suggesting tumour 
suppressing effects. 
 
10. The nDP-PHY scaffolds showed enhanced tumorigenic potential in vitro in the 
3D-OT and in vivo in the positive control xenografts, but not the negative 
control xenografts with DOKLuc alone. This raises concerns for the delivery of 
BMP-2 in reconstruction of bone defects in oral cancer patients. 
  




6. FUTURE PERSPECTIVES 
The future of growth factors’ use in bone tissue engineering applications seems 
promising. Most studies and clinical trials to date have focused on single growth factor 
delivery (rhBMP-2 or rhBMP-7). However, an ideal growth factor-delivery system 
should mimic the natural healing process, which involves the complex participation of 
multiple growth factors that perform their functions in a specific sequence and at 
specific concentrations. The findings from nDP-PHY and MICS mode of delivery here 
may serve as a basis for future investigations. They can be combined together in one 
scaffold system and assessed for sequential release of the growth factors to imitate the 
natural healing process. Studies with longer time points will allow evaluation of the 
sustainability of bioactivity of the delivered growth factors in vivo, and to evaluate the 
quality of the bone formed. Further improvement of fabrication technologies and 
introduction of computer aided 3D scaffold fabrication techniques may allow 
production of patient-specific, custom-made treatment options. In this way, it may be 
possible to regenerate more complex bone defects and osteochondral tissues in larger 
animals. 
With regard to the tumorigenicity results in Paper IV, study of the MAPK/ERK 
pathway and the EGFR pathways may help elucidate the underlying molecular 
mechanisms behind reduction of tumorigenic potential by the nanodiamond particles. 
In addition, it would be of interest to apply our established model to different cell lines 
of different origins to see if the nanodiamond modification has the same effect on 
other tumour types.  
Application of the nDP-PHY scaffolds offers intriguing possibilities as a drug 
delivery system. This would be of relevance for example, in the case of oral cancer 
after resection of a cancerous lesion, where there is a need for a system that can 
support the generation of new bone as well as delivering localised chemotherapy. In 
vivo established rodent OSCC cancer models can be used to test this, with additional 
bone defects created. 
  




Another interesting area of investigation would be evaluating the phenotypic 
dichotomy of macrophages. Macrophages are known to play switching roles in 
inflammation and cancer. Further investigations of the switching phenomenon between 
M1 and M2 in our harvested samples will be of great value to elucidate the role played 
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A low dose of 1 μg rhBMP-2 was immobilised by four different functionalising techniques on recently developed
poly(L-lactide)-co-(ε-caprolactone) [(poly(LLA-co-CL)] scaffolds. It was either (i) physisorbed on unmodified
scaffolds [PHY], (ii) physisorbed onto scaffolds modified with nanodiamond particles [nDP-PHY], (iii) covalently
linked onto nDPs that were used tomodify the scaffolds [nDP-COV] or (iv) encapsulated inmicrospheres distrib-
uted on the scaffolds [MICS]. Release kinetics of BMP-2 from the different scaffolds was quantified using targeted
mass spectrometry for up to 70 days. PHY scaffolds had an initial burst of release while MICS showed a gradual
and sustained increase in release. In contrast, NDP-PHY and nDP-COV scaffolds showed no significant release,
although nDP-PHY scaffolds maintained bioactivity of BMP-2. Human mesenchymal stem cells cultured in vitro
showed upregulated BMP-2 and osteocalcin gene expression at both week 1 and week 3 in the MICS and nDP-
PHY scaffold groups. These groups also demonstrated the highest BMP-2 extracellular protein levels as assessed
by ELISA, and mineralization confirmed by Alizarin red. Cells grown on the PHY scaffolds in vitro expressed
collagen type 1 alpha 2 early but the scaffold could not sustain rhBMP-2 release to express mineralization.
After 4 weeks post-implantation using a rat mandible critical-sized defect model, micro-CT and Masson
trichrome results showed accelerated bone regeneration in the PHY, nDP-PHY and MICS groups. The results
demonstrate that PHY scaffolds may not be desirable for clinical use, since similar osteogenic potential was not
seen under both in vitro and in vivo conditions, in contrast to nDP-PHY and MICS groups, where continuous
low doses of BMP-2 induced satisfactory bone regeneration in both conditions. The nDP-PHY scaffolds used
here in critical-sized bone defects for the first time appear to have promise compared to growth factors adsorbed
onto a polymer alone and the short distance effect prevents adverse systemic side effects.
© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).
1. Introduction
Reconstruction of critical-sized bone defects continues to be a chal-
lenge. The limitations of current treatment methods [1] highlight
the importance of introducing a potent bone substitute or a scaffold
that can induce bone healing by unlocking the body's own powers of
self-repair; not only should the substrate be osteo-inductive, it must
also act as a delivery system for the regenerative cues necessary [2].
The osteo-inductive capacity of the FDA approved recombinant
human bone morphogenetic protein (rhBMP-2) in bone and car-
tilage formation has been confirmed in preclinical models [3]
and evaluated in clinical trials [4]. It has usually been delivered in
bolus injections with supra-physiological doses to attain a therapeu-
tic effect, leading to severe side effects ranging from heterotopic
bone to oedema or high morbidity in cases of spinal fusion [5]. The
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high doses of rhBMP-2 chosen were used to compensate for short
half-life in vivo (1–4 h) [6,7].
Many studies have pursued thedesign of different carriers delivering
BMP-2 including implant coatings or organic and inorganic matrices
[8–10]. Control over its bioactivity and spatial–temporal presence is es-
sential for a beneficial effect but has been difficult to achieve [1]. To im-
prove the unsatisfactory outcomes resulting from bolus delivery of
BMP-2, attempts have been made to develop biomaterial carriers that
maintain a sufficient concentration at the application site to stimulate
the normal physiological mechanism required for bone regeneration
[11]. Adsorption to collagen sponges and soaking of collagen sponges
and hydrogels in BMP-2 are the most commonly used potential carrier
approaches due to their high binding capacities and successful induc-
tion of trabecular bone volume in critical defects of the canine has
been reported [12]. Recent reports using FDA approved polymers,
such as poly(lactide-co-glycolide) (PLGA) and polycaprolactone (PCL)
have looked at functionalising with BMP-2 [13] due to the affinity of
rhBMP-2 for molecules such as heparin or RGD peptides [14]. Covalent
immobilisation of BMP-2 to biomaterialsmodifiedwith heparin, plasma
treatment, UV light or disulphide bonds [15,16] has also been examined
in attempts to improve the stability and increase retention in regenera-
tion sites by reducing the release of BMP-2 and sustaining its activity.
The introduction of micro- and nano-structured materials has been
shown to increase the surface area of scaffolds, allowing for numerous
non-covalent interactions between the scaffold surface and protein
[17]. Protein encapsulation within microspheres is a potent tool to
protect its biological activity and enable sustained release over longer
periods [18]. PLGA has generated great interest as a copolymer for mi-
crosphere fabrication due to its biocompatibility as well as the ability
to tailor its in vivo lifetime [11]. This can be achieved by varying the
polymermolecular weight, composition,microsphere size and distribu-
tion. Several studies have shown that the rate of release depends on the
microsphere size, therefore by mixing particles with different sizes one
can obtain a degree of control over release [19]. This control of the re-
lease profile of growth factors results in optimised concentrations for
growth, making it suitable for experimental designs lasting for a long
term.
Surface coatings with diamonds at the nano-level gained signifi-
cance in the medical field after it was shown to demonstrate chemical
stability, and to enhance mechanical properties and biocompatibility
[20]. In recent years, research has focused on nano-topographic surface
modifications aiming to allow for numerous non-covalent interactions
between the surface and protein, resulting in adsorbed protein layers
which in turn increase cellular adhesion and durability of biomedical
implants [21,22], improving various biological applications including
delivery of growth factors [23,24]. Previouswork showed enhanced cel-
lular response through coating with nanocrystalline diamond (NCD)
films [25]. NCDmodified titaniumdental implant surfaceswith terminal
oxygen groups that interacted strongly with rhBMP-2 allowing the
physisorption of BMP-2. This was demonstrated by greatly enhanced
osseointegration [26]. Nanodiamond particles (nDPs) provided en-
hanced surface properties enhancing bone formation [27,28], encourag-
ing further studies of binding growth factors onto nDP to evaluate their
bioactivity.
Long-term delivery of BMP-2 in mini pig models proved enhance-
ment of in vivo osteogenic efficacy of the protein compared to short-
term delivery [29], while burst release has shown significance in an ec-
topic bone-forming model using transplanted hydrogels [30] rather
than in long-term osteogenic activity. It is, however, difficult to compare
these approaches due to the variety in animal models, doses and deliv-
ery vehicles used, although collectively, they have resulted in under-
standing how to design an optimum delivery system. Therefore, since
the release of BMP-2 and its effect on the tissues depend on the carrier,
method of immobilisation and subsequentmode of delivery, the release
kinetics and osteoinductive capacity of different loading approaches
need further evaluation.
Degradable poly(L-lactide-co-ε-caprolactone) [Poly(LLA-co-CL)], an
aliphatic polyester, copolymer of L-lactide and ε-caprolactone has
been extensively studied as a scaffold for bone regeneration [31,32]
proving its biocompatibility and osteoconductivity. Mechanical and sur-
face properties can bemodified [33] to enhance the regenerative poten-
tial, and functionalisation of these scaffoldswith nDP to improve cellular
response and subsequent bone formation has been reported [28].
In an effort to further improve these scaffolds, the aim of the current
study was to study the effect of rhBMP-2 in low amount (1 μg) im-
mobilised on poly (LLA-co-CL) scaffolds utilising four differentmethods.
The release kinetics of rhBMP-2 from the different methods was first
quantified in vitro and bioactivity evaluated on human mesenchymal
stem cells (hMSCs) and then the osteogenic effect of these different
methods was further compared in vivo.
2. Materials and methods
2.1. Poly(LLA-co-CL) scaffold fabrication (CL scaffold)
Scaffolds were fabricated as previously described [31]. Scaffolds
were punched out in twodifferent dimensions for in vitro and in vivo ex-
periments (in vitro: 12 mm diameter and 1.3 mm thickness) and
(in vivo: 6 mm diameter and 2.5 mm thickness).
2.2. Scaffold functionalisation and BMP-2 immobilisation techniques
2.2.1. BMP-2 production
BMP-2 cDNA was prepared corresponding to residues 283–396 of
the mature protein plus an N-terminal MA extension. The BMP-2 pro-
tein was expressed in Escherichia coli (E. coli), isolated from inclusion
bodies, renatured and purified as previously described [34]. One micro-
gram of BMP-2 was used per scaffold for each type of functionalisation
for in vitro with hMSC and in vivo experiments.
2.2.2. Physisorbed BMP-2 (PHY scaffold)
BMP-2 was physisorbed onto unmodified poly(LLA-co-CL) scaffolds
as follows: scaffolds were placed on a sterilised hydrophobic surface
(MBarrier Film, Parafilm®) and 1 μg of BMP-2/50 μl phosphate buffered
saline (PBS) was dropped in two increments of 25 μl each onto the sur-
face of the scaffold. The first aliquot was allowed to adsorb under humid
shaking conditions for 30 min, after which the second aliquot was
added and left for 30 min before the scaffold was used for in vitro or
in vivo experiments.
2.2.3. Colloidal nDP production
Acid purified detonation diamond (Gansu Lingyun Corp. Lanzhou,
China) was subjected to attrition milling using a method previously
described [35] achieving a narrow size distribution at ~5 nm particle
diameter (measured by dynamic light scattering in water) and low
agglomeration of the diamond particles.
2.2.4. Scaffolds modified with nDP and physisorbed with BMP-2 (nDP-PHY
scaffold)
Scaffolds were modified with the nDP solution (2% (w/v), i.e.
20 mg/ml) by a vacuum technique: 0.5ml nDP solution and one scaffold
were put in a glass beaker and perfused in vacuum. The vacuum chamber
was evacuated down to the pressure where the nDP-water-solution
changes into the vapour phase and the nDP burst into the scaffold surface.
This cycle was repeated 10 times. After the modification, the nDP modi-
fied scaffolds were rinsed with distilled water and dried in vacuum for
8 h. Brunauer–Emmett–Teller (BET) method using Argon at 87 K accord-
ing to DIN ISO 9277was performed to quantify the amount of nDP on the
porous scaffold and the concentration of nDPwasdetermined to be14mg
in 1 g scaffold material. To physisorb the BMP-2, the modified scaffolds
were treated with aforementioned protocol for PHY.
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2.2.5. nDP functionalisation with BMP-2 (nDP-COV scaffold)
To functionalise nDP with benzoquinone, 189 mg of mechanically
de-agglomerated nDP was suspended in 20 ml of PBS (pH 8) and
150 mg of benzoquinone (1.38 mmol) was added (all from VWR Inter-
national, Radnor, PA, US). After stirring for 24 h at room temperature
(RT) the reaction mixture was centrifuged and the nDP was washed
with PBS (pH 7.4) and deionized water. Then nDP scaffolds were
functionalised with BMP-2 by suspending 20 mg of benzoquinone-
functionalised nDP in 15 ml of PBS buffer (pH 6). After adding
10 μg BMP-2 the reaction mixture was stirred for 24 h at RT. The
nDP was centrifuged and then the supernatant was checked for re-
sidual BMP-2 and then discarded. The precipitate was washed with
PBS (pH 7.4) and deionized water. The scaffolds were then modified
with the functionalised nDP according to the procedure described in
Section 2.2.4.
2.2.6. Microsphere preparation and scaffold modification (MICS scaffold)
BMP-2-loaded PLGA5050 (Purac Biochem, Gorinchem,Netherlands)
microspheres were fabricated using a previously described water-in-
oil-in-water double emulsion solvent extraction technique [11,36].
Briefly, 1 ml of a 50 μg/ml BMP-2 solution was emulsified in a solution
of 15% (w/v) PLGA5050 in 5 ml of dichloromethane using a probe
ultrasonicator (Branson sonifier cell disruptor 200, USA). The mixture
was then immediately re-emulsified for 60 s in 10 ml of a 1% w/v aque-
ous poly(vinyl alcohol) (PVA, 87–89 mol% hydrolysed, Mw = 13,000–
23,000) solution to create the double emulsion. The product was then
added to 100 ml of a 0.5% w/v aqueous PVA solution and 100 ml of a
2% w/v aqueous isopropanol solution and stirred for 2 h. The micro-
spheres were centrifuged, washed 5 times and vacuum dried into a
free flowing powder (Braun Biotech International SpeedVac Concentra-
tor SVC 10H Savant, USA). BMP-2 loadedmicrosphereswere incorporat-
ed into the porous poly(LLA-co-CL) scaffold using a seeding technique
described previously [37] with slight modifications. Depending on
the amount of BMP-2 for loading, dry microspheres were dispersed in
100 μl ethanol using an ultrasonic bath (VWR International). Fifty
microlitres of the microsphere suspension was placed onto both sides
of the scaffold and dried overnight under vacuum.
The loading efficiency of the microspheres was determined using a
solvent-extraction technique [38]. Approximately 20 mg of microparti-
cles was dissolved in 1 ml of dichloromethane for 6 h at 37 °C. The
entrapped rhBMP-2 was extracted from the organic phase to the aque-
ous phase by incubationwith 5ml of PBS for an additional 24h. The con-
centration of rhBMP-2was analysed by a commercially available human
BMP-2 enzyme-linked immunosorbent assay (ELISA) (RnD Systems,
Minneapolis, Minnesota, USA). The average loading efficiency was
0.04%. This optimizationmethodwasperformed three times. Accordingly
the amount of microspheres needed to contain exactly 1 μg of BMP-2
from loading efficiency is calculated, i.e 2.5 mg microparticles contains
1 μg, each optimisation added 2.5 mg to the scaffold.
2.3. In vitro BMP-2 release kinetics
Scaffolds were immersed in 1 ml of PBS in glass test tubes
(Duran®, Wertheim, Germany) and incubated in a shaking water
bath (Julabo®, SW22, Germany) at 37 °C. Half of the supernatant
was collected and replaced with fresh PBS at predetermined time
points up to 70 days.
2.4. Sample preparation for selected reaction monitoring (SRM) analysis
rhBMP-2 (residues 283–396) expressed in E. coli was purchased
(RELIATech GmbH, Wolfenbüttel, Germany). Four peptides derived
from the 26 kDa protein by trypsinisation were tested for SRM analysis.
Only one peptide NYQDMVVEGCGCR representative of BMP-2 revealed
good transitions and was therefore selected for relative quantification
of the protein. A stable isotope-labelled internal standard (SIS)
corresponding to that signature peptide was purchased in AQUA
QuantPro quality (Thermo Fisher Scientific, Waltham, MA, USA). The
C-terminal arginine for the SIS was labelled with 13C and 15N resulting
in amass difference of 10Da to the corresponding non-labelled peptide.
In addition, cysteine was carbamidomethylated and methionine was
oxidized. The chemically synthesised modified peptides were reported
to be stable by the manufacturer. The peptide was optimised by direct
infusion on a Q-Trap 5500 (AB SCIEX, MA, USA). Twenty five femtomole
of SIS peptide NYQDMVVEGCGCR was spiked into samples containing
unknown amounts of BMP-2 in low-binding tubes (LoBind, Eppendorf).
The mixture was lyophilised (Centrivap® Centrifugal, USA) prior to in-
solution protein digestion according to the protocol described previ-
ously (http://www.uib.no/file-archive/in-solution-proteindigestion.
pdf). Prior to liquid chromatography SRM-mass spectrometry (LC
SRM-MS) analysis, the mixtures of reduced and alkylated tryptic pep-
tides were desalted using reverse phase Oasis® HLBμElution Plate
30 μm (Waters, Milford, MA, USA) as described previously [39]. The
eluted peptides were dried in a speed vacuum drier and finally
suspended in 8 μl of 1% FA and 2% ACN. In order to oxidize all methio-
nine residues, H2O2 was added in a final concentration of 0.5%, and
the samples were incubated for 30 min at 30 °C. The experiment was
performed in triplicate. For each measurement, slightly different
SRM methods were used and improved progressively to measure the
release with addition of heavy peptide. The data shown in Fig. 1 were ob-
tainedwith themost optimised SRMmethod, considered themost robust
and representative of the conclusion derived from all measurements
performed.
2.5. SRM analysis
LC SRM-MS analysis was performed on a Q-Trap 5500 coupled to a
Dionex Ultimate system (Thermo Scientific, MA, USA) as previously de-
scribed [39]. The protein digest was dissolved in 2% ACN, 0.1% FA and
loaded into the instrument. For quantification of the signature peptide
from BMP-2, all y transitions with significant intensity were used and
a mean of the ratio values calculated to obtain ratio Light/Heavy (L/H).
The Q1 values for the light peptide were 802.319, that for the SIS
heavy labelled peptide 807.32. The collision energy used for SRM analy-
sis was 45.5 eV. The raw data files generated were processed using
Skyline (MacCoss Lab Software version 2.5).
Fig. 1. Release kinetics of BMP-2 measured by SRM. (Axis-A) Relative amount released
where 100% value corresponds to the highest value observed for the total amount of
BMP-2 measured at a specific time point. (Axis-B) Release over time of rhBMP-2 from
the different scaffolds expressed by the ratio (L/H) between endogenous light (L) and
heavy synthetic (H) peptide spiked-in our sample measured by SRM. The figure is a
representative of the data from themost optimised SRMmethod obtained from triplicate
measurements.
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2.6. Cell maintenance and seeding
Primary hMSCs (StemCell™ Technologies, Vancouver, BC,
Canada) were expanded in MSCGM™ complete medium (Lonza,
Basel, Switzerland) following the manufacturer's instructions. Flow
cytometry used to assess the cells' purity showed that N90% of
cells expressed CD29, CD44, CD105, and CD166 and that they lacked
expression of CD14, CD34, and CD45. Morphology of the hMSCs was
assessed by a light microscope (Nikon TS100, Tokyo, Japan). Cells
used in the experiments were from passages 3 to 6. The cells were
seeded onto the scaffolds at a density of 2 × 105 per scaffold
and allowed to distribute better by a plate shaker (MixMate®
Eppendorf, Hamburg, Germany) for 5 min before incubation at 37
°C and 5% CO2 [40]. Once the cells reached 80–90% confluence the
medium was replaced with osteogenic medium (MSCGM™ com-
plete medium plus 50 μg/ml ascorbic acid, 10−8 M dexamethasone,
and 3.5 mM β-glycerophosphate) and changed every fourth day. All
cultures were performed in triplicate and the experiments were re-
peated three times.
Human osteoblast-like cells (HOB) were used as a positive control
for the in vitro mineralization staining (Alizarin red S) (Section 2.10).
They were isolated from routine surgical samples from patients being
treated at the Section for Oral and Maxillofacial Surgery, Department
of Clinical Dentistry, University of Bergen and Haukeland University
Hospital. The procedure was approved by the Ethics Committee at the
University of Bergen. The protocol for isolation and expansion has
been previously described [41].
2.7. Scanning electron microscope (SEM) analysis
Attachment and spreading of hMSC on scaffolds at 1 and 3 days after
seeding were analysed by SEM (Jeol JSM 7400F, Tokyo, Japan), voltage
of 10 kV as previously described [40].
2.8. Genes expressed by cultured hMSC in vitro
Total RNA was isolated from in vitro cultures at week 1 and week
3 using a Tissue RNA isolation kit (Maxwell®, Promega, Madison,
WI, USA), and reverse transcribed according to the manufacturer's
instructions using the High capacity cDNA Reverse Transcription
Kit (Applied Biosystems®, Carlsbad, CA, USA). Real-time reverse
transcription-polymerase chain reaction (RT-PCR) was performed as
previously described [40]. Taqman® gene expression assays (Applied
Biosystems®) were used to detect mRNA levels of glyceraldehyde-
3-phosphate dehydrogenase (GAPDH), Antigen KI-67 (Ki-67), Runt-
related transcription factor 2 (Runx2), BMP-2 receptor 1A (BMPRIA),
BMP-2 receptor 2 (BMPRII), Alkaline phosphatase (ALP), Collagen type
1 alpha 2 (Col1α2), Bone morphogenetic protein-2 (BMP-2) and
Osteocalcin (OC). The data were analysed with a comparative CT
method and GAPDH served as endogenous control. Unmodified scaf-
fold (CL) at week 1 was the reference.
2.9. Enzyme-linked immunosorbent assay
The culture medium was collected at week 1 and week 3. Human
BMP-2 ELISA Development Kit (900-M255, Peprotech, Rocky Hill, NJ,
US) was used to measure extracellular and intracellular BMP-2 fol-
lowing the manufacturers' instructions. To measure the intracellular
production of BMP-2, the scaffolds with cells from both time points
were washed with PBS before incubation at 4 °C on a shaker for
20 min with 175 μl RIPA buffer (Thermo Scientific), 1× Halt™ Prote-
ase Inhibitor Cocktail and 1× Halt™ Phosphatase Inhibitor Cocktail
(Thermo Scientific). This was followed by sonication for 5 min and
then centrifugation for 20 min at 16,000 g at 4 °C. The extracted pro-
tein was collected and measured using a bicinchoninic acid assay
(BCA) (Pierce BCA Protein Assay Kit, Thermo Scientific) following
the manufacturer's instructions.
2.10. In vitro mineralization
The cell/scaffold constructs were harvested at week 1 of culture,
washed thrice in PBS and fixed for 10 min in 4% paraformaldehyde
(PFA) (Merck & Co, White House Station, NJ, USA). Alizarin red S stain-
ing was performed to determine matrix mineralization. Two percent of
alizarin red S powder (Sigma Aldrich) was dissolved in distilled water
and pHwas adjusted to 4.2with 0.5% ammoniumhydroxide. Constructs
were stained for 20 min and imaged with a Nikon TS100 microscope.
HOB cells cultured on CL scaffolds for 1 week were used as a positive
control.
2.11. Animal model of mandibular defects
Male Sprague–Dawley rats (300–350 g) were anaesthetised with
isoflurane (IsobaVet®; Schering-Plough, Kenilworth, NJ, USA) com-
bined with O2 using a custom-made platform and mask. A 1 cm in-
cision was made along the lower border of the mandible and after
retracting the muscles a round-shaped bone defect (5 mm diame-
ter) was created in the mandibular angle region. A trephine bur
(Komet Medical, Lemgo, Germany) was used. The defect was filled
with a scaffold (n = 8 for each experimental group). The muscles
were repositioned and the skin closed with resorbable sutures (Vicryl
Rapide 4-0; Ethicon, Somerville, NJ, USA). Animals were euthanised
with an overdose of CO2 after 2 and 4 weeks. Mandibles were dissected
and the samples were stored in RNAlater (Invitrogen, Carlsbad, CA,
USA) for RT-PCR, micro computed tomography (micro-CT) and histolog-
ical analyses.
2.12. Gene expressions in vivo
Total RNA was isolated from in vivo scaffolds at 2 weeks. Taqman®
gene expression assays (Applied Biosystems™, USA) were used to
detect mRNA levels of GAPDH, ALP, OC, Runx2, Col1α2, BMP-2, Bone
morphogenetic protein-4 (BMP-4), Tartrate-resistant acid phosphatase
(TRAP) and Cathepsin K (CTSK). The data were analysed with a com-
parative CT method and GAPDH served as endogenous control. CL
served as reference.
2.13. Micro-CT analysis
The amount of bone formationwithin the defectswas examined using
micro-CT (micro-CT 40, Scanco Medical AG, Bruettisellen, Switzerland)
with 19 μm isotropic voxel size and 70 kV, 43 μA tube current, 380ms ex-
posure time, and 1000 projections [42]. Three-dimensional isosurface
rendering and images were constructed with the software provided by
Scanco Medical and measurements included the ratio of new bone vol-
ume relative to the tissue volume (BV/TV).
2.14. Histological evaluation
Specimens for histological examinationwere processed as previous-
ly described [43]. Sectionswere then stainedwithMasson's trichome to
confirm the osteoid-like tissue and images were made with an inverted
microscope (Nikon Ti, Tokyo, Japan) using the software NIS-Elements
AR 4.10.
2.15. Statistical analysis
The average values were analysed using SPSS Statistics 21.0 (IBM,
Armonk, NY, US). The data were expressed as mean +/− standard
deviation (SD). Data were tested for variance homogeneity and normal
distribution and One-way ANOVA were followed by a multiple-
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comparison Tukey test. Analysis of the in vivo experiment data was
performed with the Kruskal–Wallis test. Differences between the
means were considered statistically significant when p b 0.05.
3. Results
3.1. In vitro kinetics of BMP-2 release
The release of BMP-2 was monitored through identification of
signature peptide NYQDMoxVVEGCcamGCcamR as analysed by SRM.
The amount of a signature peptide (L, endogenous peptide) for BMP-2
is related to a known amount of internal standard (H, heavy synthetic
peptide) spiked-in our sample, and the ratio (L/H) is used as an index
for the amount of BMP-2 released (Fig. 1). The figure is a representative
of the data from themost optimised SRMmethod obtained from triplicate
measurements.
In the first 24 h, the PHY scaffolds had an initial burst of release.
There was a steady release from the MICS scaffolds starting from 24 h
while the nDP-COV scaffold group showed no release. MICS scaffolds
showed a gradual increase in release from day 7 on, with the greatest
release being found between days 21 and 40. In comparison to the
MICS scaffolds, the PHY scaffolds showed a smaller increase in release
between days 21 and 40, while the nDP-PHY scaffolds showed a main-
tained level.
3.2. hMSC attachment and proliferation
SEM images at day 1 and day 3 of culture show the spreading and
attachment of hMSC on the different scaffolds. Significantly more cells
on the MICS modified group were proliferating on day 7 compared to
the other scaffold groups (Fig. 2 G).
3.3. BMP-2 signalling and hMSC differentiation
Similar results were seen between the groups (Fig. 3) for expression
of the two main receptors of BMP-2 signalling (BMPRIA and BMPRII).
Results showed the highest expression of receptor significantly from
the MICS at 3 weeks (p = 0.033, p = 0.029). At week 1 the nDP-PHY
group showed higher but not statistically significant expression com-
pared with the PHY group, while at week 3 the PHY group showed a
higher trend, coinciding with the release profile during that period,
which was again not statistically significant. A tendency was seen for
an increase in the master transcription factor Runx2 in all groups at
week 3 compared to week 1 (Fig. 3). Col1α2 was upregulated in all
groups at week 3 compared to week 1 except in the nDP-COV group,
where itwas downregulated. In all the other groups, ALPwas upregulat-
ed atweek 3with nDP-PHY showing the highest tendency (Fig. 3). MICS
and nDP-PHY showed the highest BMP-2 expression at both early and
late time points (Fig. 3), although this was only significant in the MICS
group at week 3. OC was significantly upregulated at week 3 in the
MICS group followed by the nDP-PHY group, compared with the other
groups.
3.4. In vitro endogenous BMP-2 protein expression
The medium was collected at week 1 and week 3 to determine
the extracellular release of endogenous BMP-2 from hMSC. The BMP-2
ELISA kit used is sensitive to natural and mammalian-expressed BMP-
Fig. 2 Attachment and proliferation of hMSC cultured on the different scaffolds. SEM im-
ages at days 1 and 3 showing attachment of hMSCs (red arrows) (A) CL, (B) PHY,
(C) nDP-PHY, (D) nDP-COV and (E) MICS. Scale bar = 200 μm. (F) Higher magnification
of MICS scaffold without cells showing the increased surface area resulting from the mi-
crospheres. Scale bar = 2 μm. (G) The proliferative activity of the hMSC seeded onto the
different scaffolds evaluated in terms of mRNA expression of the proliferative marker
(Ki67) (*p b 0.05, **p b 0.001).
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2 and does not recognize E. coli-expressed rhBMP-2. The levels detected
here were therefore protein originating solely from hMSC. Extracellular
endogenous BMP-2 showed the lowest expressions in the CL and nDP-
COV groups, with minor differences between time points. The highest
expression was seen from the MICS group at early and late time points
and nDP-PHY at week 1 (Fig. 4A). Intracellular BMP-2 showed the
highest levels in the MICS group at both time points and lowest in the
nDP-PHY group (Fig. 4B). None were significant.
3.5. Alizarin red staining for in vitro mineralization
Staining revealed surface mineralization. Most groups showed vari-
able reddish extracellular matrices while vast extracellular darker spots
could be observed in theMICS and nDP-PHY group scaffolds as evidence
of calcium deposits in the matrix (Fig. 5).
3.6. Gene expressions from in vivo experiments
In vivo RT-PCR results showed coherence in several genes with the
expressions in vitro. The transcription marker Runx2 showed the
highest expression on the MICS scaffolds, although not significant. Sig-
nificant upregulation of the early osteogenic marker ALPwas expressed
on MICS while COL1 was higher from the PHY scaffolds. OC was upreg-
ulatedmost onMICS scaffolds, followed by expression on nDP-PHY scaf-
folds, consistent with the in vitro results indicating deposition of bone
matrix andmineralization.MICS scaffolds also demonstrated significant
upregulation of the osteoclast markers TRAP and CTSK at 2 weeks.
3.7. De novo bone formation
Morphometric results with micro-CT show that most of the treated
groups had increased bone volume inside the defined defect area com-
pared to the empty group. Bone volume recoverwas greatest in the PHY
and MICS groups at 4 weeks, and that both were significant in compar-
ison to the nDP-COV scaffold group (Fig. 7A). They were followed by
nDP-PHY.
Masson's trichrome staining was carried out to identify the osteoid-
like tissue and collagen enriched areas in the defects. In the empty
group (Fig. 7 B) it was predominantly soft tissues growing around and
into the defect. The scaffold architecture was highly preserved in
the CL and nDP-COV groups compared with other 3 functionalised
scaffold groups. Most of the pores of the CL scaffolds were filled
with loose fibrous connective tissue without much evidence of oste-
oid tissue formation. Histological results were in line with themicro-
CT analysis showing mostly osteoid formation among the pores of
the scaffolds in PHY, nDP-PHY and MICS at an early time point of 4
weeks (Fig. 7D, E and G).
4. Discussion
We evaluated the in vitro and in vivo efficacy of four different modes
of rh-BMP-2 delivery utilising a low dose of 1 μg.
Fig. 3. Relative MRNA expression from hMSC cultured in vitro after week 1 and week 3.
Relative mRNA levels of BMP-2 signalling receptors, transcription factor and osteogenic
markers (*p b 0.05, **p b 0.001).
Fig. 4. In vitro endogenous BMP-2 protein expression by ELISA at week 1 and week 3.
(A) for extracellular concentration of BMP-2 secreted in medium and (B) intracellular
BMP-2.
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In vitro rhBMP-2 release from scaffolds was evaluated with targeted
quantification using SRM and an absolute quantification method
(AQUA). The SIS peptide was chemically identical to the native peptide
with respect to retention time, ionization efficiency, and fragmentation
characteristics. Its mass unit was higher and could therefore be distin-
guished from the native counterpart during MS analysis permitting
the detection of very low concentrations [44]. In the PHY scaffold most
of the BMP-2 was located superficially with weak bonds causing the
initial burst release. A second increase in release from PHY was seen at
a time point when the scaffold is beginning to degrade. This hypothesis
is supported by the degradation profile from the same scaffold analysed
by in vitro hydrolysis where forty days showed to be a sufficient time for
significant reduction of its molecular weight contributing to increased
degradation [45].
In contrast, the release of BMP-2 from MICS scaffolds was different.
Several factors explain this difference, such as the microsphere size
and its rate of degradation, which controlled the BMP-2 diffusion in a
steadily increased fashion retaining the BMP-2 for an extended time.
OC was highly expressed in cells grown on MICS at week 1 (p b 0.05)
and week 3 in vitro and at 2 weeks in vivo, implying increased mineral-
ization in comparison to that seen on PHY scaffolds. This demonstrates
how long-term sustained delivery of BMP-2 enhances its osteogenic ef-
ficacy at the same dose compared to short-term delivery [46]. Differ-
ences in the initial burst release of BMP-2 from PHY and nDP-PHY
scaffolds could be attributed to the lower amount of protein being
only weakly bound to the scaffold in the case of nDP-PHY. No burst re-
lease was encountered as in PHY because the interaction of proteins
with nDPs is known to be rather strong [47]. Also previous reports
where spectroscopic and theoretical investigations were carried out,
showed a strong binding of BMP-2 with NCD surfaces [25], supporting
the contention that nDP could express similar properties [27]. The nDP
modification of copolymer scaffolds has been shown to increase its hy-
drophilicity [28], facilitating stronger physisorption of rhBMP-2. An
overview of different O-termination techniques facilitating surface at-
tachment of organic groups has been reported [21]. The overall binding
strength of the noncovalent interaction is governed by a multitude of
individual interactions. Several forces were reported to contribute to
the overall binding on NCD, such as van der Waals forces, H-bonds
and electrostatic interactions. Although the release kineticswere not re-
markably different between nDP-PHY and nDP-COV scaffolds, it is clear
from our results that the bioactivity of rhBMP-2was conserved on nDP-
PHY scaffolds. Studies suggest that slightly acidic environments stimu-
late the release of proteins loaded noncovalently on nDP modified sur-
faces [24], a condition that was absent in our PBS buffer set-up. Body
fluids aid degradation of carriers and release of BMP-2 in a variable
manner, which is why comparison to the present in vivo results is
important.
The burst release and degradation of the scaffoldsmight be accentu-
ated in vivo [45], explainingwhy PHYmight show higher trends of early
markers such as Runx2 and COL1 in vivo, although the difference was
not significant. Several factors play a role in bone regeneration in vivo
[48], which could have assisted the PHY to form mineralized tissue
in vivo but not in vitro. The in vivo experiments had different time points
from the in vitro, bringing another variable to the effect of the release ki-
netics of the various scaffolds. At 2 weeks in vivo, the release profile
showed a relatively higher release from MICS, which continued to in-
crease, compared to PHY, and thus had a significant effect on the
Fig. 5 3Dmineralization in vitro visualisedwith Alizarin red S staining.Macroscopic images
(round) and increased magnifications (×4) images of (A) unseeded CL scaffold,
(B) cultured hMSC for 1 week on CL scaffold (C) on PHY, (D) on nDP-PHY, (E) on nDP-
COV, (F) on MICS, and (G) HOB cells on CL scaffold (positive control). Scale
bar = 500 μm.3D mineralization in vitro visualised with Alizarin red S staining. Macro-
scopic images (round) and increasedmagnifications (×4) images of (A) unseeded CL scaf-
fold, (B) culturedhMSC for 1 week onCL scaffold (C) on PHY, (D) onnDP-PHY, (E) onnDP-
COV, (F) onMICS, and (G) HOB cells on CL scaffold (positive control). Scale bar = 500 μm.
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osteogenic marker, ALP. The second cross-sectional analysis in vivowas
at four weeks which corresponds to bet'ween 21 days and 40 days of
in vitro release kinetics. PHY and MICS showed the significantly higher
bone regeneration and nDP-PHY came later, perhaps suggesting the ef-
fects of sustained release in low doses from the latter group as seen in
the release curve (Fig. 1). Longer-term evaluation in vivo is required to
fully assess the quality and architecture of new bone.
The in vitro results in the present study demonstrated lower ALP ex-
pression by cells grown ontoMICS scaffolds than on nDP-PHY,with cells
from the MICS group still significantly highly proliferative as seen by
Ki67 expression at week 1, possibly related to the increased surface
area from the microspheres. It has been reported that osteosarcoma
cells cultured on NCD implant surfaces showed increased ALP activity
in less than 2 weeks of culture [25]. In vivo, a significantly higher
expression of mRNA ALP was demonstrated from MICS scaffolds indi-
cating bone induction. ALP expression tended to be higher in cells
on nDP-PHY scaffolds than on PHY scaffolds both in vitro and in vivo,
although not significantly so, highlighting the effect of nanoparticles
on enhancing the osteoinduction of copolymer scaffolds. A slight up-
surge in the BMP-2 kinetic release after almost 40 days in nDP-PHY is be-
lieved to be due to the degrading polymer, but in this case the rhBMP-2 is
still bound to nDP and bioactive in levels to increase osteogenic differen-
tiationwhen comparedwith PHY scaffold. Thiswas confirmed by Alizarin
red staining in the nDP-PHY and MICS scaffold groups.
The nDP-COV group showed no release of BMP-2 during the 70 days
of incubation and also showed lesser osteogenic potential both in vitro
and in vivo. This demonstrates the high stability of the covalent immo-
bilization of the protein on the diamond surface. The loss of the BMP-2
functionality indicates that the protein is most likely deformed during
the binding onto the diamond surface by both the covalent linker and
additional, non-covalent interactions. Similar results have been report-
ed previously for the covalent immobilization of other proteins such
as enzymes [49]. This brings to our notice the necessity of improving
the method for covalently bonding the rhBMP-2 to the nDP without af-
fecting the bioactivity of rhBMP-2. Furthermore, we take into consider-
ation that the in vitro design of 3 weeks was not suitable for the nDP-
COV group; additional degradation of the scaffold is required to release
rhBMP-2. This was evidenced by the observation of limited osteoid
tissue around the nDP areas at 4 weeks in vivo (Fig. 7F).
BMP-2 exerts a bipolar effect depending on its concentration:
osteoprogenitor cells are recruited and differentiated at low doses,
whereas osteoclasts are transiently activated at high doses [50]. This
was reflected by the in vivo expression of TRAP and CTSK, (Fig. 6),
both highly expressed by osteoclasts. They were significantly highly
expressed in the MICS scaffold group after 2 weeks; in vivo this release
could be amplified due to environments favourable to erosion of themi-
crospheres. Recent reports [51] have underlined the importance of de-
creasing the dose of BMP-2 to the lowest level that is compatible with
the desired effect of bone formation. BMP-2 is expressed from days 1 to
21 during bone healing [48], hence for delivering BMP-2 for bone regen-
eration, the ideal carrier would provide sustained release over a period of
at least three weeks. Following injury, BMP-2 is released locally into the
defect site from the surrounding matrix [48], consistent with the in-
creasedBMP-2 levels in vivo seenhere in all groups, although this increase
was not statistically significant. Also consistent with trends seen here,
BMP-2 expression is upregulated in differentiating osteoprogenitor cells
andmaintained for about 21 days [52]. At week 3 in vitro, the highest ex-
pression was seen in the MICS (p b 0.05) and followed by nDP-PHY at
both time points. A similar trend in the extracellular protein levels of
BMP-2was shown by ELISA. Comparing the gene and protein expressions
of BMP-2between PHYandnDP-PHYhighlights the valuable effect of nDP
functionalisation. BMP-2 is an extracellular signalling molecule which is
washed out rapidly, thus the protein level of extra- and intra-cellular
BMP-2 was reduced at week 3 in all groups [53]. Small amounts induce
cellular responses in vitro; however exogenously delivered BMP-2
requires ultra-physiological doses for humans compared to animals to
overcome the rapid wash out.
It is important to note that in vitro statistical relevance was seen in
mRNA expressions of the potent osteogenic markers BMP-2 and OC
in vitro, hence our discussion and subsequent conclusions are based
on this finding. Significance in vivo was only demonstrated for ALP
mRNA from MICS scaffold compared to other osteogenic markers.
However, microCT and histological evaluations disclosed a confirmative
dimension supporting the interpretations and conclusions related to the
osteogenic potential of these scaffolds. The nDP-PHY andMICS scaffolds
have strong potential for future applications due to their controlled
release of growth factors. Furthermore, the data demonstrated that
the protein on nDP-PHYwas bioactivewith comparable efficacy despite
being strongly bound to the carrier (scaffolds), indicating a short dis-
tance effect on the local surrounding tissues.
In the clinical trials, high doses of not less than 1 mg BMPs per ml
have been used and the complications of this dose have been discussed
[54]. However, it is difficult to establish a correlation from animals to
humans due to different bone healing mechanisms [55]. Interestingly,
Fig. 6. Relative mRNA expression in vivo after week 2. Expression of BMP-2 transcription,
osteogenic genes and remodellingmarkers by RT-PCR from animals samples after 2weeks
in place (*p b 0.05).
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in our study a low dose of only 1 μg was sufficient to induce de novo
bone. Very few experiments using comparably low doses in vivo have
been reported. Researchers used carrier minerals, which might have a
confounding osteoinductive effect [56] or including osteoprogenitor
cells in the construct [57]. A recent study using collagen sponges in crit-
ical sized defects in rat calvaria [58] concluded that rhBMP-2 accelerates
local bone formation once reaching an osteoinductive dose threshold at
1.25-2.5 μg in their model, which is not load bearing. Previous reports
also proved that non-glycosylated BMP-2 which is produced via bacte-
rial expression systems is less soluble. Despite it having lower biological
activity and release in vitro compared to glycolysated BMP-2, it signifi-
cantly increased bone formation at low dosages [59].
Taken together, we conclude fromour results that lowdoses of BMP-
2 are found to be bioactive for bone regeneration. Obtaining bone after
just 4 weeks in vivo suggests accelerated bone regeneration in the
PHY, nDP-PHY and MICS groups. Physisorption onto nDP modified co-
polymer scaffolds is a material reported for the first time in critical
sized bone defects and appears to hold great promise compared to
growth factors adsorbed solely onto a polymer.
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ABSTRACT: Background. Microenvironmental cues play a major role in
head and neck cancer. Biodegradable scaffolds used for bone regenera-
tion might also act as stimulative cues for head and neck cancer. The
purpose of this study was to establish an experimental model for precise
and noninvasive evaluation of tumorigenic potential of microenvironmen-
tal cues in head and neck cancer.
Methods. Bioluminescence was chosen to image tumor formation. Early
neoplastic oral keratinocyte (DOK) cells were luciferase-transduced
(DOKLuc), then tested in nonobese diabetic severe combined immunode-
ficient IL2rgnull mice either orthotopically (tongue) or subcutaneously for
their potential as “screening sensors” for diverse microenvironmental
cues.
Results. Tumors formed after inoculation of DOKLuc were monitored eas-
ier by bioluminescence, and bioluminescence was more sensitive in
detecting differences between various microenvironmental cues when
compared to manual measurements. Development of tumors from
DOKLuc grown on scaffolds was also successfully monitored noninva-
sively by bioluminescence.
Conclusion. The model presented here is a noninvasive and sensitive
model for monitoring the impact of various microenvironmental cues on
head and neck cancer in vivo. VC 2015 The Authors Head & Neck Pub-
lished by Wiley Periodicals, Inc. Head Neck 00: 000–000, 2015
KEY WORDS: cancer, microenvironment, bioluminescence, tissue
engineering, scaffold
INTRODUCTION
Recent evidence implicates environmental cues as key factors
in cancer progression.1 Among the important determinants is
the surrounding stroma, including fibroblasts, endothelial
cells, infiltrating immune cells, and extracellular matrix com-
ponents.2,3 The scaffolds used in tissue engineering as provi-
sional matrices for cell proliferation and extracellular matrix
deposition can also act as microenvironmental cues. The sur-
rounding tissues might react toward these by foreign body
reactions or even tumor formation,4 and long-term subcutane-
ous implants of nonabsorbable or slowly degrading materials
were shown to be tumorigenic.5,6 Thus, there is a great con-
cern that certain biomaterials may be potential initiators of
malignancies, and the size and surface roughness of certain
biomaterials were already suggested to influence tumor for-
mation.7 To date, at the regulatory level, the basic approach
for biomaterials’ safety is defined in the International Organi-
zation for Standardization 10993.8,9 These tests start with an
initial safety evaluation targeting leachable for cytotoxicity.
Genotoxicity and evaluation of mRNA levels of proto-
oncogenes and tumor suppressor genes10 from mammalian or
bacterial cells exposed to the biomaterials has also been used
as methods for safety check.11 Current carcinogenicity tests
determine the tumorigenic potential of materials and/or their
extracts from either single or multiple exposures or contacts
over a period of the major portion of the life span of the test
animal or transgenic mice.12 Long-term, conventional 2-year
rodent bioassays are often not feasible, with questionable
relevance also because of limitations associated with species
extrapolation.13,14 Finding a relevant animal model for every
kind of human cancer is impractical, but preclinical animal
xenograft tumor models, particularly heterotopic (subcutane-
ous), have proven useful especially in identifying cytotoxic
agents.15–18 On the other hand, although more technically
demanding, the orthotopic xenograft models simulate the
same local microenvironment and thus offer the advantage of
less complicated translation to the clinical setting.19
Scaffolds used for bone regeneration in the oral and
maxillofacial area might come in contact with the oral
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epithelium. Because over 90% of head and neck cancers
are, as most of the human malignancies, of epithelial ori-
gin,20,21 there is a need to study the potentially carcino-
genic effect of degradable bioengineered scaffolds on oral
epithelial cells. To study oral and head and neck carcino-
genesis, both orthotopic and heterotopic (subcutaneous)
models were previously developed by use of malignant
cells derived from established oral or head and neck can-
cer.22 In this study, we chose to develop a xenotransplan-
tation model by use of an early neoplastic oral
keratinocyte (DOK) cell line derived from early neoplas-
tic oral mucosa.23 These cells were found to be partly
transformed but nontumorigenic in nude mice, and were
described as having potential as “screening recipients” for
carcinogens in vitro.23
Different in vivo optical imaging modalities have been
tested in various tumor models.24–26 However, there is a
need for a noninvasive head and neck cancer model with
the ability to detect possible tumorigenic effects of vari-
ous microenvironmental cues, including implanted scaf-
folds. Bioluminescent imaging is a well-established
method in preclinical investigation of the complexity of
cancers27–29 including head and neck cancer,30,31 but for
a screening of the potential to fully transform and gener-
ate malignant tumors from the early neoplastic cells, the
application of bioluminescence would offer a novel non-
invasive approach. In carcinogenicity testing of biomateri-
als, controls of a comparable form and shape should be
included. However, in the presented system, the use of
appropriate controls is not necessary because the inclusion
of a positive environment with the use of carcinoma-
associated fibroblasts (CAFs) has been developed. The
noninvasive in vivo visualization for several weeks also
provides additional unique advantages over the aforemen-
tioned established carcinogenicity testing systems.
To achieve real-time bioluminescence in this study,
DOK cells were first transduced to contain the firefly
luciferase. They were then tested in vivo in NSG mice
for their potential as “screening sensors” for diverse
microenvironmental cues, such as various types of head
and neck CAFs and copolymer scaffolds intended for tis-
sue engineering. The biodegradable poly L-lactide-co-E-
caprolactone (poly[LLA-co-CL]), an aliphatic polyester
copolymer of L-lactic acid and E-caprolactone, has been
extensively studied at our laboratory as a scaffold for
bone regeneration proving its biocompatibility and osteo-
conductivity,8,32 and, hence, was chosen for developing
this model.
MATERIALS AND METHODS
Cell choice and maintenance
The DOK cell line was purchased from The European
Collection of Cell Cultures (Salisbury, Wiltshire, UK).23
They were maintained in Dulbecco’s modified Eagle’s
medium (DMEM) supplemented with 10% fetal calf
serum (FCS; Invitrogen, Waltham, MA), 20 lg/mL
L-glutamine, 5 lg/mL hydrocortisone (all from Sigma, St.
Louis, MO).
CAFs (n 5 3; CAF1, CAF15_13, and CAF15_23) were
isolated from histologically confirmed head and neck squa-
mous cell carcinoma, after receiving informed consent.
They were maintained in FAD medium: DMEM/Ham’s
F12 1:3 mixture, 1% L-glutamine, 0.4 lg/mL hydrocorti-
sone, 50 lg/mL ascorbic acid, 10 ng/mL epidermal growth
factor, 5 lg/mL insulin, and 20 lg/mL transferrin and lino-
leic acid (all from Sigma) with 10% FCS.
Luciferase transduction of early neoplastic oral
keratinocytes
Virus production. DOK wild type (DOKWT) cells were
transduced with a tTA, L192 construct (expressing lucif-
erase).33 Infectious retroviral vector particles were pro-
duced in Phoenix A cells (LGC Standards AB, Boras,
Sweden) cultured in DMEM, supplemented with 10%
FCS, 1% penicillin-streptomycin, and 1% glutamine.
When 70% to 80% was confluent, 8 lL of 50 mM chloro-
quine (Sigma) was added. Four micrograms of DNA con-
struct (tTA, L192) was mixed with 128 lL of 2M
calcium chloride (CaCl2) and sterile ddH2O to a total vol-
ume of 1 mL plus 1 mL of 23HEPES-buffered (Sigma)
and transferred onto each plate. After 12-hour incubation,
the medium was replaced by a fresh medium and by
DOK’s medium after 24 hours.
Infection and selection of luciferase-transduced early neoplastic
oral keratinocyte. The virus supernatant was collected, fil-
tered, and gene transfer enhanced with protamine sulfate
(5 lg/mL). DOKWT were seeded at 3 different seeding
densities (25 3 103; 50 3 103; and 100 3 103 cells/well)
in a 6-well plate and centrifuged at 1200 g for 90
minutes. The virus supernatant was replaced with the
DOK medium 24 hours postinfection. Successfully
infected DOK cells were selected by puromycin (1 lg/
mL; Sigma). To obtain a cell-clone with a stable, high
expression of luciferase, transduced DOK cells were
sorted using fluorescence-activated cell sorter (FACS
Aria SORP, BD Biosciences, San Jose, CA).
Selection of highly bioluminescent early neoplastic oral
keratinocyte luciferase-transduced cells
Approximately 1 3 106 cells of each group in 100 lL
DOK medium were transferred to 96-well plate with 1 well
containing 100 lL of DOK medium only for background
autofluorescence. Luciferin, (1.6 g/L of D-luciferin; Bio-
synth AG, Staad, Switzerland) was added 10 minutes
before imaging in the Time-Domain Small Molecular
Imager Optix MX3 (ART; GE Healthcare, Little Chalfont,
UK). Using the OptiView acquisition software (ART
Advanced Research Technologies, Quebec, Canada), the
region of interest was chosen and plates were scanned with
the scan step 1.0 mm and integration time 0.1 seconds.
Assessment of cell morphology and proliferation
Both cell types, DOKWT and early neoplastic oral kera-
tinocyte luciferase-transduced (DOKLuc), were cultured at
passages (45–48) and their morphology was compared
under a light microscope (Nikon TS100; Nikon, Tokyo,
Japan). The growth rate was analyzed using a colorimet-
ric assay based on methylthiazol tetrazolium (Sigma) and
measured at 570 nm using a microplate reader (BMG
LABTECH, GmbH, Ortenberg, Germany).
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Assessment of tumorigenicity in vivo
Both DOKWT and DOKLuc cells were cultured and
allowed to reach their log phase before they were trypsi-
nized and suspended in 50 lL of growth factor-reduced
matrigel (BD Biosciences). The cells were inoculated at 2
different densities, low (1 3 103) and high (1 3 105), at
2 different locations, the tongue and subcutaneously in
the back of 8 to 10 weeks old male nonobese diabetic
severe combined immunodeficient IL2rgnull mice (NSG)
(University of Bergen - originally a generous gift from
Prof. Leonard D. Shultz, Jackson Laboratories, Bar Har-
bor, ME; n 5 24, 6 mice for each group). Weekly for 6
weeks, tumor volumes for both cell types were manually
assessed by digital caliper, using the formula [length 3
(width2)/2]. In the group inoculated with DOKLuc, tumor
development was also measured weekly by biolumines-
cence. We euthanized the mice after 45 days and har-
vested tissues for histology.
Orthotopic tongue xenograft mouse model for early
neoplastic oral keratinocyte 1 carcinoma-associated
fibroblast co-inoculations
To create a positive tumor formation control, 1 3 103
DOKWT were suspended with 1 3 105 CAFs (CAF1) in
50 lL matrigel and inoculated in the tongue of NSG mice
(n 5 12; 6 mice for each group). Tumors were measured
manually up to 45 days.
To assess the sensitivity of bioluminescence to differen-
tiate between tumors formed by different strains of CAFs,
DOKLuc in a density of 1 3 103 were co-inoculated in
combination with 1 3 105 of 2 different strains of CAFs
(CAF15_13 and CAF15_23) in the tongue. The total
number of animals was 24 with at least 6 for each group.
The development of the tumors in this group was fol-
lowed up manually and evaluated weekly by
bioluminescence.
Preparation of cell-seeded poly L-lactide-co-E-
caprolactone scaffolds for ectopic subcutaneous
scaffold xenograft
The copolymer poly(LLA-co-CL) was polymerized
from E-caprolactone (Sigma–Aldrich, Germany) and LLA
(Boehringer, Ingelheim, Germany) by ring-open-
polymerization, as previously described.32 The average
molecular weight of the purified copolymer was 100,000
and polydispersity index 1.3 determined by Size Exclu-
sion Chromatography (Polymer Laboratories, Shropshire,
UK). The copolymer was composed of 75 mol % LLA
and 25 mol % caprolactone, confirmed by 1H-NMR
(Bruker Avance 400, Billerica, MA). The porous scaffolds
were prepared by solvent casting particulate leaching32
and a disc-shaped scaffold (diameter approximately 6
mm, thickness approximately 1.3 mm) was formed with
>83% porosities. Porosities were calculated by a Micro-
CT (Sky Scan 1172 scanner, Kontich, Belgium) using 40
kV and 2.4 micron voxel and 3D analysis was carried
using the software CT-Analyzer version 1.13 (Bruker).
The scaffolds were pre-wet with DOK medium and left
for 2 to 3 hours before being then seeded with cells,
DOKLuc alone or DOKLuc 1 CAFs (CAF1). Three differ-
ent densities of DOK were used (1 3 103, 1 3 105, and
1 3 106); the density of CAFs was fixed to 1 3 105.
Plates were vortexed (Eppendorf, Hamburg, Germany)
and the cells were allowed to attach overnight before
scaffolds were xenotransplanted in 8 to 10-week-old NSG
mice.
The mice were anesthetized with Isoflurane (Isoba
VetTM; Schering Plough, Kenilworth, NJ) before 2 inci-
sions (1 cm) were made on their back. One incision was
FIGURE 1. (A) Bioluminescence of early neoplastic oral keratino-
cyte luciferase-transduced (DOKLuc) cells at a density of 50 3
103 early neoplastic oral keratinocyte wild type (DOKWT) trans-
duced 4 times, displaying the highest photons/mm2/sec, white
arrow. (B) Light microscopy showing that DOKWT and DOKLuc
exhibit the same typical morphology and pattern of growth in the
form of coherent islands. (C) Growth curves for both cell types,
showing no significant difference (p 5 .262) between the in vitro
growth potential of DOKWT and DOKLuc. [Color figure can be
viewed in the online issue, which is available at wileyonlineli-
brary.com.]
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made between the upper limbs and another between the
lower limbs, providing sufficient space for implantation
of scaffolds and to avoid bioluminescence bleeding. Two
scaffolds were implanted into each mouse, 1 scaffold
with DOKLuc alone and the other with DOKLuc 1 CAFs.
The different densities were distributed among all mice (n
5 6). Wounds were closed with Histoacryl tissue adhe-
sive (B. Braun Surgical AS, Melsungen, Germany). At 12
weeks, the animals were euthanized with CO2 overdose
and scaffolds processed for histology.
Optical bioluminescence imaging
Mice were depilated and scanned after intraperitoneal
delivery of 150 mg/kg of D-luciferin. Animals were main-
tained under 1% gas anesthesia during scanning. Images
were captured using In Vivo MS FX PRO (Carestream
Health, Rochester, NY) and analyzed using Carestream
MI SE version 5.0.6.20, 1 exposure of 90-second
duration.
Histology and immunohistochemistry
Samples were fixed in 4% paraformaldehyde before
embedding in paraffin. Sections of 3 to 4 lm were
stained with hematoxylin-eosin (Sigma). For p53 immu-
nostaining, paraffin sections were deparaffinized and
rehydrated. Epitope retrieval was performed by heating
the sections in citrate buffer pH 6.0 in a microwave.
Endogenous enzyme activity and unspecific binding were
blocked using peroxidase block (DAKO, Golstrup, Den-
mark) and 10% normal goat serum (DAKO) for 5 minutes
and 30 minutes, respectively, at room temperature. As
primary antibody, p53 with a monoclonal specific anti-
body (DO-7 clone, DAKO) 1:50 was incubated for 1 hour
at room temperature. For negative controls, samples were
treated with antibody diluents alone. The bound reaction
was visualized using 3, 30-diaminobenzidine tetra hydro-
chloride (DAB, DAKO). Double staining with vimentin
(DAKO) 1:1000 was carried out using a double stain kit
(Envision Gj2 double stain system; DAKO), in accord
with the manufacturer’s instructions. Tumor areas were
FIGURE 2. Graphs comparing the
growth rate (tumor volume) and
the total area of tumors formed
by either early neoplastic oral
keratinocyte wild type (DOKWT)or
early neoplastic oral keratinocyte
luciferase-transduced (DOKLuc)
inoculated at cell densities of 103
or 105 in the tongues (A and C),
and subcutaneously (B and D) of
NSG mice (*p < .05). Histological
sections with hematoxylin-eosin
stain showing 6 weeks after inoc-
ulation of the tongue (E, F, H, and
I) and skin (G and J). The tumors
retain the characteristics of squa-
mous cell carcinoma (original
magnification 325 and 3200).
Scale bar 1 mm5 325 and 200
lm 5 3200. [Color figure can
be viewed in the online issue,
which is available at wileyonline-
library.com.]
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calculated from areas of interest in hematoxylin-eosin
sections using Olympus DP Soft 5.0 software (Munster,
Germany).
Ethics statement
The ethical approval for patients with head and neck squa-
mous cell carcinoma samples was obtained from the Regional
Committees for Medical and Health Research Ethics (REK
NO. 2010/48) and lesions were collected following ethical
approval and written informed consent of the patients. All ani-
mal experiments were approved by the Norwegian Animal
Research Authority and conducted in strict accordance with
the European Convention for the Protection of Vertebrates
used for Scientific Purposes (FOTS no. 20134643/20123961).
All procedures were performed under isoflurane gas anesthe-
sia, and all efforts were made to minimize suffering.
Statistical analysis
Average values were analyzed by IBM SPSS Statistics
21.0 (SPSS, Chicago, IL) and the data expressed as mean
6 SEM. Paired t test or the independent Mann–Whitney
U tests were used to compare differences between the
tumors formed. Spearman’s correlation was used to corre-
late the manual tumor measurements and histological
measurements with corresponding bioluminescence sig-
nals. Differences were considered statistically significant
when p < .05.
RESULTS
Successful transduction of early neoplastic oral
keratinocyte with luciferase containing vector generated
a new cell line
The bioluminescence signal recorded for DOKLuc cells
cultured in vitro for 2 to 3 weeks posttransduction showed
that the seeding density of 50 3 103 displayed the highest
photons/mm2/sec (Figure 1A, white arrow). Cells derived
following this protocol were expanded and used for fur-
ther in vivo experiments. Light microscopy showed that
DOKWT and DOKLuc had typical epithelial morphology
and similar patterns of growth in the form of coherent
islands. No signs of epithelial-to-mesenchymal transition
could be observed in either (Figure 1B). The growth
curve was comparable for the 2 cell types (p 5 .262),
indicating that transduction with luciferase did not alter
the in vitro growth potential of these cells (Figure 1C).
The in vivo tumorigenic potential of DOK cells before
and after transduction with luciferase expressing gene was
evaluated after DOKWT and DOKLuc were inoculated in the
tongue and also subcutaneously in NSG mice at low (1 3
103) and high (1 3 105) density. At the high inoculation
density, visible tumors were detected with the same inci-
dence after 2 weeks, at both sites, for both DOKWT and
DOKLuc. At the low density, tumors formed only in the
tongue, and after 4 weeks, with the same incidence for
FIGURE 3. Bioluminescence (BLI) of mice for 5 weeks after inoculation with early neoplastic oral keratinocyte luciferase-transduced (DOKLuc) cells
(105 and 103 densities) in the tongue (A) and in the skin (B). Graphs depicting increasing total photon intensities from tongue inoculations (C) with
a lower overall photon count produced from 103 densities (**p < .01). (D) Total photon intensities of cells for 5 weeks after subcutaneous inocula-
tion (**p < .01). Data shown as means 6 SEM. [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
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DOKWT and DOKLuc. There was no statistical significance
between the volume of the tumors formed in both tongue
and subcutaneously by DOKWT and DOKLuc at all time-
points (Figures 2A and 2B). The histological area of the
tumors derived from DOKWT and DOKLuc at low density in
the tongue (Figure 2C) and at high density subcutaneously
(Figure 2D) did not show any statistical significant differ-
ence. The only statistical significant difference was found for
the tongue tumors formed at higher inoculation density by
DOKLuc than tumors formed by DOKWT (p < .05; Figure
2C). Tumor xenografts generated from DOKWT (Figures 2E–
2G) showed the same histological picture as DOKLuc xeno-
grafts (Figures 2H–2J), with epithelial islands of atypical epi-
thelial cells in the host stroma and keratin pearls.
Development of tumors formed after inoculation of early
neoplastic oral keratinocyte luciferase transduced cells
was easily monitored by bioluminescence
Luciferase activity increased with time after both
tongue and subcutaneous inoculations for both inoculation
densities (Figures 3A and 3B). The bioluminescence sig-
nal was significantly higher for the inoculations of
DOKLuc at higher inoculation density at both tongue and
subcutaneous locations (Figures 3C and 3D), at all time-
points, correlating well with the tumor growth curve as
assessed by the manual measurements.
Both early neoplastic oral keratinocyte wild type and
early neoplastic oral keratinocyte luciferase-transduced
were responsive to carcinoma-associated fibroblast-
derived microenvironmental cues and bioluminescence
was more sensitive than manual measurement in
detecting differences between various types of
microenvironmental cues
Co-inoculating DOKWT with 105 CAFs in the tongues of
NSG mice increased tumor incidence from 16.66% to
57.14% (Figure 4A). Histological sections of the tumors
formed by DOKWT 1 CAF showed typical squamous cell
carcinoma histology with invasive epithelial islands growing
in the host stroma and keratin pearl formation (Figures 4D
and 4E). The only 1 tumor formed by the DOKWT alone,
which was detected manually, was found histologically to be
surviving DOKWT cells within remnants of undissolved
matrigel (Figures 4B and 4C). When 2 different types of
fibroblasts (CAF15_13 and CAF15_23) were tested for their
stimulative support for the in vivo growth of DOKLuc, biolu-
minescence seemed to be more sensitive than the manual
FIGURE 4. (A) Carcinoma-associated fibroblasts (CAFs) increased tumor incidence of early neoplastic oral keratinocytes wild type (DOK)WT when
co-inoculated in the tongues of NSG mice. (B and C) Hematoxylin-eosin section of the tumor detected in DOKWT group presenting surviving DOK
cells (black arrows) within remnants of matrigel (yellow arrows). (D and E) Hematoxylin-eosin section of tumor formed by DOKWT 1 CAF; depicting
typical squamous cell carcinoma morphology with keratin pearls (black arrows). (F) Graphs comparing the volumes by manual measurements from
the last timepoint (week 7) of the tumors formed by 2 different strains of CAFs. (G) Comparison of total photon intensities at week 7 measured by
bioluminescence. (H) Comparing tumor area from histology after 7 weeks (*p 5 .028). [Color figure can be viewed in the online issue, which is
available at wileyonlinelibrary.com.]
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measurement in detecting differences in the tumor growth of
xenografts (Figures 4F and 4G), although the difference was
not statistically significant. This difference was also observed
by histological area calculations after 7 weeks, this time with
statistical significance (p 5 .028; Figure 4H).
Both bioluminescence and manual measurement
showed high correlation with histological area of the
tumors, but tumor formation was detected earlier by
bioluminescence
Bioluminescence consistently disclosed a higher number of
tumors throughout all 5 weeks of monitoring compared to
visible tumors measured manually by calipers (Figures 5A–
5D). Both the tumor volume as quantified by caliper (man-
ual) measurements and the bioluminescence signal from the
corresponding tumor at the last timepoint showed a positive
correlation with the tumor area quantified from histological
sections (considered to be the “golden standard”). A stronger
significant correlation (r 5 0.846; p < .001) was found
between the histological tumor area and bioluminescence sig-
nals than between the histological tumor area and the manual
measurement (r 5 0.739; p < .001; Figures 5E and 5F).
Development of tumors from early neoplastic oral
keratinocyte luciferase-transduced grown on poly L-
lactide-co-E-caprolactone scaffolds under different
microenvironmental cues was successfully monitored
noninvasively by bioluminescence
DOKLuc were cultured on poly(LLA-co-CL) scaffolds
at 3 different densities with or without CAFs. Total pho-
ton count from bioluminescence showed significantly
higher bioluminescence intensity of scaffolds
FIGURE 5. (A and B) Compari-
son of number of tumors
detected by bioluminescence
(BLI) and manually in the
tongue inoculations at both
densities. (C and D) Comparison
in the skin inoculations (p 5
.043; n 5 24). (E) Histological
areas correlate with biolumi-
nescence signals with a stron-
ger correlation (Spearman’s
correlation, r 5 0.847; p <
.001); than with (F) manual
measurements.
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xenotransplanted with DOKLuc 1 CAFs than of DOKLuc
alone at all densities, just above the threshold 1 week
after xenotransplantation and throughout the 12 weeks of
in vivo imaging (106: p < .001; 105: p < .001; 103: p 5
.017; Figure 6C). In the scaffolds xenotransplanted with
DOKLuc alone, no tumors were formed outside the scaf-
folds and the bioluminescence signal stayed within the
same range throughout the 12 weeks of imaging (Figure
6A). In contrast, the bioluminescence intensity of scaffolds
cocultured with CAFs increased with time (Figure 6B),
indicating an increase in tumor growth over time, and this
was confirmed by histology. After 12 weeks, histological
analysis of xenotransplants of scaffolds with DOKLuc cells
alone showed the presence of few atypical epithelial cells,
limited to the scaffold area (Figures 7A, 7B, 7F, and 7G).
Around the remnants of the scaffolds, scattered giant cells
of mouse origin were observed (Figure 7K, blue arrow).
The origin of the epithelial cells was confirmed by immu-
nostaining using an antibody against human p53, recogniz-
ing only p53 mutated human cells, DOK. In contrast, the
histology of xenografts of DOKLuc 1 CAFs scaffolds
showed squamous epithelial tumor nests (confirmed by
p53 positive staining; Figures 7C, 7D, 7I, and 7J), with
many of the islands retaining differentiation and containing
keratin pearls, growing within and outside the scaffold
area, invading the surrounding connective tissue and mus-
culature, thus displaying the characteristic hallmarks of
head and neck carcinoma. Few fibroblasts were observed
in the xenotransplants even after 12 weeks of growth in
vivo in mice (Figure 7K, black arrow). Figure 7E shows
the pronounced macroscopic differences observed during
harvesting of the scaffolds.
DISCUSSION
This study describes the development of a noninvasive,
in vivo model for testing the tumorigenic potential of var-
ious microenvironmental cues, including scaffolds
intended for use in tissue engineering. Numerous studies34
support the concept that carcinogenesis, including head
and neck cancer, is a multistep process involving a pre-
malignant phase of long-term accumulated chromosomal
alterations.35 The use of normal cells in tumor models is
time-consuming, if not irrelevant, because it is well-
known that the transformation of human cells is a long
process, involving at least 5 to 7 mutagenic events, which
are difficult to achieve in an experimental setting.20,36 For
the present model, the DOK cell line, exhibiting early
neoplastic epithelial dysplastic features was selected as a
“screening sensor.”23 To facilitate the noninvasive visual-
ization of these cells after xenotransplantation, they were
transduced with luciferase gene, successfully generating a
new cell line, DOKLuc. The in vitro growth and behav-
ioral characteristics of the transfected cells were compara-
ble to those of the parent cells. To evaluate their behavior
in vivo, both cell lines (DOKWT and DOKLuc) were xeno-
transplanted alone at low and high densities, both ortho-
topically, in the tongue, and ectopically, on the back of
NSG mice. With a single exception for the tumor size
when injected in the tongue at high density, DOKWT and
DOKLuc showed a comparable in vivo behavior as well.
FIGURE 6. (A) Bioluminescence images of a representative mouse carrying a scaffold with a low density (1 3 103) in the upper right back and high
density (1 3 106) of early neoplastic oral keratinocyte luciferase-transduced (DOKLuc) alone in the upper left back. (B) Developing tumors with bio-
luminescence imaging of mice carrying low density (upper right) and high density (lower left) of DOKLuc cocultured with (1 3 105) carcinoma-
associated fibroblasts (CAFs). (C) Total photon count from in vivo imaging using DOKLuc at different densities showed significantly higher biolumi-
nescent intensity of scaffolds xenotransplanted with DOKLuc 1 CAFs than of DOKLuc alone throughout 12 weeks of imaging (106: p < .001; 105: p <
.001; and 103: p5 .017; n5 6). [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
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This indicates that the DOK cell line retained a high
degree of stability after transfection, although it carried a
complex karyotype and multiple mutations, including p53
mutations. In accordance with previous oral carcinogene-
sis animal studies, the incidence and size of subcutaneous
tumors in the present study was lower than those of
tongue tumors.16 This could be related to a greater stimu-
lation of lymphangiogenesis in the tongue area16 or sim-
ply because of the fact that orthotopic models allow cells
to grow better in their original environment.
When DOKWT cells were co-inoculated with CAFs in
the tongue, the incidence of tumor formation increased by
more than 40% compared with tumors formed by DOKWT
alone. This further highlights the important role of the
microenvironmental cues in tumor initiation and early
growth, supporting previous studies.37,38 The tumor
detected by manual measurements formed by DOKWT
was proven later on, histologically, to contain mainly
remnants of matrigel, which might have given the mass
that could be measurable by the caliper, and only few
islands of nonproliferative DOK cells. This illustrates one
of the drawbacks of the manual measurements that can be
avoided by the use of other methods, such as
bioluminescence.
In this study, bioluminescence detected more than 50%
of the total number of tumors formed in the tongue by
DOKLuc from the first week; much earlier than tumor
detection with caliper measurements. In the skin tumors,
FIGURE 7. (A–D) Hematoxylin-eosin staining showing histology of early neoplastic oral keratinocyte luciferase-transduced (DOKLuc) and DOKLuc 1
carcinoma-associated fibroblasts (CAFs) xenografts respectively. (E) Dissection of a mouse after 12 weeks showing implanted scaffolds with: (1)
105 DOKLuc cells alone; (2) 105 DOKLuc cocultured with 105 CAF; and (3) empty scaffold. (F and G) Human p53 immunohistochemistry (IHC) showing
the presence of few surviving human p53 mutated transformed epithelial cells in a scaffold xenotransplanted with DOKLuc alone. (I and J) Human
p53 immunohistochemistry showing islands of atypical epithelial cells within and outside the scaffold in DOKLuc 1 CAFs xenografts (original mag-
nification 325 and 3200). Scale bar 5 1 mm and 200 lm, respectively. (H and K) Double staining for human vimentin (red cytoplasmic stain) and
human p53 (brown nuclear stain). (K) Positive vimentin stained human fibroblasts present after 12 weeks in DOKLuc 1 CAFs xenografts (black
arrow). The giant cells are negative for both human markers (blue arrow). Scale bar 100 lm (original magnification 3400). [Color figure can be
viewed in the online issue, which is available at wileyonlinelibrary.com.]
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6 of 7 were visible by bioluminescence from the first
week. One of the tumors was from low density inocula-
tions, which were too small for detection by manual
measurements, but it was later confirmed histologically.
The total number of tumors detected by bioluminescence
was significantly greater than manual detection (p 5
.043), and in concordance with the histological findings,
indicating higher sensitivity for early detection using the
bioluminescence method.
The measurements from the last timepoint of tumor
growth assessment period showed higher bioluminescence
signals from tumors with CAF15_23 than those with
CAF15_13; this difference was not detected by the man-
ual measurements. Histological evaluation confirmed stat-
istically bigger tumors formed by DOKLuc co-injected
with the CAF15_23, a difference that was not indicated
by the manual measurements. This brings further indica-
tions for the greater sensitivity of the bioluminescence
method compared to the manual method that might carry
subjective evaluations (eg, inflammation, tongue pull,
position of the mouse, and lesion margins).
Degradable copolymer scaffolds were used to further
optimize and validate the model for use in screening tests
for tumorigenesis of various microenvironmental cues
from biomaterials. The manual monitoring of tumors at
early stages was impossible because the tumors initially
developed within the scaffold. However, this was not an
impediment for bioluminescence. The correlation between
bioluminescence signals and the golden standard method
of histological examination was higher, confirming the
method is more sensitive than manual measurements.
Therefore, bioluminescence was further used solely to
monitor the scaffolds when developing the model.
A challenge for using the bioluminescence method
would be monitoring of bigger tumors. We monitored a
drop in intensity for a tumor developed from very high
seeding density of DOKLuc 1 CAFs xenografts (1 3
106). We interpreted that to be an underestimation of the
real bioluminescence signal from the cells because that
tumor was later found to be cystic. Cystic content or
necrosis that can occur in large or late stage tumors might
reduce the production of light because of decreased pro-
liferation or hypoxia.27,39 Therefore, we recommend inoc-
ulating fewer cells per area of scaffold in order to
circumvent these limitations and monitor tumor formation
for longer period of times, as required in carcinogenesis
studies. Although the use of such immunodeficient mod-
els greatly aids the development of “humanized” models
of cancer using biomaterials,25 it does come with the
caveat of no innate host immunity. Whereas this limita-
tion prevents the current study of role of the immune sys-
tem in tumor prevention in such models or the use of
immunotherapeutic interventions, steps have been made
to circumvent such constraints. Recent efforts have dem-
onstrated that introduction of distinct human immune
components are possible in mice xenografted with cancer
cell lines,40 suggesting that further evolution of the NSG
mice system may yet render models to study human
immune reactions in cancer.
Our model provides an abridged alternative to the years
spent in rodent models to get tumors from biomaterials
implanted solely in animals and foreign body tumorigene-
sis has several stages, with specific sequences of preneo-
plastic characteristics.12,41 The processing time is reduced
because of the ability of screening several animals simul-
taneously, which makes it cheaper compared to other
high throughput imaging methods used in the field, such
as MRI.
CONCLUSIONS
The model generated and validated in this study is a
sensitive and reliable model for monitoring microenviron-
mentally induced carcinogenesis providing early, consist-
ent surveillance of tumor development associated with
implantation of scaffolds for tissue engineering.
Acknowledgments
The authors thank Dr. Joan Bevenius–Carrick, Dr.
Andrew Davis, and Prof. Mustafa Nur Elhuda for English
revision and constructive criticism of the manuscript. We
are grateful to Tereza Osdal (University of Bergen) for
assistance with cell transduction, Gunnvor Øijordsbakken
(Gade Laboratory for Pathology) for support with histol-
ogy, and Mihaela Popa (KinN Therapeutics AS, Bergen)
for bioluminescence imaging training. The biolumines-
cence imaging was performed at the Molecular Imaging
Centre (MIC), University of Bergen.
REFERENCES
1. De Wever O, Mareel M. Role of tissue stroma in cancer cell invasion.
J Pathol 2003;200:429–447.
2. Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer 2006;6:392–
401.
3. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflamma-
tion. Nature 2008;454:436–444.
4. Anderson JM, Rodriguez A, Chang DT. Foreign body reaction to biomate-
rials. Semin Immunol 2008;20:86–100.
5. Nakamura T, Shimizu Y, Okumura N, Matsui T, Hyon SH, Shimamoto T.
Tumorigenicity of poly-L-lactide (PLLA) plates compared with medical-
grade polyethylene. J Biomed Mater Res 1994;28:17–25.
6. Nakamura T, Shimizu Y, Takimoto Y, et al. Biodegradation and tumorige-
nicity of implanted plates made from a copolymer of epsilon-caprolactone
and L-lactide in rat. J Biomed Mater Res 1998;42:475–484.
7. Kirkpatrick CJ, Alves A, K€ohler H, et al. Biomaterial-induced sarcoma: a
novel model to study preneoplastic change. Am J Pathol 2000;156:1455–
1467.
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